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1.1 Brief introduction to lymphatic filariasis 
 
1.1.1 Infection and disease 
Lymphatic filariasis is a vector-borne parasitic disease that is endemic in many tropical 
and subtropical countries. The disease is caused by thread-like, parasitic filarial worms: 
Wuchereria bancrofti, Brugia malayi or B. timori. W. bancrofti is most widely spread and is 
responsible for more than 90% of the infections (Michael et al. 1996). B. malayi is found in 
several Asian countries, whereas B. timori is only found in Indonesia. Many different 
mosquito species can act as vector for transmission of lymphatic filariasis (Zagaria & 
Savioli 2002).  
This thesis focuses on bancroftian filariasis. The life cycle of the parasite is shown in 
Figure 1-1. The adult worms (macrofilaria) are located in the lymphatic system of the 
human host, where they live for 5-10 years (Vanamail et al. 1996; Subramanian et al. 2004). 
During their lifespan, after mating, female worms bring millions of immature microfilariae 
(mf) into the blood. Some of these mf may be engorged by mosquitoes taking a blood 
meal. Inside a mosquito, mf develop in about 12 days into L3 stage larvae (L3). These L3 
are infectious to human: they can enter the human body when a mosquito takes a blood 
meal. Some will migrate to the lymphatic system and develop into mature worms. 
Maturation takes 6-12 months (World Health Organization 1992). Mf cannot develop 
into adult worms without passing through the developmental stages in the mosquito. The 
life span of mf in the human body is estimated at 6-24 months (Plaisier et al. 1999). 
Figure 1-1. Schematic representation of the life cycle of lymphatic filariasis, showing parasite 
development in the human host and vector.
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Until recently, microscopic examination of peripheral blood for mf has been the 
only way to diagnose infection. Inconvenient night blood sampling is required, because in 
most areas mf only appear in the blood during the night. It is possible to find mf in day 
blood after provocation with the drug diethylcarbamazine (DEC), but this is less reliable. 
In the ’90s, antigen detection tests have become available. This includes a simple card test 
to determine the presence of adult worm antigen in day or night blood (Weil et al. 1997). 
Antigens can be detected in nearly all microfilaraemic individuals, but also in a 
considerable part of the amicrofilaraemics. Using ultrasound it has now also become 
possible to visualize living adult worms in the male scrotum and superficial lymphatic 
vessels (Norões et al. 1996).  
Lymphatic filariasis infection is chronic in nature due to the long life span of the 
worms and accumulation of infection over time. Many people may be infected without 
even knowing it, but on the long-term some people may develop severe chronic 
manifestations, including hydrocele and lymphoedema. These chronic manifestations are 
the result of accumulating, worm-induced damage in the lymphatic system. Hydrocele is 
an enlargement of the scrotum in males, caused by accumulation of serous fluid inside the 
scrotal sac, around the testicles. Hydroceles can be small and unnoticed by the patients, 
but can also become very large so that surgery is required. Lymphoedema is a swelling of 
the extremities, breasts or vulva, caused by accumulation of fluid in the subcutaneous 
tissue due to impaired lymph drainage. Lymphoedema sometimes progresses into 
elephantiasis: the skin of the enlarged body part becomes thickened, rough and hard like 
elephant-skin. Physical exercise and elevation of the affected body part may help to 
prevent progression of lymphoedema. Advanced lymphoedema and elephantiasis cannot 
be cured. Besides these chronic manifestations, lymphatic filariasis can cause 
incapacitating and painful acute episodes of lymphangitis or lymphadenitis. Such attacks 
can be triggered by secondary bacterial infections (Dreyer et al. 1999). They occur more 
frequently in people with lymphoedema and are an important cause of progression of the 
disease. Secondary infections and acute attacks can be prevented by simple measures 
(including hygienic measures, wearing shoes, care of small wounds), which may help to 
stop progression of lymphoedema (Dreyer et al. 2002; Shenoy 2002). Chyluria and tropical 
pulmonary eosinophilia are less frequently occurring manifestations of lymphatic filariasis. 
 
 
1.1.2 Magnitude of the public health problem 
Lymphatic filariasis is endemic in many countries in Africa, South Asia, the Pacific Islands 
and the Americas. Worldwide, an estimated 120 million people are affected by lymphatic 
filariasis, with about one third of them suffering from hydrocele or lymphoedema 
(Michael et al. 1996). Amicrofilaraemic, asymptomatic infections are not included in this 
estimate and the true number of affected people may even be higher. India alone 
accounts for about 40% of the global burden and Sub-Sahara Africa for about 37% 
(Ramaiah et al. 2000; Zagaria & Savioli 2002). 
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Lymphatic filariasis does not directly cause death, but its chronic manifestations are 
an important cause of disability and reduced quality of life. Hydrocele and lymphoedema 
are associated with impaired mobility and social activity, reduced work capacity, sexual 
dysfunction, severe psycho-social problems, stigma and bad marital prospects (Evans et al. 
1993; Ramaiah et al. 1997; Ahorlu et al. 2001). The burden of disease in 2002 was 
estimated at 5.8 million disability adjusted life years (DALYs) (World Health Organization 
2004). For comparison: the burden of disease for malaria and schistosomiasis was estima-
ted at 46.5 and 1.7 million DALYs respectively. 
 
 
1.1.3 Control of lymphatic filariasis 
There are different ways to control lymphatic filariasis infection and to reduce the public 
health burden. Main strategies are treatment of the human population with anti-filarial 
drugs and vector control.  
Treatment of human populations with antifilarial drugs has become the mainstay of 
lymphatic filariasis control (Ottesen et al. 1997). Three drugs are available for treatment of 
this infection: diethylcarbamazine (DEC), ivermectin and albendazole. DEC kills part of 
the mf and adult worms (Ottesen 1985; Norões et al. 1997). Ivermectin is a strong 
microfilaricidal drug; it probably does not kill adult worms, but may reduce their fertility 
(Dreyer et al. 1995; Plaisier et al. 1999). Albendazole is a broad-spectrum antiparasitic 
drug, which can be given in combination with DEC or ivermectin to enhance the 
effectiveness. Treatment with a single dose of DEC, ivermectin, or their combinations 
with albendazole leads to a strong reduction in mf intensity in the blood, which is usually 
sustained for over one year. Mass treatment programmes can be organized to treat all 
individuals in a community at the same time, which will lead to a strong reduction in the 
mean worm burden and transmission. Such mass treatment programmes aim at treating 
all individuals, irrespective of their infection status. This is preferred above selective 
treatment of infected individuals, because screening for infection is cumbersome, costly 
and leaves many false-negatives untreated. Mass treatment is considered safe, since side 
effects of treatment are mild and usually related to high intensity of infection. However, 
because of severe side effects, DEC cannot be used in the large parts of Africa where 
Onchocerca volvulus is endemic, and neither DEC nor ivermectin should be used in Loa loa-
endemic areas (some African countries).  
Vector control is a general term for measures that aim to reduce human-vector 
contact. The number of mosquitoes can be brought down by reducing the number of 
breeding sites for mosquitoes, killing of adult mosquitoes in houses with insecticides, or 
measures against mosquito larvae (chemical or biological). Bed nets and other personal 
protection methods can be used to reduce the number of mosquito bites (Anonymous 
1994). The choice of methods depends on the local mosquito species, because species 
vary in their breeding, resting and feeding habits. Vector control played an important role 
in the control of lymphatic filariasis in the past, and is still recommended as a 
complementary tool in mass treatment programmes. 
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1.1.4 The Global Programme to Eliminate Lymphatic Filariasis 
Yearly mass treatment effectively brings down the prevalence and intensity of infection. 
There is no non-human reservoir of W. bancrofti and animals also play no role in the 
transmission of B. malayi or B. timori infection, although brugian parasites have been 
found in several animal species (World Health Organization 1992; Fischer et al. 2004). 
These considerations have led to the recognition that it may be possible to eliminate 
lymphatic filariasis by repeated mass treatment, if it is continued sufficiently long (Centers 
for Disease Control 1993). In 1997, the World Health Assembly adopted a resolution, 
calling for the world wide elimination of lymphatic filariasis as a public health problem 
(World Health Organization 1997) and in 1998 the Global Programme to Eliminate 
Lymphatic Filariasis (GPELF) was initiated.  
GPELF aims to eliminate the disease, and where possible to interrupt transmission, 
by yearly mass treatment. In addition, improved morbidity management should reduce 
the suffering of people with chronic disease. The recommended treatment regimen is a 
single dose of DEC and albendazole for countries outside Africa and a single dose of 
ivermectin and albendazole for African countries, where onchocerciasis may be present 
(Gyapong et al. 2005). Mass treatment is not recommended for Loa loa-endemic areas. 
Both albendazole and ivermectin are donated to the GPELF by their manufacturers 
(Molyneux & Zagaria 2002). In 2004, 39 countries worldwide had started mass treatment 
programmes to achieve the goal of elimination and this number is still growing (World 
Health Organization 2005). Figure 1-2 shows the endemic countries that are currently 
providing annual mass treatment. 
 
 
1.2 Prospects of achieving elimination by mass treatment 
There is a great sense of optimism that yearly mass treatment will lead to elimination of 
lymphatic filariasis. Based on the common assumption that adult worms live for about 5 
years, it is thought that 4-6 yearly mass treatments would interrupt transmission if a 
sufficiently large proportion of the population receives treatment (Ottesen et al. 1999). 
The evidence base for this assumption is rather limited, though. 
Lymphatic filariasis has successfully been eliminated in several areas. Active distri-
bution of DEC and vector control have led to elimination of lymphatic filariasis from 
large parts of China, Malaysia, Korea and several islands of the Pacific (Ottesen 2000). In 
several endemic foci in Brazil, lymphatic filariasis seems to have been virtually eliminated 
after seven years of 6-monthly mass or selective treatment with DEC (Schlemper et al. 
2000). However, in several other areas intensive control measures have not led to 
elimination of the infection. In French Polynesia recurrence of transmission occurred 
after cessation of a long-term mass treatment programme (Cartel et al. 1992). Another 
study from French Polynesia showed continued transmission of infection in spite of long-
term intensive control programmes (Esterre et al. 2001). An ongoing Indian study had 
promising results after 6 rounds of mass treatment with DEC or ivermectin (Ramaiah et 
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Figure 1-2. Lymphatic filariasis endemic countries currently under annual mass drug administra-
tion (MDA) (as of April 2005). China already achieved basic elimination in the 90’s and is now in 
the surveillance phase.
al. 2002; Ramaiah et al. 2003), but the goal of elimination was not yet achieved after 
respectively 9 or 8 rounds of mass treatment with DEC or ivermectin (KD Ramaiah, 
personal communication). Differences in outcomes of earlier control programmes and 
field studies may be related to the use of different treatment regimens, variation in the 
operational performance (e.g. the proportion of the population that received treatment), 
and differences in transmission dynamics between areas (e.g. related to the mosquito 
species responsible for transmission or characteristics of the local parasite strain).  
The central question is this thesis is whether it will be possible to eliminate lymphatic 
filariasis by mass treatment and under what circumstances. Field experience is insufficient 
and not specific enough to answer this question. We will therefore address it using a 
mathematical model that simulates the transmission dynamics of lymphatic filariasis and 
can predict the long-term of interventions, while taking account of characteristics of a 
specific endemic setting.  
 
 
1.3 Transmission dynamics 
The many processes involved in parasite development and transmission were briefly 
described in section 1.1.1. For predicting trends in infection and the impact of control 
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measures, it is important to take account of density dependence and heterogeneities in 
these processes.  
 
 
1.3.1 Density dependence 
Density dependence means that the outcome of a process depends on the density of the 
parasite stages involved. Such density-dependent processes may impose a natural limit to 
the growth of the parasite population, but they also determine how easy or difficult it will 
be to eliminate the parasite (Dietz 1988; Duerr et al. 2005).  
Density dependence is known to occur in the uptake and development of infection 
in the mosquito vector, although there are important differences between species. Let us 
for example consider Culex quinquefasciatus (the main vector in India and widespread in the 
world) and Anopheles (the main vector in Africa). In Cx. quinquefasciatus, the number of L3 
developing in mosquitoes does not linearly increase with mf density in the blood meal, 
but approaches a constant value at higher mf densities (Subramanian et al. 1998). In other 
words, the proportion of mf developing into L3 declines with increasing mf uptake. Such 
negative density dependence is called limitation. In Anopheles species, the proportion of 
mf developing into L3 increases with mf density (Brengues & Bain 1972; Pichon et al. 
1974; Southgate & Bryan 1992). This positive density dependence, called facilitation, 
occurs only at lower mf densities: at higher densities the limiting mechanisms will get the 
upper hand. Limitation also occurs because of reduced mosquito survival with higher 
parasite load (Krishnamoorthy et al. 2004). These density dependent processes were 
adequately quantified for Cx. quinquefasciatus, but information is lacking for most other 
mosquito species. 
Density dependence may also occur in parasite establishment, worm maturation or 
survival, and mf production in the human host. This is difficult to investigate, because we 
cannot directly measure an individual’s exposure to L3 or the number of adult worms 
present in the body. There may be limitation in parasite establishment due to acquisition 
of immunity. Evidence for this comes from animal studies, which show that previous 
exposure to filarial larvae protects the animals against new infection (Selkirk et al. 1992), 
but it has been difficult to prove in humans. Although immunological studies found many 
differences in immune responses between infected and presumably uninfected hosts, it is 
uncertain to what extent these differences reflect protective immunity (Ravindran et al. 
2003). Epidemiologist found evidence for the operation of acquired immunity by studying 
age-patterns of filarial infection: in several locations, prevalence or intensity of infection 
was found to decline in older age groups, which may indicate that the older individuals 
have acquired immunity against infection (Woolhouse 1992; Michael & Bundy 1998). 
However, there may be other explanations for these observations and age-patterns have 
to be studied more systematically to investigate whether these patterns are common in 
lymphatic filariasis endemic areas. 
Understanding density dependence in parasite development in vector and host is 
crucial for assessing the prospects of elimination. Due to density dependence, 
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transmission intensity is not linearly related to parasite density. Because of limiting 
mechanisms, transmission becomes less efficient when parasite density increases and 
approaches a maximum. Vice versa, transmission becomes more efficient if parasite 
density declines, so that the decline in transmission intensity is less than proportional. The 
reverse is true for facilitation, which helps for elimination. The balance between limiting 
and facilitating mechanisms will determine the eradicability of the infection. Part of the 
work in this thesis aimed to enhance our understanding of density dependent mechanisms 
in human host and vector. 
 
 
1.3.2 Heterogeneity 
Human individuals may vary with respect to their exposure to mosquitoes, susceptibility 
to infection, compliance to treatment, their responsiveness to treatment, etc. Because of 
such heterogeneities, the distribution of parasites over the population is not even: whereas 
some people may be uninfected, others may have high worm burdens (i.e. aggregation). 
The importance of heterogeneity as determinant of transmission and the persistence of 
infection in the human population is often overlooked. Ignoring such heterogeneities, 
however, may lead to overestimation of the effectiveness of population-based control 
measures and the probability of elimination (Duerr et al. 2005). The people with highest 
worm burdens contribute most to transmission, but also receive most new infections. The 
probability of male and female worms mating and the intensity of transmission are 
therefore higher than expected based on the average worm burden per individual. Also, to 
clear infection from all individuals, including the most-heavily infected, treatment may 
have to be continued longer than would be expected based on the average worm load per 
individual. Sometimes it may be useful to adapt the design of control programmes, e.g. by 
targeting high-risk groups (Anderson & May 1991). For predicting the impact of mass 
treatment, it is also important to consider individual variation in compliance and 
responsiveness to treatment (Plaisier et al. 1999; Stolk et al. in press). 
 
 
1.4 Simulating lymphatic filariasis transmission and control 
 
1.4.1 The LYMFASIM simulation model 
Research on lymphatic filariasis at the Department of Public Health of Erasmus MC 
has aimed at predicting the impact of different control strategies to inform policy makers 
and public health authorities involved in the control of lymphatic filariasis. For this 
purpose, the LYMFASIM modelling framework has been developed.  
LYMFASIM aims at realistic prediction of the effects of control measures. It mimics 
the acquisition and loss of infection in individual humans. Individuals form together a 
dynamic population and they interact through biting mosquitoes. The model mimics the 
key-processes involved in transmission of lymphatic filariasis as outlined in section 1.1.1. 
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Density dependence in the uptake and development of mf in mosquitoes is taken into 
account and acquired immunity can optionally be included in the model. Human 
individuals may differ with respect to their exposure to infection, immune responsiveness 
or compliance to treatment, so that the infection intensity varies between individuals. 
Adult worms, which are also simulated at the individual level, vary with respect to their 
life span and (optionally) the rate of mf production. A schematic representation of this 
part of the model is provided in Figure 2-1 in the next chapter. Other parts of the model 
concern the development of chronic morbidity, the efficacy of antifilarial drugs, 
characteristics of vector control or population treatment interventions, and the diagnosis 
of infection. 
The design of this modelling framework reflects current knowledge about the 
dynamics of lymphatic filariasis. All processes and mechanisms that are relevant for 
transmission and control of lymphatic filariasis in the human population are described by 
mathematical equations. A full mathematical description of the model is provided 
elsewhere (Plaisier et al. 1998). LYMFASIM is based on the technique of stochastic 
microsimulation model (Habbema et al. 1996). This is a powerful technique that allows 
explicit simulation of the (chance) processes involved in transmission, taking account of 
heterogeneities. Probability distribution functions are used to describe heterogeneity in 
the human or parasite population. The same technique was used in the ONCHOSIM 
model for onchocerciasis (river blindness), which was earlier developed at the 
Department of Public Health (Plaisier et al. 1990; Plaisier 1996) and has been used widely 
for evaluation of the large-scale Onchocerciasis Control Programme in West-Africa that 
ran from 1975 – 2002.  
LYMFASIM was developed in close collaboration with experts from research 
institutes from India (Vector Control Research Centre, Pondicherry) and Brazil (Centro 
de Pesquisas Aggeu Magalhães, Recife).  
 
 
1.4.2 Simulating transmission dynamics in a specific area 
As part of model development, the many processes and parameters in the model must be 
quantified carefully, taking account of local characteristics. The value of various biological 
parameters can be expected to be independent of the area under study (e.g. the adult 
worm or mf life span, the duration of the premature period). The value of others may 
depend on the mosquito species responsible for transmission (e.g. those related to the 
development of the parasite in the mosquito) or characteristics of the study population 
(e.g. demography, exposure to mosquitoes). Several parameters represent typical 
characteristics of the control programme under study. With respect to mass treatment 
programmes, this concerns for example the choice of drugs, the number and timing of 
treatment rounds, and the proportion of the population covered in each round. Sources 
of information for parameter quantification include scientific literature, expert opinion, 
local field observations, routinely collected statistical data, and operational data collected 
for evaluation of ongoing control programmes. If data are not available, additional data 
General introduction 
17 
may have to be collected to obtain the necessary information. The value of remaining 
parameters can be estimated by comparing model predictions to observed data. Such 
comparison is crucial for validation of the model. 
 
 
1.4.3 Other models for lymphatic filariasis  
LYMFASIM is not the only mathematical model for lymphatic filariasis. An overview of 
the use of different types of models in lymphatic filariasis research was recently published 
(Das & Subramanian 2002). Targeted models, which consider part of the processes 
involved in transmission, have been developed to clarify for example the role of acquired 
immunity (Michael & Bundy 1998; Michael et al. 2001), the effects of treatment on adult 
worm (Plaisier et al. 1999), or the trends in infection intensity during mass treatment 
(Plaisier et al. 2000). There is one other model, called EPIFIL, which simulates the full 
transmission cycle (like LYMFASIM) and is also being used to predict the long-term 
impact of control measures (Chan et al. 1998; Norman et al. 2000; Michael et al. 2004). The 
two models and their predictions are compared in chapter 5 of this thesis. 
 
 
1.5 Objectives and research questions 
The primary objective of this thesis is to quantify the parameters of the LYMFASIM 
model and to use the model for predicting the long-term impact of mass treatment and 
assessing elimination prospects. A secondary objective is to clarify some of the gaps in 
our knowledge of the transmission dynamics. Specific research questions are: 
 
1. What are the prospects for elimination of lymphatic filariasis by mass treatment?  
2. Does protective immunity develop after prolonged exposure to lymphatic filariasis 
infection? 
3. How do mosquito species differ with respect to their efficiency in transmitting 
lymphatic filariasis infection? 
4. What are the effects of DEC, ivermectin, and their combinations with albendazole, 
on adult worms and microfilariae? 
 
 
1.6 Structure of the thesis  
The work reported in this thesis can be divided into two parts.  
In the first part of the thesis, we apply the LYMFASIM simulation model to 
Pondicherry in India, addressing research question 1 on the conditions under which 
lymphatic filariasis can be eliminated. Pondicherry offers an ideal starting point for our 
studies, because a wealth of epidemiological and entomological data is available from this 
area. Using these data, we quantify the model parameters (chapter 2). The model is 
subsequently used to investigate how many yearly mass treatment rounds with ivermectin 
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or other drugs would be required to eliminate lymphatic filariasis from Pondicherry 
(chapters 3 and 4). Our predictions are compared with published predictions from the 
other available model for lymphatic filariasis, EPIFIL, and advances and challenges in 
predicting the impact of lymphatic filariasis programmes are discussed (chapter 5).  
In the second part of the thesis, we report studies that were done to enhance our 
understanding of lymphatic filariasis and to quantify specific model parameters. Research 
questions 2-4 are addressed in these studies. We first review age-patterns of filarial 
infection from India and Africa, to investigate whether acquired immunity protects older 
people from infection (chapter 6). The differences between mosquito species in their 
efficiency in transmitting infection are subsequently addressed, focusing on mf uptake 
and development of mf into L3 in Cx. quinquefasciatus and Ae. polynesiensis (chapter 7). 
Lastly, the effects of DEC or ivermectin and their combinations with albendazole are 
studied (chapters 8 and 9).  
The general discussion (chapter 10) completes this thesis. This final chapter 
provides concise answers to the questions posed in the introduction, discusses remaining 
challenges for model-based support of lymphatic filariasis control, and lists the main 
conclusions and recommendations. 
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Abstract 
This paper presents a model-based analysis of longitudinal data describing the impact of 
integrated vector management on the intensity of Wuchereria bancrofti infection in 
Pondicherry, India. The aims of this analysis were (1) to gain insight into the dynamics of 
infection, with emphasis on the possible role of immunity, and (2) to develop a model 
that can be used to predict the effects of control. Using the LYMFASIM computer 
simulation program, two models with different types of immunity (anti-L3 larvae or anti-
adult worm fecundity) were compared with a model without immunity. Parameters were 
estimated by fitting the models to data from 5071 individuals with microfilaria-density 
measurement before and after cessation of a 5-year vector management programme. A 
good fit, in particular of the convex shape of the age-prevalence curve, required inclusion 
of anti-L3 or anti-fecundity immunity in the model. An individual's immune-
responsiveness was found to halve in ~10 years after cessation of boosting. Explanation 
of the large variation in microfilaria density required considerable variation between 
individuals in exposure and immune responsiveness. The mean life span of the parasite 
was estimated at about 10 years. For the post-control period, the models predict a further 
decline in microfilaraemia prevalence, which agrees well with observations made 3 and 6 
years after cessation of the integrated vector management programme. 
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Introduction 
Despite availability of effective anti-parasitic treatment and other tools for control, 
lymphatic filariasis continues to be a major public health problem in tropical areas of 
Asia, Africa, the Western Pacific and parts of the Americas. More than one-third of the 
estimated 120 million infected people live in India (Michael et al. 1996). There is 
increasing interest in applying strategies for transmission control based on mass-
chemotherapy with annual single dose diethylcarbamazine (DEC), ivermectin, or a 
combination of either of these with albendazole (Ottesen et al. 1997; Ottesen et al. 1999). 
Where feasible, vector control is recommended as an adjunct to chemotherapy based 
strategies (Ottesen & Ramachandran 1995). Worldwide elimination of the disease as a 
public health problem is considered feasible (World Health Organization 1997). 
To evaluate the effects of control measures, to anticipate the effectiveness of 
population-based interventions and to aid decision-making about control strategies, the 
transmission dynamics of the parasite should be well understood. Epidemiological models 
have proven to be valuable tools in this respect (Anderson & May 1985; Isham & Medley 
1996). Various deterministic models have been used to study the dynamics of infection 
and disease due to Wuchereria bancrofti (Hairston & Jachowski 1968; Subramanian et al. 
1989b; Vanamail et al. 1989; Rochet 1990; Day et al. 1991b; Srividya et al. 1991; Das et al. 
1994; Michael et al. 1998; Michael et al. 2001b). In the present paper, we use the 
LYMFASIM (Plaisier et al. 1998) model, which is based on the stochastic microsimulation 
technique (Habbema et al. 1996). 
LYMFASIM offers a framework for integrating current knowledge on the dynamics 
of transmission. By simulating the processes and mechanisms involved in parasite 
development and transmission, and taking individual variation in exposure to infection 
into account, the model allows prediction of trends in infection prevalence and intensity 
over time. However, a considerable number of parameters needs to be quantified. For 
this purpose, we use data collected by the Vector Control Research Centre (VCRC) of the 
Indian Council of Medical Research, for the evaluation of integrated vector management 
in urban Pondicherry, India (Rajagopalan et al. 1989; Subramanian et al. 1989a; Das et al. 
1992; Manoharan et al. 1997). The VCRC-database is unique in that it combines 
entomological and epidemiological observations and that it includes a very large sample of 
the population of Pondicherry (almost 25000 observations in 1981). Furthermore, the 
infection status of humans has been measured at 4 time points (1981, 1986, 1989, and 
1992), which enables the study of longitudinal cohorts. 
In this study, LYMFASIM is fitted to data for a cohort of individuals examined both 
in 1981 and 1986, i.e. before and after the integrated vector management programme in 
Pondicherry. The aim of the present analysis is two-fold. The first objective is to provide 
more insight into the dynamics of lymphatic filariasis, and more specifically into the 
possible role of the host immune response in regulating infection. Different types of 
models – with and without immunity – are compared and parameters that are important 
for the dynamics of infection are quantified. The second objective of the study is to arrive 
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at models that can be used to predict the effectiveness of vector control or mass 
treatment strategies for the control of W. bancrofti in Pondicherry, India. The resulting 
models are tested, by comparing model predictions 3 and 6 years after cessation of vector 
control with the actual observations. 
 
 
Material and Methods 
 
Description of LYMFASIM 
LYMFASIM is a stochastic microsimulation model for the epidemiology of lymphatic 
filariasis in human populations (Habbema et al. 1996; Plaisier et al. 1998). The model 
simulates the life-histories of human individuals (birth, acquisition and loss of parasites, 
death) and individual parasites (maturation, mating, production of microfilariae (mf), 
death). Together, the simulated persons constitute the population of an endemic village or 
area. A detailed description and mathematical formulation of the model has been given in 
an earlier publication (Plaisier et al. 1998). Here we restrict ourselves to a brief description 
of the model and the factors that are directly relevant to the effects of vector control. Of 
particular importance are the regulation of parasite density in both the vector and the 
human host. 
 
 
Transmission and parasite dynamics 
A graphical representation of the model is given in Figure 2-1. In this figure, the monthly 
force-of-infection (foi) indicates the number of parasites that enter the human host in a 
month and the proportion that develops successfully into adult worms, sr. The force-of-
infection varies between individuals and over time; its calculation is explained below. 
In the case of a constant force-of-infection, the expected equilibrium worm-load (M, 
number of mature worms) in a person is found by multiplying the force-of-infection for 
this person times the average reproductive life span (i.e. total life span minus duration of 
immature stage) of an adult parasite. The total life span of the worm is assumed to vary 
between parasites, and is described by a Weibull distribution with mean Tl and shape-
parameter αTl . Estimates for the life span of Onchocerca volvulus (another filarial nematode 
species causing human onchocerciasis), indicated less than exponential variation (αTl > 1) 
and hence we have fixed the value of αTl to 2.0 (Plaisier et al. 1991). The duration Ti of the 
immature stage is considered to be 8 months (World Health Organization 1992). The 
parasite life span not only determines the equilibrium worm-load, but also the rate of 
worm-mortality and thereby the rate at which the worm-load declines in the case of 
interruption of transmission. 
Female adult worms produce mf, provided that the human host harbours at least 
one adult male parasite, assuming a totally polygamous system in W. bancrofti. The mf 
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production is equal to r0 per month per 20 µl blood per female parasite in the absence of 
an anti-fecundity immune response, but is reduced when the human hosts develop such a 
response (see below). The simulated true mf density, m, in a person is expressed in terms 
of the average number per 20 µl peripheral blood taken for diagnosis and is updated 
monthly using the number of mf produced by each female worm per month. Mf mortality 
is governed by a monthly survival fraction s=0.9 for the mf (Plaisier et al. 1999). The 
variability (between blood samples within a host) in the actual (discrete) number of mf 
counted in the smear is described by a negative binomial distribution with a mean equal to 
the true mf density in an individual and a parameter of dispersion km. Overdispersion will 
be smaller (km larger) when a larger volume of blood is examined (due to increased 
sensitivity). Due to intra-host and observer variability in mf counts, false mf negative 
cases (count=0) can occur. 
Based on experimental data, the relation between the mf density m in a human and 
the number of L3 that will develop in Culex quinquefasciatus mosquitoes, the principal 
vector of W. bancrofti in Pondicherry, feeding on such a person (L3 from bloodmeal) is 
described by the following hyperbolic function (Subramanian et al. 1998), 
m
mL ζ
ϕ
+= 13  (2-1) 
with parameter values in Table 2-1. This relationship saturates at φ/ζ at high human mf 
densities and has an initial slope of φ. Because of this saturation, the development of the 
parasite in the vector is one of the density regulation mechanisms in the transmission of 
the parasite. 
The number of L3-stage larvae released per mosquito bite (L3) depends on this 
relationship between mf density in human and L3 developing in a mosquito, and also on a 
number of mosquito-related factors, such as the survival of the mosquitoes between the 
uptake of mf and the development to the L3-stage under natural conditions, the fraction 
of mosquitoes that is potentially infectious (i.e. taking into account that some mosquitoes 
never had a bloodmeal before), and the probability that a L3-larva will actually be released 
during the act of biting. These mosquito-related factors have been combined in the factor 
v. Since v and sr are linear multiplication factors in the same sequence of calculations, we 
decided to arbitrarily fix the proportion v at 0.1, and estimate sr. The average number of 
infective larvae L3 released per mosquito-bite is calculated as a population average, by 
weighting each person’s contribution by his/her relative exposure. 
An individual’s relative exposure to bites depends on his/her age, but there is also 
inter-individual variability. We assume the following relation between age and exposure: at 
birth a person has a relative exposure of E0, and thereafter it increases linearly until age 
amax at which a maximum exposure is reached, which remains at this level for the 
remainder of life. The variation in mosquito bites between individuals is captured by a 
personal ‘exposure index’. This exposure index is assumed to be a life-long characteristic 
of a person. Its value is randomly selected from a gamma probability distribution with 
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mean=1 and shape-parameter αE. This gamma-distribution allows for persons to have low 
or very low relative exposure, but it does not allow for zero exposure. We therefore 
consider an additional parameter, the fraction f0 of persons that is never exposed to the 
bites of mosquitoes. We assume that males and females are equally exposed to mosquito 
bites. 
 
 
 
 
Table 2-1. Description of state variables and parameters of LYMFASIM with values compiled from
field observations, experiments and the literature (expressed in months unless otherwise stated). 
Parameter/Variable  Value (95%CI) Source 
mbr Monthly biting rate 2200 per person 
per month 
See Figure 2-2 
v Fraction of the L3 larvae, resulting from a 
single blood meal, that is released by a 
mosquito 
0.1 Fixed1 
φ Proportion of mf (in 20 µl blood) developing to 
the L3 stage within the mosquito vector as mf 
density tends to zero 
0.09 (0.04 – 
0.24) 
(Subramanian et al. 
1998) 
ζ Severity of density-dependent limitation of L3 
output within the mosquito vector 
0.013 (0.0025 – 
0.0510) per mf  
(Subramanian et al. 
1998) 
αTl Shape-parameter for the Weibull-distribution 
describing the variation in the adult parasite 
life span 
2.0 Fixed2 
Ti Duration of the immature stage of the parasite 
in the human host 
8 months (World Health 
Organization 1992) 
s Proportion of mf surviving per month 0.9 (Plaisier et al. 1999) 
Hw Cumulative experience of worm-load, which is 
a determinant of the duration of 
immunological memory (THw, see Table 2-2) 
State variable N.A. 
Rw Level of anti-fecundity immune response, 
which is a function of strength of anti-
fecundity immune response (γw) and 
individual ability to elicit such a response (αw) 
State variable N.A. 
Hl Cumulative experience of L3-infection, which 
is a determinant of the duration of 
immunological memory (THl, see Table 2-2) 
State variable N.A. 
Rl Level of anti-L3 immune response, which is a 
function of strength of anti-L3 immune 
response (γl) and individual ability to elicit 
such a response (αl) 
State variable N.A. 
1  Both v and sr are linear multiplication factors in the same sequence of calculations (see 
Materials and Methods section). Only sr is estimated by model fitting. 
2  A value of αTl =1 means an exponential distribution. This is often (implicitly) assumed in
mathematical models. Estimates for the life span of the closely related parasite species 
Onchocerca volvulus suggest less variation (αTl >1). 
N.A. – not applicable, mf – microfilaria 
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The monthly transmission potential (mtp) is defined as the number of incoming L3 
larvae per person per month, which varies between individuals and over time. The 
transmission potential is calculated as the product of the average monthly biting rate (mbr, 
number of mosquito-bites per month for an adult person), the relative exposure to bites 
of this person, and the average number of infective L3 released per mosquito-bite into a 
human host. Only a fraction of the larvae that entered the human body will survive the 
larval stages and develop into mature adult worms. This brings us back to the monthly 
force-of-infection, which depends on the monthly transmission potential, on the 
proportion (sr) of inoculated larvae that will survive the L3 and L4 stages, and on the 
individual's level of immunity to L3-larvae, which may vary between 0 (no immunity) and 
1 (full immunity, no larva will survive). 
 
 
Immune-regulation of parasite numbers 
In LYMFASIM we assume two mechanisms for the working of the immune system on 
the dynamics of the parasite: anti-L3 immunity and anti-fecundity immunity. Anti-L3 
immunity is triggered by exposure to L3-antigens and reduces the success of inoculated 
L3-larvae to mature in the human body. This mechanism is proposed on the basis of 
work by Day et al. (1991a, b) who found, among people followed for one year, an increase 
in antibodies to the L3 surface mainly in subjects aged 20 years and older, i.e. subjects 
with the longest history of L3-inoculation. Beuria et al. (1995) also found an age-specific 
increase in the presence of antibodies and further concluded that antibody levels were 
highly variable between individuals. Further, a recent study showed that the prevalence of 
antibodies to L3 surface antigens was higher among amicrofilaraemic persons with or 
without antigenaemia than in subjects with microfilaraemia (Helmy et al. 2000). Several 
other epidemiological studies also provide indirect evidence for the possible role of 
acquired immunity in regulating filarial infections (Vanamail et al. 1989; Das et al. 1990; 
Bundy & Medley 1992; Michael & Bundy 1998; Michael et al. 2001b). However, the above 
field observations (Day et al. 1991a, b; Beuria et al. 1995) corroborate the evidence from 
laboratory studies on cat-Brugia pahangi (Denham et al. 1972; 1983; Grenfell et al. 1991; 
Michael et al. 1998; Devaney & Osborne 2000) and jird-Acanthocheilonema viteae (Eisenbeiss 
et al. 1994; Bleiss et al. 2002) models that immunity acts against re-infection. 
Anti-fecundity immunity reflects that prolonged presence of adult parasites may 
cause a breakdown in tolerance to the parasites, resulting in clearance of mf and progress 
of disease (Maizels & Lawrence 1991). Whether and to what extent the adult worms or 
the mf are the target of this response is not yet clear. In the model we assume that the 
immune response causes a reduction in mf production. 
The modelling of these two types of immunity is similar (see Figure 2-1), and is 
analogous to Woolhouse’s (1992) ‘larval antigens, anti-larval response (LL)’ and ‘adult 
worm antigens, anti-egg response (AE)’ models. In the following, those parameters 
referring to the anti L3-immunity and the anti-fecundity models are denoted by,  
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Table 2-2. Parameters of LYMFASIM describing the transmission dynamics of Wuchereria 
bancrofti in humans and their estimated values arising from the fit of models with and without 
immunity. Units are in years unless otherwise stated. The sign ‘—’ denotes parameters that are not 
included in a particular model. Values in parentheses are the boundaried of the 95% confidence 
interval (CI) for the duration of the immunological memory and success ratio, and are the estimates 
for the strength of the immune-response corresponding to lower and upper boundaries of the 
duration of immunological memory. 
 Numerical value estimated (95% CI) 
Parameter and description 
Anti-L3 
immunity 
model 
Anti-
fecundity 
immunity 
model 
 
No 
immunity 
model 
sr Success ratio: fraction of inoculated L3-larvae 
developing to an adult male or female worm in 
the absence of immune-regulation (x10-3)  
1.03 
(0.66 - 1.36) 
0.42 
(0.34 - 2.07) 
0.58 
E0 Relative exposure at birth  0.26 0.40 0.41 
amax Age at which maximum exposure is reached  19.1 21.3 19.0 
αE Shape-parameter for the gamma-distribution 
describing individual variation in exposure 
(mean = 1)  
1.13 1.14 0.93 
f0 Fraction of the population not exposed to 
mosquito bites  
— — 0.64 
Tl Mean lifespan of the adult parasite in the human 
host  
10.2 11.8 9.1 
km Overdispersion parameter of the Negative 
Binomial distribution describing the variation in 
mf counts in bloodsmears for an individual  
0.35 0.35 0.33 
r0 No. of mf produced per female parasite per 
month per 20 µl peripheral blood in the absence 
of immune-reactions and in the presence of at 
least 1 male worm  
0.61 4.03 0.58 
γl Strength of the anti-L3 immune-response (x10-5) 5.89  
(8.55 - 4.65) 
— — 
αl Shape-parameter for the gamma-distribution 
describing individual variation in the ability to 
develop an anti-L3 immune-response  
1.07 — — 
THl Duration of immunological memory: period in 
which strength of anti-L3 immune response is 
halved in the absence of boosting by L3   
9.60 
(5.0 - 18.3) 
— — 
γw Strength of the anti-fecundity immune-response — 0.026 
(0.042 - 0.025) 
— 
αw Shape-parameter for the gamma-distribution 
describing individual variation in the ability to 
develop an anti-fecundity immune-response  
— 1.07 — 
THw Duration of immunological memory: period in 
which strength of  anti-fecundity immune 
response is halved in the absence of boosting 
by adult worms  
— 11.2 
(5.0 - 16.7) 
— 
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respectively, attaching a suffix l or w to the corresponding symbols. Cumulative 
‘experience’ (H) of, respectively, L3 infection (Hl) and adult worm infection (Hw) 
determines the level of immunity, Rl and Rw. Loss of experience is governed by THl and 
THw, the half-life (in years) of experience of infection in the absence of boosting. The 
factor γ (‘strength of immunity’) translates the experience of infection into an immune 
response (γl and γw). The immune responsiveness levels Rl and Rw vary between 
individuals according to a gamma-probability distribution with mean 1 and shape-
parameters αl and αw. A list and definitions of the model variables and parameter values, 
for which we used external sources (observations, experiments, and literature) or for 
which we simply fixed the value within plausible ranges, is given in Table 2-1. Table 2-2 
summarizes the parameters estimated from fitting the models to the Pondicherry data. 
 
 
Model quantification 
The population of Pondicherry in 1981 is simulated by quantifying the life-table and 
human fertility from statistics for that year (Registrar General of India and Census 
Commissioner 1981). The values for the monthly biting rate (mbr, see Figure 2-2) during 
the vector management programme were estimated from fortnightly collection of human 
landing mosquitoes in one site in Pondicherry (Ramaiah et al. 1992). The mbr was used to 
assess the seasonal effect on vector population and also to monitor the impact of 
integrated vector management. Entomological observations indicated that the vector 
management programme has achieved a large reduction in transmission but did not 
achieve a total interruption (Ramaiah et al. 1992): within 2 years the annual infective biting 
Figure 2-2. Observed monthly biting rate in Pondicherry over the period 1980-1986.
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rate was reduced by 86% and in 4 years by 94%; the average annual infective biting rate 
during the programme period was 45, compared to 228 prior to its start (80% reduction). 
Assuming that the observed pre-control monthly biting rate is representative for the 
situation in Pondicherry prior to the year 1981, we fixed the monthly biting rate at 2200 
per adult person for the period before the start of vector management and after its 
cessation. 
Simulations are always started 150 years before 1981 in order to ensure an 
equilibrium age-composition of the human population and a dynamic equilibrium for the 
parasite population. The two types of immune response are considered in separate 
models. The parameters for the anti-L3 immunity are estimated by assuming that there is 
no anti-fecundity immunity, and vice versa. Adding the possibility of no immune-
regulation, we have three versions of the full LYMFASIM model: anti-L3 immunity 
model, anti-fecundity immunity model, and no-immunity model. 
 
 
Data 
Epidemiological data are from the five-year Integrated Vector Management programme 
in Pondicherry. Surveys were carried out right before and after the completion of the 
programme (in 1981 and 1986). Details of sampling design and parasitological data 
collection are given by Rajagopalan et al. (1989) and Subramanian et al. (1989a). Mf counts 
in 20 µl blood smears for both 1981 and 1986 are available for a cohort of 5071 persons. 
To enable a comparison of simulation results with the observations, the longitudinal data 
are represented as age-specific cross-tabulations of the mf count in 1981 versus the mf 
count in 1986 (Table 2-3). Data on overall mf prevalence in 1989 and 1992 (Manoharan et 
al. 1997) are used for a first validation of the model. 
 
 
Goodness-of-fit 
Simulation results from the three models are compared with data for each of the cells in 
Table 2-3. The agreement between observed and simulated data is assessed by the 
following statistic,  
( )
( )∑ +−= jia aaija aijaaij CEC
ECO
X
,,
2
2
1
 (2-2) 
with: Oaij : Observed no. of persons in age-class a (3-7, 8-10, etc.) of whom the mf count 
in 1981 was in class i (0, 1-5, or >5 mf per smear) and the mf count in 1986 was in class j. 
Eaij : see Oaij , for the simulated population. Ca : Oa/Ea, with Oa total observed and Ea total 
simulated no. of persons in age-class a. 
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Table 2-3. Cross-tabulation of the observed frequencies of Wuchereria bancrofti
microfilarial counts in 1981 and 1986 by age group, in Pondicherry, India. 
Mf count in 1986 Age in 1981 
(Years) 
Mf count in  
1981  0 1-5  6+ 
3-7 0  693  13  11 
 1-5  7  2  3 
 6+  6  4  4 
8-10 0  560  10  6 
 1-5  12  6  2 
 6+  11  3  5 
11-14 0  616  22  10 
 1-5  28  6  2 
 6+  17  9  8 
15-19 0  462  18  9 
 1-5  27  6  5 
 6+  20  6  12 
20-29 0  709  18  15 
 1-5  34  7  10 
 6+  24  10  18 
30-39 0  594  15  7 
 1-5  29  6  2 
 6+  8  1  6 
40-49 0  451  6  5 
 1-5  16  5  3 
 6+  9  1  9 
50+ 0  366  8  8 
 1-5  14  1  3 
 6+  5  4  3 
All ages 0  4451  110  71 
 1-5  167  39  30 
 6+  100  38  65 
 
 
 
In some age-classes, cells with i and j combinations have been merged to ensure that 
they comprise at least 5 observed individuals. The factor (1+Ca) in the denominator 
accounts for the stochastic variation in the simulated population (i.e. the ‘expected’ 
number is derived from a finite simulated population; with increasing simulation size, Ca 
approaches zero). 
A P-value for the goodness-of-fit is calculated by assuming that Χ2 follows a χ2-
distribution with D.F.=42 for models with anti-L3 or anti-fecundity immunity, and D.F.= 
44 for the model without immunity. The number of degrees of freedom is derived from 
the number of cells in Table 2-3 (72), minus the number of cells combined with other 
cells to ensure a minimum of 5 persons in each (combined) cell (12), minus the number 
of age-groups (8), minus the number of parameters to be estimated on the basis of the 
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data (10 for the immunity models and 8 for the model without immunity). P-values > 0.05 
are taken to indicate a satisfactory agreement between estimations and observed data. 
Due to the stochastic nature of the various processes involved in the model, the 
simulation output will be subject to random variation and will only represent an estimate 
of the true outcomes of the model. As a compromise between random variation and 
computing time for each version of the model (no immunity, anti-L3 or anti-fecundity 
immunity), a maximum of 1500 simulation runs was carried out and the total number of 
individuals per simulation run is approximately 50000. 
As a result of variability in simulation output the standard estimation procedures 
(e.g. maximum likelihood estimation) are not applicable. Instead parameters in Table 2-2 
are estimated by minimizing Χ2 in Equation 2-2 through a downhill-simplex routine 
(Nelder & Mead 1965). For the immunity models, a 95%-CI was determined for the 
immunological memory (parameters THl and THw ) and for the success ratio (parameter 
sr) following the method of Plaisier et al. (1995). Starting from the best-fitting values of 
these parameters, alternative lower and higher values are tested and the other parameters 
re-estimated. Those values that result in a Χ2-difference of approximately 3.84 (95th 
percentile of a χ2-distribution with D.F.=1 are considered to be the CI-boundaries. 
 
 
Results 
Goodness-of-fit of models with and without immunity 
Table 2-2 gives a complete list of the estimated parameters and their values in the 
different models. The two immunity models and the model without immunity have all 
been fitted to the cross-tabulated 1981 and 1986 mf counts of the people in the 
integrated vector management area (Table 2-3 and Figure 2-3). Figure 2-3 shows the 
observed and predicted mf distributions before (1981) and after (1986) vector control. 
Results in terms of age-specific prevalence, incidence and loss of infection are shown in 
Figure 2-4. The goodness-of-fit was satisfactory for both the anti-L3 (Χ 2 = 49.5; D.F. = 
42; P = 0.20) and the anti-fecundity immunity model (Χ 2 = 48.8; D.F. = 42; P = 0.22); no 
good agreement with the data was obtained for the model without immunity (Χ 2 = 117.9; 
D.F. = 44; P < 0.001). 
The model without immunity had difficulty in fitting the relatively low pre-control 
mf prevalence; a prevalence of 8.5% could only be reproduced by assuming that nearly 
two-thirds of the population was not exposed (f0 = 0.64), which is very unlikely given the 
ubiquity of the mosquito vector, C. quinquefasciatus. Also, this model failed to reproduce 
the observed decline in mf prevalence after the age of 20 (Figure 2-4). 
The two models with immunity show a satisfactory fit to the low overall mf 
prevalence and the age-specific data on prevalence, incidence and loss-of-infection 
(Figure 2-4). For this fit, a long immunological memory of about 10 years is needed for 
both the anti-L3 and the anti-fecundity model. The values of the other parameters in 
Table 2-2 will be addressed in the discussion section. 
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Figure 2-3. Observed and simulated distributions for the number of mf per blood smear in the 
integrated vector management programme in 1981 and 1986. The upper graph shows the 
percentages of persons that were mf-negative in 1981 and that showed 0, 1-5 or ≥6 mf per blood 
smear in 1986. The middle graphs apply to persons with 1-5 Mf in 1981, etc. Values are shown 
for all age-classes combined. The simulation outcomes of the 3 models with and without immunity 
are standardized to the age-distribution of the observed cohort.
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Prevalence of mf and adult worms 
Figure 2-5 compares the prevalence of adult (male or female) worms for the immunity 
models with the mf prevalence. In both models, the worm-prevalence (dashed line) is 
much higher than the mf prevalence as determined by a blood-smear (solid line). For the 
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Figure 2-4. Observed (dots) and simulated age-specific mf-prevalence (in 1981 and 1986, A & B 
respectively), incidence of infection (% of mf-negatives in 1981 that were positive in 1986, C) and 
loss of infection (% of mf-positives in 1981 that were mf-negative in 1986, D). The solid line is the 
prediction with anti-L3 immunity model, the dashed line applies to anti-fecundity immunity model, 
the dot-dashed line to model with no-immunity and the bars are 95% confidence limits for the 
prevalence calculated using normal approximation to binomial distribution.
anti-L3 immunity model, the main reason for this difference is the presence of single-sex 
infections (Figure 2-5A). Production of mf will only occur in hosts that harbour at least 
one female and one male worm. The percentage of persons that satisfy this condition is 
depicted in Figure 2-5A (dot-dashed line). The difference between the proportion of 
people harbouring both male and female worms and the simulated mf prevalence is 
mainly caused by the occurrence of negative counts at low mf densities because of the 
variability of the number of mf counted in a blood-smear of 20 µl. The difference 
between adult worm-prevalence and mf prevalence is larger for the anti-fecundity 
immunity model (Figure 2-5B), which is caused by the anti-fecundity response. 
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Figure 2-5. Simulated age-specific mf-prevalence (in 1981; solid line), prevalence of persons with 
at least one adult worm (dashed line) and prevalence of persons with at least one male and at 
least one female worm (dot-dashed line). Predictions of the models with anti-L3 (A) and anti-
fecundity immunity (B).
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Confidence intervals 
In estimating the confidence boundaries for the duration of immune responsiveness (THl 
and THw ), the remaining parameters listed in Table 2-2 were re-estimated for each value 
of the duration, optimising the goodness-of-fit. The sensitivity of the remaining 
parameter values to the value of the duration of immunological memory is as follows. 
The strength of immunity (parameters γl and γw) decreases approximately hyperbolically 
with increasing memory duration, indicating that the strength and duration compensate 
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Figure 2-6. Predicted and observed trend in the mf prevalence (% of persons with a positive 
blood smear). Lines: predicted mf prevalence for the anti-L3 immunity model (solid line) and anti-
fecundity immunity model (dashed line). Circles: observed prevalence levels in 1981 (8.9%), 1986 
(6.4%), 1989 (5.2%) and in 1992 (4.8%). Window bar highlights the duration of the integrated 
vector management programme (1981-1986). Bars are 95% confidence limits calculated using 
normal approximation to binomial distribution.
for each other in a multiplicative way. The values for other parameters listed in Table 2-2 
remained virtually unchanged (data not shown). The 95%-CI indicates that neither a very 
short (under 5 years) nor a very long (over 18 years) duration of immunity is in agreement 
with the data and that the duration of immunity does not differ significantly between the 
two types of immunity. We also determined the confidence intervals for the success ratio 
(Table 2-2). 
 
 
Long-term predictions 
In order to explore the predictive validity of the immunity models, the trends in 
prevalence after cessation of the vector control are also assessed (Figure 2-6). The 
observations (circles) are for the entire surveyed population in 1981, 1986, 1989 and 1992 
in the integrated vector management area. The predicted prevalence is standardized to the 
age-distribution in the 1981 population. Both models predict the continuing down-going 
trend during the first few years after cessation of vector control, but the anti-L3 immunity 
gives the most accurate prediction. There are no data to check the long-term model 
prediction of a rapid increase in prevalence. 
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Discussion 
In this paper we analysed longitudinal data describing the impact of a 5-year integrated 
vector management programme on the intensity and prevalence of W. bancrofti infection 
in Pondicherry, India. The analysis helped us to gain further insight into the dynamics of 
the parasite in the human host. Emphasis was put to arrive at plausible estimates for the 
duration of immunological memory. Further, the analysis rendered a model that can be 
used for evaluation and prediction of the effects of vector management and other control 
measures including mass chemotherapy. 
 
 
Immune-regulation of parasite numbers 
Immune regulation in lymphatic filariasis is complex (Piessens 1981; Ottesen 1992), and it 
is not yet known how the immune system regulates parasite density in the human host. 
To cover this uncertainty, we considered two immunity models that have been proposed 
for helminth infection by Woolhouse (1992), i.e. anti-L3 and anti-fecundity immunity. 
Immune regulation appeared essential in describing the observed mf distribution in 
Pondicherry. A model without immunity failed to explain the decreasing prevalence levels 
in older age groups. Our conclusions on the role of acquired immunity critically depend 
on the ability of the models to explain the observed age-specific data. As was shown in 
previous studies, models with immunity can reproduce a peak in the age-prevalence curve 
(Fulford et al. 1992; Woolhouse 1992). The position of the peak-age, its height, and the 
declining trend after the peak depend on the present and past transmission intensity, the 
worm life span, the strength of the immune response and the duration of the 
immunological memory (Anderson & May 1985). 
The data from Pondicherry did not allow us to distinguish between the two types of 
immunity: both models could reproduce the observed data on mf prevalence and 
intensity equally well. The anti-L3 type of immunity was found compatible with cross-
sectional data from Pondicherry and other areas (Day et al. 1991a; Beuria et al. 1995; Chan 
et al. 1998; Michael & Bundy 1998; Michael et al. 2001b), and is supported by data from 
animal infection experiments (Grenfell et al. 1991; Denham et al. 1992; Michael et al. 
1998). The anti-fecundity immunity assumption has not previously been applied in 
lymphatic filariasis, and it remains to be seen whether it could also explain the results 
obtained in the above-mentioned studies. 
Because the two immunity models predicted different age-specific patterns of adult 
worm prevalence, an indication of their suitability to mirror observations could be 
obtained by comparing predicted adult worm prevalence with observed prevalence of 
circulating filarial antigen. The latter reflects the presence of live adult worms by 
detecting the presence of their excretory/secretory antigens. The Pondicherry dataset 
does not include data on antigenaemia, since this test was not available at the time of 
data-collection, but several other studies present age-specific data on mf and antigen 
prevalence (Lammie et al. 1994; Ramzy et al. 1994; Chanteau et al. 1995; Itoh et al. 1999; 
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Sunish et al. 2001; 2002; Weerasooriya et al. 2002). These studies generally show a much 
higher prevalence of antigenaemia than of microfilaraemia, although the patterns of mf 
and antigen prevalence by age are more or less similar. These observations are more 
consistent with the results of the anti-L3 immunity model than with the results of the 
anti-fecundity immunity model (Figure 2-5). 
Our analysis suggests that the decay of immunity after interruption of transmission 
is slow: it takes about 10 years to reduce the ‘experience of infection’ by 50%. How this 
translates into levels of herd immunity depends on the pre-control level of immunity in 
the population and the variation between individuals (Anderson & May 1985). 
Alternative explanations of a convex pattern of infection intensity by age are 
possible, such as a decrease in exposure to infection in older groups (Fulford et al. 1992; 
Duerr et al. 2003) or mechanisms that reduce the probability of an incoming larva to 
develop into mature adult worms at older ages (Michael et al. 1998). These alternative 
mechanisms have not been examined in this paper, since most studies have stressed the 
possible role of acquired protective immunity (Simonsen 1985; Bosshardt et al. 1991; Day 
et al. 1991a; b; Maizels & Lawrence 1991; Beuria et al. 1995; Simonsen & Meyrowitsch 
1998; King 2001). 
 
 
Life span 
Our analysis also yielded an estimate of the life span of W. bancrofti in the human host. 
The mean life span of W. bancrofti in the human host was estimated to vary between 10 
and 12 years in the present study, including the 8-month immature period. These 
estimates lie within the range of previous estimates, which varied from 8 to 15 years 
(Jachowski et al. 1951; Conn & Greenslit 1952; Manson-Bahr 1959; Leeuwin 1962; 
Nelson 1966; Hairston & Jachowski 1968; Mahoney & Aiu 1970), but is about twice as 
high as the estimate by Vanamail et al. (1989; 1996), which was based on the same data. 
The reason for our longer life span estimate is that we took the possibility of false 
negative counts in 1981 and 1986 into account. What naively is counted as loss or 
acquisition of infection between 1981 and 1986 is often the consequence of false negative 
counts. By neglecting the possibility of false-negatives, Vanamail et al. (1989; 1996) 
estimated a short duration in view of the observed high frequency of apparent loss and 
acquisition of infections. 
 
 
Individual variation 
A good fit of the immunity models to the data was achieved only by assuming 
considerable between-person variability in exposure to the vector and in immune 
response, and by allowing for sampling variation in the number of mf counted in a 20 µl 
night blood sample at a given true mf density (Sasa 1976). A significantly worse fit is 
obtained if one of these sources of variation is ignored. 
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The existence of exposure variation has been demonstrated by a study in Egypt, 
which revealed a positive association between the presence of microfilaraemia and 
residing in houses located near vacant land where Culex biting rates were higher (Gad et 
al. 1994). Recent results also suggest wide inter-individual variation in exposure to 
mosquito bites, as measured by matching mosquito blood-meals with human blood 
samples using the polymerase chain reaction (PCR) technique (Michael et al. 2001a). Our 
estimate suggests that the monthly biting rate in Pondicherry for individuals aged ≥20 
years could vary between 100 and 4000. 
Mf counts are highly variable between smears from an individual. This variability in 
mf counts can result from several sources: variations in blood sampling time (Sasa 1976; 
Simonsen et al. 1997), short-term variation in mf density (Rachou 1954, 1955; Pichon et al. 
1981), sampling variability (Southgate 1974; Sasa 1976; Pichon et al. 1980; Park 1988; Das 
et al. 1990; Grenfell et al. 1990; Dreyer et al. 1996; Simonsen et al. 1997), and variability in 
counting mf. An important implication is that the false negative rate is a function of the 
mf density (the mean of the distribution of mf in an individual). In terms of our 
estimated km (0.33) value, and for persons with (true) mean densities of 5, 10 and 20 
mf/20 µl, the probability of finding (false) zero mf counts according to the negative 
binomial distribution would be 40, 32 and 26%, respectively ( p (0) = [1 + m / km ] – km  ). 
Analysis of mf frequency distributions among human populations in Pondicherry showed 
that about 5% of the mf negatives were in fact false-negatives, and that the proportion of 
false negatives varied between 5 and 20% for different age-classes (Das et al. 1990). Thus, 
the potential for false negative counts may be considerable (Grenfell et al. 1990). 
 
 
Long-term predictions 
The model predictions are in agreement with the observations during the first few years 
after cessation of control, especially those of the anti-L3 immunity model (Figure 2-6). In 
a sensitivity analysis, it appeared that the post-control results could also be predicted with 
a slightly longer immunological memory for the anti-L3 model and a shorter memory for 
the anti-fecundity model. Otherwise, the predictions become inaccurate. Because 
entomological observations suggest that stopping the integrated vector management 
programme has resulted in a return of the vector to pre-control densities (Das et al. 1992), 
we assumed that from 1986 onwards the mbr returned to the pre-control level of 2200 
bites/adult/month. The most striking difference between the models is the more 
pronounced decline and subsequent increase in mf prevalence predicted by the anti-
fecundity immunity model. Both models predict that about 25 years after cessation of 
vector control the mf prevalence would reach the pre-control level of 1981. After this 
period the prevalence continues to increase beyond the pre-control level returning to this 
level after about 65 years. Although long-term predictions with a model that is based on 5 
years of observations should be considered with caution, the predictions do illustrate the 
impact of loss of immunity by showing this (damped) oscillation. The higher peak with 
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the anti-fecundity immunity model is not surprising if we realize that, as a result of a 
reduced transmission, many persons will have lost all their worms and, hence, boosting 
will be completely interrupted in these persons. Also, the reduced transmission may result 
in a much longer period before a newborn child acquires his/her first worm, i.e. the 
moment that the build-up of immunity starts. In anti-L3 immunity model, boosting (rate 
of inoculation of L3-larvae) is not interrupted but reduced to lower values and this 
reduction applies to all individuals in the population. 
 
 
Model validation and generalization 
The next step in the development of LYMFASIM is to validate the fitted models. 
Necessarily, the model is a simplified representation of reality and several aspects related 
to transmission of infection in a dynamic population have not been considered, such as 
mobility of the human and vector population or focality of transmission. 
We focussed on the role of acquired immunity in regulating infection intensity in the 
human host. Two alternative immunity models were in agreement with the longitudinal 
data from Pondicherry. To assess the validity of these models and their implication for 
the role of immunity, it is necessary to test the models against independent data sets from 
a range of endemic areas. Such a study is also necessary because of the different 
epidemiological patterns observed in Pondicherry and in other areas. In Pondicherry, the 
prevalence and intensity curves depict a convex relationship with age (monotonic 
increase over the age range 0–20 years and a declining trend in adults). In many places, 
though, the age-prevalence curves are better described by a saturating non-linear pattern 
(increasing in children until a stable prevalence is reached at adult age, see for example, 
(Kumar & Chand 1990; Kar et al. 1993; Gyapong et al. 1994; Kumar et al. 1994; Lammie et 
al. 1994; Meyrowitsch et al. 1995; Kazura et al. 1997). While the convex-pattern is 
suggestive of the role of acquired immunity or a decrease in exposure with increasing age, 
the saturating non-linear pattern could merely reflect the balance between gain and loss 
of infection due to natural death of parasites or age-dependent exposure levels until at 
adult age the exposure level is constant (Duerr et al. 2003). 
Application of LYMFASIM to other areas would demand adaptation to the local 
epidemiological situation, taking differences in the vector-parasite combination and 
individual heterogeneity in exposure to mosquito biting into account. C. quinquefasciatus is 
the principal vector of W. bancrofti infection in Pondicherry. The non-linear saturating 
relationship between numbers of W. bancrofti L3 developed in C. quinquefasciatus and 
human mf density is one of the important regulating mechanisms considered in 
LYMFASIM. Therefore application of LYMFASIM to other areas where the vector or 
parasite species are different would require re-quantification of this relationship. If the 
parasite species is the same but the vector is different, most of the parameters describing 
the dynamics of parasites in human (success ratio, mf production, variation in smear 
count, life span of the parasite) may not differ very much. Heterogeneity in exposure to 
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mosquito biting is expected to vary between areas, and hence would have to be re-
quantified. 
 
 
Conclusion 
In order to explain the dynamics of W. bancrofti infection in Pondicherry, immune 
regulation and inter-individual variations in both exposure and immunity are necessary. 
Our analyses rendered quantified models that can be used to prospectively evaluate the 
effectiveness of various control strategies. Indeed, the models have already been used to 
simulate the effects of mass treatment programmes in Pondicherry and to assess the 
probability of elimination in relation to population coverage and the number of treatment 
rounds (Stolk et al. 2003). The robustness of the model in other situations has yet to be 
assessed, as the urban Pondicherry epidemiological pattern may not be applicable. 
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Abstract 
LYMFASIM, a microsimulation model for transmission and control of lymphatic 
filariasis, was used to simulate the effects of mass treatment, in order to estimate the 
number of treatment rounds necessary to achieve elimination. Simulations were 
performed for a community that represented Pondicherry, India, and that had an average 
precontrol microfilariae prevalence of 8.5%. When ivermectin was used, 8 yearly 
treatment rounds with 65% population coverage gave a 99% probability of elimination. 
The number of treatment rounds necessary to achieve elimination depended to a large 
extent on coverage, drug efficacy, and endemicity level. Changing the interval between 
treatment rounds mainly influenced the duration of control, not the number of treatment 
rounds necessary to achieve elimination. Results hardly changed with alternative 
assumptions regarding the type of immune mechanism. The potential impact of mass 
treatment with a combination of diethylcarbamazine and albendazole is shown under 
different assumptions regarding its efficacy. Human migration and drug resistance were 
not considered. Results cannot be directly generalized to areas with different vector or 
epidemiological characteristics. In conclusion, the prospects for elimination of 
bancroftian filariasis by mass treatment in Pondicherry seem good, provided that the level 
of population coverage is sufficiently high. 
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Introduction 
Lymphatic filariasis currently affects >128 million individuals worldwide, with 43 million 
people suffering from chronic lymphedema or hydrocele (Michael et al. 1996; Michael & 
Bundy 1997). In 1997, the 50th World Health Assembly passed a resolution to eliminate 
lymphatic filariasis as a public health problem (World Health Organization 1997). The 
main strategy for reaching this goal is interruption of transmission, through annual mass 
treatment with antifilarial drugs, combined with individual management of patients, to 
improve the condition of individuals suffering from chronic disease due to infection 
(Ottesen et al. 1997). 
Mass treatment aims at reducing the microfilariae (mf) load in the population, 
thereby reducing both mf uptake by mosquitoes and transmission of infection. Several 
studies have shown that mass treatment with a single dose of diethylcarbamazine, 
ivermectin, or a combination of these drugs leads to a strong reduction in the prevalence 
and intensity of mf (Laigret et al. 1980; Balakrishnan et al. 1992; Kimura et al. 1992; 
Bockarie et al. 1998; Meyrowitsch & Simonsen 1998; Gyapong 2000; Das et al. 2001; 
Ramaiah et al. 2002). Although the results of community-based trials are promising, the 
number of treatment rounds in these studies is usually limited. Therefore, it is uncertain 
whether continuation of mass treatment would lead to elimination. In a Wuchereria bancrofti 
positive locality in Brazil, lymphatic filariasis was virtually eliminated after 7 years of 
6-monthly mass treatment (Schlemper et al. 2000), whereas in French Polynesia 
transmission continued despite long-term intensive control (Cartel et al. 1992; Esterre et al. 
2001). 
In view of the worldwide initiation of programs to eliminate lymphatic filariasis, it is 
crucial to have an indication of the number of treatment rounds necessary to achieve 
elimination. To get a first indication, we used the mathematical simulation model 
LYMFASIM, which simulates the dynamics and transmission of lymphatic filariasis 
(Plaisier et al. 1998). The model had been quantified previously to mimic the life cycle of 
W. bancrofti transmitted by Culex quinquefasciatus and to represent the endemic situation in 
Pondicherry, India (Subramanian et al. 2004). In the present study, using the same model 
quantification, we simulated the effects of mass-treatment programs and assessed how the 
probability of elimination depends on the population coverage and the number of 
treatment rounds. 
Predicting the impact of mass treatment requires quantitative estimates of the 
efficacy of treatment, distinguishing between the killing of mf, the killing of adult worms, 
and a permanent or temporary fecundity reduction in the surviving female worms. As yet, 
such estimates have only been published for ivermectin (Plaisier et al. 1999). Therefore, 
we focused our analysis on the impact of mass treatment with ivermectin (200-µg/kg 
body weight). 
In our baseline analysis, we calculated the probability that elimination could be 
achieved by mass treatment with a 200-µg/kg dose of ivermectin, and we predicted how 
many treatment rounds would be necessary to achieve a 99% probability of elimination. 
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In a sensitivity analysis, we assessed the impact of uncertainty in estimates of efficacy of 
treatment. We also tentatively predicted how many treatment rounds would be necessary 
to achieve elimination when the population was treated with either a higher, 400-µg/kg 
dose of ivermectin or with the combination of diethylcarbamazine and albendazole, 
which is currently recommended for use in mass treatment in India. For mass treatment 
with a 200-µg/kg dose of ivermectin, we further investigated how the results change 
when variation in efficacy of treatment is taken into account, and we studied the impact 
of changes in the interval between treatment rounds and in transmission intensity. 
 
 
Methods 
 
LYMFASIM 
LYMFASIM simulates the transmission and control of W. bancrofti in a dynamic 
population over time. A detailed description of the structure of the model has been 
published elsewhere (Plaisier et al. 1998). Here we restrict ourselves to a brief description. 
A more detailed description of the basic transmission model is provided in chapter 2 of 
this thesis, and in Appendix B of the electronic publication on the website of the Journal 
of Infectious Diseases.  
The transmission model. LYMFASIM is based on stochastic microsimulation. 
The model simulates life histories of human individuals, which, considered together, 
constitute a dynamic population that, because of the birth and death of individuals, 
changes over time. During their lifetimes, individuals gain and lose infections. Human 
individuals differ with respect to exposure to mosquitoes, age at death, ability to develop 
immune responses, inclination to participate in mass treatment, and responsiveness to 
treatment. Consequently, infection intensity varies between humans.  
Transmission is mimicked by modeling both exposure to mosquitoes and the life 
cycle of the parasite. Exposure to mosquitoes increases with the age of the human host, 
until maximum exposure is reached at ~20 years of age. The model mimics uptake of mf 
by biting mosquitoes, the development of mf to L3 in the vector, the release of L3 larvae 
when a mosquito bites, the development of L3 larvae into adult worms in the human 
host, and the mf production by adult female worms after mating. 
Both the development of parasites and their fecundity in human individuals can be 
influenced by host immune responses. In the present study, we consider two alternative 
immune mechanisms—anti-L3 immunity and antifecundity immunity. Anti-L3 immunity 
is triggered by incoming L3 larvae and reduces the probability that incoming larvae 
develop into adult worms; antifecundity immunity is triggered by the presence of adult 
worms and reduces the mf production per female worm. In the absence of boosting, both 
types of immunity diminish, which can be interpreted as loss of immunological memory. 
The predicted mf prevalence in the model is based on mf counts for all individuals 
in the population. Mf counts reflect values that would have been measured by 
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microscopic examination of a 20-µL smear of finger-prick blood taken at night; sampling 
variation in individuals’ mf counts is taken into account and may result in false negatives.  
Elsewhere, we have reported the quantification of the basic transmission model for 
Pondicherry, India, where W. bancrofti is transmitted by C. quinquefasciatus and where the 
precontrol mf prevalence is ~8.5% (Subramanian et al. 2004). As far as possible, this 
quantification was based on knowledge from the literature, observed data, and expert 
opinion: for example, the mosquito-bite rate for an adult human was assumed to be 2200 
per month (Subramanian et al. 2004), the demographic parameters were directly quantified 
on the basis of census data (Registrar General of India and Census Commissioner 1981), 
and the average mf life span and the duration of the prepatent period of adult worms 
were assumed to be 10 and 8 months, respectively (World Health Organization 1992; 
Plaisier et al. 1999). For 2 variants of the model—one including anti-L3 immunity and the 
other including antifecundity immunity—values for biological parameters that could not 
be directly quantified were estimated by fitting the model to longitudinal data from urban 
Pondicherry (a model without immunity could not be fitted to these longitudinal data); in 
this way, in both variants of the model, the life span of adult worms was estimated to be 
>10 years, and the half-life for immunological memory in the absence of boosting was 
estimated to be ~10 year. The 2 model quantifications that were obtained for Pondicherry 
when either anti-L3 immunity or antifecundity immunity was assumed were used in the 
present study. 
Simulation of the effects of mass treatment. The effectiveness of mass treatment 
depends on the assumed efficacy of the treatment regimen. Quantitative estimates of the 
efficacy of treatment with ivermectin are taken from a meta-analysis by Plaisier et al. 
(1999). This meta-analysis used a simple deterministic simulation model to analyze trends 
in mf density and to estimate efficacy of treatment. The results suggest that a 200-µg/kg 
dose of ivermectin kills virtually all mf and also irreversibly reduces net mf production in 
treated individuals. Such a reduction in net mf production could result from different 
mechanisms—for example, the killing of fertile adult worms or a fecundity reduction in 
the female worms; the simple model cannot distinguish between these different 
mechanisms. Because a macrofilaricidal effect could not be demonstrated for ivermectin 
(Dreyer et al. 1995), we assume that the irreversible productivity loss is due to a 
permanent fecundity reduction in the female worms. The quantitative estimates of this 
fecundity reduction were found to depend to a large extent on assumptions regarding mf 
life span (Plaisier et al. 1999). In our baseline simulations, we use the point estimate for 
efficacy of a 200-µg/kg dose of ivermectin that is obtained under the assumption of a 
1-year mf life span; in our sensitivity analysis, we consider a range of other 
quantifications, which take into account the uncertainty in this estimate (see Table 3-1). 
The meta-analysis does not provide insight into the amount of variation in efficacy 
of treatment. In our baseline quantification for a 200-µg/kg dose of ivermectin, we 
assume that efficacy of treatment is constant. In the sensitivity analysis, we consider the 
impact of variation in fecundity reduction that is caused by treatment. We assume that 
this variation is described by a beta distribution with a mean of 0.77 (equal to the constant 
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efficacy in our baseline quantification) and a SD of 0.2. Variation occurs randomly either 
between treatments (intertreatment variation) or between individuals (interindividual 
variation). In intertreatment variation, the proportion of the fecundity reduction is 
randomly drawn from the beta distribution whenever someone is treated, independent of 
the individual being treated. In interindividual variation, the per-treatment proportion of 
the fecundity reduction is randomly drawn from the beta distribution for each individual, 
but an individual will always have the same response; consequently, treatment may always 
have poor efficacy in some individuals but complete efficacy in others.  
Ivermectin alone probably will not be used in mass-treatment programs in India; for 
this region, a combination of diethylcarbamazine and albendazole is recommended 
(Ottesen 2000). Evidence of the efficacy of this combination regimen is still limited 
(Ismail et al. 1998; Shenoy et al. 1999; Dunyo et al. 2000a, b; Shenoy et al. 2000; Ismail et al. 
2001; Dunyo & Simonsen 2002), and quantitative efficacy estimates are not yet available. 
However, this combination is expected to have macrofilaricidal effect: the macrofilaricidal 
efficacy of diethylcarbamazine has been proven (Ottesen 1985; Figueredo-Silva et al. 1996; 
Norões et al. 1997) and may be further enhanced by albendazole, which, when given in 
Table 3-1. Quantification of efficacy of different treatment regimens used in the baseline simula-
tion experiment and sensitivity analysis. 
Treatment Mf killed 
Fecundity 
reduction 
Adult 
worms 
killed 
    
Baseline simulation experiment    
 Ivermectin (200 µg/kg) a 1 0.77 - 
    
Sensitivity analysis    
 Uncertainty in fecundity reduction, 200-µg/kg dose of ivermectin 
  95% Confidence interval    
   Lower boundary a 1 0.64 - 
   Upper boundary a 1 0.85 - 
  Minimum estimate b 1 0.39 - 
  Maximum estimate c 1 0.91 - 
 400-µg/kg dose of ivermectin a 1 0.92 - 
 Combination: diethylcarbamazine plus albendazole d 
  1 1 - 0.50 
  2 1 - 0.75 
NOTE. Data are decimal fractions. Mf, microfilariae, - Effect is not considered. 
a Estimate from meta-analysis, assuming an mf lifespan of 1 year (Plaisier et al. 1999). 
b Estimate from meta-analysis, assuming an mf lifespan of 2 years (Plaisier et al. 1999). 
c Estimate from meta-analysis, assuming an mf lifespan of 6 months (Plaisier et al. 1999). 
D Assumptions are as explained in the LYMFASIM subsection in the main text. 
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high doses, seems to have macrofilaricidal efficacy of its own (Jayakody et al. 1993). We 
assumed that such a treatment kills a constant proportion—either 50% or 75%—of (male 
and female) adult worms and kills 100% of mf. 
The effectiveness of mass treatment also depends on both the population coverage 
and individuals’ compliance with treatment over time. Population coverage is defined as 
the percentage of the total population that receives treatment and is assumed to be the 
same in all treatment rounds, although not always the same individuals are treated. We 
assume a “partial systematic” compliance pattern (Plaisier et al. 1998). Each individual has 
a certain inclination to attend mass-treatment programs: some persons will attend most 
treatment rounds, others hardly any; a random mechanism determines whether the 
individual actually attends. This mechanism was found to give a fair representation of the 
attendance pattern in a mass-treatment program for onchocerciasis in Asubende, Ghana 
(Plaisier et al. 2000). 
 
 
Simulation Experiments 
Each simulation starts with a “warming-up” period, during which the population grows to 
an average size of ~3700 persons and a more or less stable endemic situation develops. 
After this warming-up period, mass treatment is introduced into the simulation. Since 
LYMFASIM is a stochastic model, repeated simulations never give exactly the same 
results, even when the input is exactly the same. When the model quantifications for 
Pondicherry are used, the approximate variation in precontrol prevalence (just before the 
first treatment) is 4%–11%, whereas 10% of the simulations may produce values that are 
more extreme. Similarly, the effects of mass treatment may differ between runs. To deal 
with this stochastic variation in the output, large series of runs are performed, and 
standard statistical techniques are used to analyze the simulation results.  
In a baseline simulation experiment, we assessed the effectiveness of yearly mass 
treatment with a 200-µg/kg dose of ivermectin and compared the outcomes of the 2 
immunity variants of the model—anti-L3 immunity and antifecundity immunity. A large 
series of simulation runs (n=5550) is performed for each of the 2 immunity variants. 
Within each series of runs, we varied the population coverage (10%–100%) and the 
number of treatment rounds (1, 2, …, 15) and kept all other assumptions the same. We 
stored the simulation results for further analysis, recording for each run the precontrol mf 
prevalence and whether infection was eliminated (i.e., zero mf prevalence 40 years after 
the first round of mass treatment). In some simulation runs, infection disappeared by 
chance during the warming-up period; when the precontrol mf prevalence was ≤1.0%, a 
run was excluded from further analysis. 
In a sensitivity analysis, we performed a number of series of 5550 simulation runs, 
using different assumptions. First, we studied the impact of uncertainty regarding the 
estimated fecundity reduction after treatment with a single dose of 200-µg/kg ivermectin. 
Next, we investigated the impact of assuming random or interindividual variation in 
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responsiveness to treatment. We also explored the effectiveness of mass treatment with a 
higher, 400-µg/kg dose of ivermectin and with a combination of diethylcarbamazine and 
albendazole. In addition, the impact of changing the interval between subsequent 
treatment rounds to 6 months or 2 years was studied. Last, we assessed the impact of 
transmission intensity or endemicity level. In the model, endemicity is largely determined 
by the monthly biting rate: a higher biting rate results in higher transmission intensity and, 
consequently, in higher prevalence and greater intensity of infection. We changed the 
mosquito-bite rate of 2200/person/month by ±10% and ±25%—that is, to 1650, 1980, 
2420, and 2750. 
 
 
Statistical Analysis 
The results of each series of simulation runs were analyzed by means of the Statistical 
Package for the Social Sciences program (SPSS version 9), by logistic regression, to 
predict the probability of elimination in relation to the population coverage and the 
number of treatment rounds. For the question at hand, the resulting statistical model can 
be regarded as a summary of the relation between LYMFASIM input and output. Because 
the simulated precontrol mf prevalence varied between runs and may confound the 
relationship, we included this term in the logistic-regression equation. To determine 
which variables and interaction terms had to be included in the equation, we fitted several 
alternative equations to results from our baseline simulation experiment. We considered 
different transformations for the population coverage and for the number of treatment 
rounds, with the condition that the resulting equation would describe a continuous 
increase in the probability of elimination with a higher population coverage and with a 
larger number of treatment rounds. The most parsimonious model that gave a good fit to 
the simulation results of our baseline simulation experiment is given in Equation 3-1; the 
fit of the equation could not be improved by including higher-order terms (likelihood-
ratio test). The following logistic-regression equation was used to analyze and summarize 
all simulations results, with the β’s being estimated separately for each series of runs: 
)ln()ln( 43210 ncncprevY βββββ ++++=  (3-1) 
where Y is the logit transformation of the probability that elimination will not be achieved 
in a simulation, β0–β4 are the estimates of the coefficients in the regression model, “prev” 
is the precontrol mf prevalence, c is the population coverage, and n is the number of 
treatment rounds. 
To check whether the resulting logistic-regression models adequately summarize 
simulation results in our baseline simulation experiment, we compared the predicted 
probability of elimination by logistic regression against the proportion of 100 repeated 
simulation runs that resulted in elimination: for each combination of population coverage 
(40%, 50%, 65%, 80%, and 90%) and number of treatment rounds (2, 4, …, 12), we 
performed 100 runs with exactly the same input and calculated the 95% confidence 
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interval (95% CI) for the proportion of runs resulting in elimination (Newcombe & 
Altman 2000). 
The logistic-regression equations were numerically solved by Microsoft Excel Solver, 
to find the population coverage and the number of treatment rounds that give a 1% 
probability that elimination would not be achieved—or, equivalently, a 99% probability of 
elimination. A precontrol mf prevalence of 8.5% was entered into the formula; this was 
the average precontrol prevalence from the simulations in our baseline-simulation 
experiment, which corresponds to the observed precontrol mf prevalence in Pondicherry 
(Rajagopalan et al. 1989). Only when we analyzed the impact of endemicity level did we 
use the average mf prevalence of the series of simulations for a specific monthly biting 
rate and immunity model.  
 
 
Results 
 
Baseline Simulation Experiment 
Figure 3-1 shows the probability of elimination after yearly mass treatment with a single 
200-µg/kg dose of ivermectin, for both the anti-L3 variant of the model and the 
antifecundity variant of the model. The corresponding regression equations are given in 
the Appendix. The predictions of logistic regression matched well with the results of 100 
repeated runs, for several combinations of population coverage and number of treatment 
rounds. With high population-coverage levels of 80%–90%, a few rounds of mass 
treatment already give a high probability of elimination. When the population coverage in 
each treatment round is low (40%–50%), many rounds of mass treatment will be 
necessary to achieve a high probability of elimination. Inspection of Figure 3-1 shows that 
the results for the anti-L3 variant were not much different from those for the 
antifecundity variant.  
The number of yearly treatment rounds, with a 200-µg/kg dose of ivermectin, and 
the population coverage that are necessary to achieve a 99% probability of elimination are 
shown in Figure 3-2. For both the anti-L3 variant of the model and the antifecundity 
immunity variant of the model, the predicted probability of elimination has reached 99% 
after 8 rounds of mass treatment with ivermectin when coverage is 65%. 
 
 
Sensitivity analysis 
The results of the sensitivity analysis, for a population coverage of 65%, are summarized 
in Figure 3-3. We found differences between the 2 types of immunity and have presented 
the results separately for the 2 models. The horizontal lines in the figures represent the 
results of the baseline simulations. The symbols indicate the number of treatment rounds 
necessary to achieve a 99% probability of elimination, under alternative assumptions. 
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Figure 3-1. Probability of elimination, in relation to the population coverage and the number of 
yearly rounds of mass treatment with a 200-µg/kg dose of ivermectin, for the anti-L3 (A) and 
antifecundity (B) variants of the model. The curves indicate the probability of elimination as 
predicted by the logistic regression model (see Appendix). Each symbol indicates the proportion 
of 100 repeated runs that resulted in elimination for each combination of population-coverage 
proportion (40% [Y], 50% [X], 65% [W], 80% [^], and 90% []]) and yearly treatment rounds (2, 4, 
6, 8, 10, and 12); the vertical bars indicate the 95% confidence intervals. To be able to 
differentiate these confidence intervals for different population-coverage levels when curves 
overlap, several points have been displayed slightly to either the right or the left of the exact 
number of treatment rounds.
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Figure 3-2. Number of yearly treatment rounds, with a 200-µg/kg dose of ivermectin, and the 
population coverage that are necessary to achieve a 99% probability of elimination under 
baseline assumptions for anti-L3 (unbroken line) and antifecundity (broken line) immunity. The
"drop lines" (i.e., the fainter, intersecting horizontal and vertical lines) indicate the number of 
treatment rounds that would be necessary to achieve a 99% probability of elimination, when the 
population coverage is 65%, calculated by solving the regression equations of the Appendix.
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The estimated number of treatment rounds was strongly influenced by uncertainty in 
the estimated fecundity reduction. In the best case, 7 treatment rounds were sufficient; in 
the worst case, 15 or 16 treatment rounds were necessary to achieve elimination, 
depending on the type of immunity. The results were somewhat less favorable when 
variation in the efficacy of treatment was taken into account, and this was especially true 
when the response to treatment in some individuals was systematically lower than that in 
others (i.e., interindividual variation). 
The number of treatment rounds was reduced when more-effective treatment 
regimens were used. With a higher dose of ivermectin, the total number of treatment 
rounds necessary was reduced by 1 or 2, respectively, when anti-L3 immunity or 
antifecundity immunity was assumed. For combination treatment, the impact clearly 
depended on the assumed macrofilaricidal efficacy. When 50% of adult worms were killed 
by combination treatment, this treatment regimen did not give much better results than 
did a 200-µg/kg dose of ivermectin. However, when 75% of worms were killed, the 
number of treatment rounds necessary to achieve elimination was reduced to 5 or 6.  
Reducing the interval between subsequent treatment rounds resulted in a small 
increase in the total number of treatment rounds necessary to achieve a 99% probability 
of elimination, although the total duration of the mass-treatment program was reduced. 
Increasing the interval to 2 years resulted in a slight reduction in the necessary number of 
treatment rounds. 
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Figure 3-3. Sensitivity analysis of the number of mass-treatment rounds necessary to achieve a 
99% probability of elimination, when the population coverage is 65%, for the anti-L3 (A) and 
antifecundity (B) immunity models. The horizontal lines indicate the baseline situation and 
correspond to the values indicated by the drop lines in Figure 3-2. The symbols indicate the 
number of treatment rounds necessary to achieve elimination when one of the assumptions is 
changed; the way in which assumptions were changed is noted at the top of each column. For 
quantifications of treatment efficacy (pertaining to the “Uncertainty in drug efficacy,” Variation in 
efficacy,” and “Other treatment regimens” sections of the figure), see Table 3-1. For precontrol Mf 
prevalence levels corresponding to alternative monthly biting rates, see the “Sensitivity Analysis”
subsection in the main text. Abbreviations: alb, albendazole; CI, 95% confidence interval; DEC, 
diethylcarbamazine; iverm, ivermectin.
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The right-hand column of Figure 3-3 shows the impact of endemicity level when the 
mosquito-bite rate of 2200/person/month was varied by ±10% and 25%—that is, to 
1650, 1980, 2420, and 2750. The corresponding average precontrol mf prevalence levels 
were 5.5%, 7.6%, 9.2%, and 10.0% when anti-L3 immunity was assumed and were 4.7%, 
7.4%, 9.5%, and 10.5% when antifecundity immunity was assumed. Endemicity appeared 
to have a strong impact on the total number of treatment rounds necessary to achieve 
interruption of transmission: it was much more difficult to achieve elimination when 
endemicity levels were higher and much easier when they were lower. 
 
 
Discussion 
We used LYMFASIM to assess the prospects for elimination of lymphatic filariasis by 
mass treatment and to determine the number of treatment rounds necessary to achieve a 
99% probability of elimination. Simulations were performed for a community with 8.5% 
precontrol mf prevalence, reflecting the endemic situation in Pondicherry, India. 
 
 
Baseline Simulation Experiment 
Coverage. Our baseline-simulation experiment concerned mass treatment with a 
200-µg/kg dose of ivermectin, a treatment regimen for which evidence-based estimates of 
efficacy are available (Plaisier et al. 1999). The number of treatment rounds necessary to 
achieve elimination was found to depend to a large extent on the population coverage. 
When the population coverage in each treatment round was 65%, 8 yearly rounds of mass 
treatment gave a 99% probability of elimination, for both types of immunity; however, 
when the population coverage in each treatment round was low (40%–50%), many more 
yearly rounds of mass treatment were necessary. Data from a large-scale mass-treatment 
program in Tamil Nadu, India, showed that a population-coverage level of 65% is realistic 
in rural areas but that low population coverage, ~40%, occurs in urban areas (Ramaiah et 
al. 2000); clearly, for successful control, the population coverage in urban areas should be 
improved.  
Efficacy of treatment. The estimated number of treatment rounds necessary to 
achieve a 99% probability of elimination depended to a large extent on assumptions 
regarding efficacy of treatment: with 65% population coverage, the estimates ranged from 
7 to 10 when the 95% CI for the estimated fecundity reduction for an mf life span of 1 
year was taken into account; the estimates ranged from 6 to 15 when we used the more 
extreme, minimum and maximum estimates of fecundity reduction. The high level of 
uncertainty in estimates of efficacy of treatment hampers accurate prediction of the 
impact of mass treatment. More-precise estimates of efficacy of treatment are needed. It 
will not be easy to get better estimates, however, because the adult-worm burden in the 
human body cannot be measured directly.  
Chapter 3 
 62 
Variation in efficacy of treatment. The amount of variation in efficacy of 
treatment influences the impact of mass treatment; and, especially when there is 
systematic interindividual variation in efficacy of treatment, results may be less favorable. 
To clear infection in individuals who always have a poor response to treatment, more 
treatments are necessary, compared with what is necessary in individuals who have a 
better response to treatment. As yet, there is not much evidence regarding the extent of 
interindividual variation in responsiveness to treatment.  
Treatment regimen. The prospects for elimination obviously depend on the 
treatment regimen used. A single 400-µg/kg dose of ivermectin is more effective than a 
lower, 200-µg/kg dose (Cao et al. 1997; Plaisier et al. 1999; Brown et al. 2000); indeed, with 
65% population coverage, the number of treatment rounds necessary to achieve 
elimination could be reduced by 1 or 2 when the higher dose is used. Currently, a 
combination of diethylcarbamazine and albendazole is recommended for use in mass 
treatment in India (Ottesen 2000). Quantitative estimates of the efficacy of 
diethylcarbamazine plus albendazole are not yet available. To predict the possible impact 
of mass treatment with this combination regimen, we used 2 plausible, alternative 
quantifications, which differed in terms of macrofilaricidal efficacy. If a single treatment 
would kill 50% of adult worms and all mf that are present in a human host, then mass 
treatment with diethylcarbamazine plus albendazole is approximately as effective as mass 
treatment with a 200-µg/kg dose of ivermectin. This may be unexpected, because 
treatment with ivermectin, which reduces mf production by 77%, initially may result in a 
stronger reduction in transmission intensity. However, because male worms are not 
affected by ivermectin, recrudescence of transmission may occur more easily after 
treatment with ivermectin than after treatment with the combination regimen, which is 
assumed to kill both male and female worms. If combination treatment would kill 75% of 
the worms, the goal of elimination could be achieved in 5 or 6 rounds, with 65% 
population coverage. 
Important potential benefits of using a combination of 2 drugs with different 
working mechanisms include (1) a reduction in the number of people with no or poor 
response to treatment and (2) a reduction in the risk that parasites develop resistance 
against treatment. Furthermore, albendazole (like ivermectin) also has an effect on other 
parasitic diseases as well, which may lead to additional public health benefits and may 
enhance compliance with the mass-treatment program (Ottesen et al. 1999; Horton et al. 
2000). 
Treatment interval. The intertreatment interval influences the number of treatment 
rounds necessary to achieve elimination, through several mechanisms. Giving the same 
number of treatments within a shorter period causes a more rapid decline in transmission 
intensity, which tends to increase the probability of elimination. This effect is 
counteracted by a higher number of (preexisting and new) worms that survive during the 
control program and remain fertile, resulting in a higher level of residual transmission and 
a lower probability of elimination. In our simulations, this relates to male worms that are 
never affected by ivermectin and to female worms that, by chance, escape treatment. 
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These opposing mechanisms influence the number of treatment rounds necessary to 
achieve elimination. This number further depends on the immune status of the 
population, which, in turn, is related to the effectiveness and duration of control. When 
coverage was 65%, the number of treatment rounds necessary to achieve elimination was 
lowest for a 2-year interval; however, both for practical reasons and for reduction of the 
total duration of the program, a 1-year interval may be preferable.  
Endemicity level. A very important determinant of the number of treatment 
rounds necessary to achieve elimination is the precontrol endemicity level. In our baseline 
simulation experiment, precontrol mf prevalence was, on average, 8.5%. We investigated 
the impact that endemicity level has on the prospects for elimination, by varying the 
monthly biting rate. A higher monthly biting rate results in a higher prevalence of 
infection, a higher precontrol worm load, and a higher probability that any residual 
transmission will cause recurrence of infection. Compared with the large variation in mf 
prevalence levels that occurs in the field, the 4.5%–10.5% prevalence range considered in 
the sensitivity analysis is relatively small; nonetheless, it resulted in a big difference in the 
number of treatments necessary to interrupt transmission (4–10 rounds, with 65% 
population coverage).  
Model variants. All analyses were performed with 2 variants of the model, with 
different assumptions regarding the type of immune regulation. Although several studies 
have suggested that acquired immunity plays a role in lymphatic filariasis (Day et al. 1991; 
Steel et al. 1996; Michael & Bundy 1998; Michael 2000; Subramanian et al. 2004), the 
human immune response against this infection is not fully understood. With regard to the 
estimated number of treatment rounds necessary to achieve elimination, we found small 
differences between the 2 models, but the main conclusions did not change.  
Pattern of attendance. An important threat to the effectiveness of mass treatment 
is the existence of a group of individuals who never attend the mass-treatment program 
and therefore continue to contribute to transmission of lymphatic filariasis in the 
population. This has not been investigated in the present study, but it has been clearly 
presented in a previous model exercise (Plaisier et al. 2000). It is very likely that some 
people will systematically miss treatment, because of either refusal, absence, or 
ineligibility.  
 
 
Elimination 
The way in which elimination is defined influences the results of our analysis. In the 
literature, the term “elimination” has been used to denote complete absence of an 
infectious agent, absence of transmission, absence of specific clinical manifestations 
caused by infection, or control of clinical manifestations such that an infection is no 
longer regarded as a public health problem (Centers for Disease Control 1993). The 
present study considers elimination of transmission, which we have operationalized as 
zero mf prevalence 40 years after the start of control, with mf positivity determined in 
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each individual in the population by a 20-µL thick smear of blood drawn by finger prick. 
We assessed mf prevalence after a 40-year period because this interval allows transmission 
to decline slowly after cessation of control. Zero mf prevalence does not always imply 
absence of infection, because individuals may still carry single-worm or single-sex 
infections and because mf tests may give false-negative results. It is extremely unlikely 
that this residual infection would cause recrudescence. The simulated mf prevalence 
shows a continuous decline after cessation of control, before finally reaching zero, 
indicating that the overall mf load already had been brought below the threshold level 
necessary to sustain transmission. In the Pacific Islands, where filariasis is transmitted by 
Aedes mosquitoes, recrudescence of infection has been found to occur <2 years after mass 
treatment, although mf prevalence had been reduced to almost zero (Ichimori 2001); this 
fast recrudescence probably is due to the high efficiency of Aedes in transmitting infection 
at low mf densities. 
With our definition of elimination, we have provided a minimum estimate of the 
efforts necessary to achieve local elimination. If elimination is to be achieved sooner or if 
programs are aimed at elimination of infection rather than at interruption of transmission, 
mass treatment will have to be continued for a longer period. 
 
 
Underlying assumptions 
The numerical results of our analyses depend on a number of underlying assumptions 
concerning both the circumstances under which control programs are carried out and the 
effectiveness of these programs. First, the simulated community is geographically isolated: 
there is no human migration into or out of the endemic area, and there is no mosquito 
invasion from other areas. The impact of these factors depends on several aspects, 
including the rates of human migration and mosquito invasion, whether control programs 
cover the outside population, the endemicity level in the outside population, the biting 
rate, and the efficiency of vectors in the transmission of infection. Elimination obviously 
becomes more difficult when there is human immigration or mosquito invasion from 
endemic areas. Second, we have assumed that the endemic situation had been stable 
before the start of control efforts and that the biting rate is constant over time. An 
increasing trend in either endemicity level or biting rate will make it more difficult to 
achieve elimination, and vice versa. Third, we have assumed that mosquitoes 
homogeneously mix with the human population, although some human individuals may 
be bitten more frequently than others. In practice, because of the limited flight range of 
mosquitoes, transmission may be more focal, and there may be geographical subareas 
with higher vector density, transmission, and infection intensity. Foci of more-intense 
transmission may be found, for example, in the proximity of breeding sites (Gad et al. 
1994). To eliminate lymphatic filariasis from these foci, mass treatment would have to be 
continued longer than would be expected on the basis of the overall prevalence in the 
community. 
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We have assumed that efficacy of treatment does not depend on the number of 
times that an individual has previously been treated. Furthermore, the possible existence 
of either parasites that are resistant to treatment or development of resistance in the 
parasite population has not been taken into account. In practice, these assumptions may 
not hold. 
 
 
Generalizability 
The model used in the present study was quantified for Pondicherry, India. Differences in 
the vector species, in the parasite strain, and in the prevalence and intensity of the 
infection in the population limit the generalizability of the results of our simulation. 
Mosquito species differ with respect to the proportion of engorged mf developing into 
infectious L3 larvae, efficiency in transmission of infection to the human host, and 
survival in the presence or absence of parasites (Southgate 1992). In Pondicherry, 
W. bancrofti infection is transmitted by C. quinquefasciatus. This parasite-vector complex 
shows “limitation”—that is, a decreasing yield of L3 with increasing mf uptake by the 
mosquito (Subramanian et al. 1998). The effectiveness of control strategies may be 
different when the number of L3 larvae developing per engorged mf either is 
proportional to or increases with mf uptake (i.e., when there is either proportionality or 
facilitation). Differences between parasite strains—for example, with respect to either life 
span or mf production—also may influence the number of treatment rounds necessary to 
achieve elimination. For areas with the same vector-parasite combination, our sensitivity 
analysis of the monthly biting rate may give some indication of the efforts necessary to 
achieve elimination of filariasis in areas with higher or lower endemicity levels; however, 
in this case, too, generalizability is limited, because of demographic differences between 
populations in different areas, differences in heterogeneity in exposure to mosquito bites, 
and differences in individuals' inclinations to comply with mass treatment.  
 
 
Prospects for elimination 
Because factors such as human migration and resistance were not considered in the 
present study, our results should be regarded with caution; nonetheless, the prospects for 
elimination of lymphatic filariasis by mass treatment in Pondicherry, India, are positive. 
Our predictions show that elimination is very likely after 8 rounds of mass treatment with 
ivermectin, provided that population-coverage levels are sufficiently high (i.e., ≥65%). 
The number of treatment rounds necessary to achieve elimination depends, to a large 
extent, on coverage, efficacy of the treatment regimen, and endemicity level. Although the 
results in Pondicherry cannot simply be generalized to other areas, qualitatively our 
conclusions are applicable in other situations with the same vector-parasite complex.  
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Appendix  
 
Logistic regression equations for the baseline simulation experiment 
Logistic regression analysis of results from our baseline simulation experiment, in which 
we simulated the impact of mass treatment with a 200-µg/kg dose of ivermectin, yielded 
the following equations:  
- for anti-L3 immunity, Y = 17.98 + 0.70 prev - 19.45 c - 3.74 ln(n) - 6.31 c ln(n);  
- for antifecundity immunity, Y = 9.29 +0.59 prev - 10.56 c - 1.35 ln(n) - 7.11 c ln(n).  
Results are shown in Figures 3-1 and 3-2. The logistic regression analysis was based on 
simulations with up to 15 rounds of mass treatment; extrapolation of results to more 
treatment rounds is not warranted. 
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Mass treatment with antifilarial drugs is the mainstay of the Global Programme to 
Eliminate Lymphatic Filariasis (Molyneux & Zagaria 2002), a parasitic disease which is an 
important cause of chronic morbidity in tropical countries. Current drugs—
diethylcarbamazine or ivermectin, usually given with albendazole—effectively kill the 
microfilariae (larval offspring of the parasite), but their effect on the macrofilariae (adult 
worms) is incomplete. The search for macrofilaricides remains a research priority 
(Anonymous 2004). One of the most promising leads is treatment directed at Wolbachia, 
the intracellular bacterial symbiont of filarial parasites (Taylor et al. 2000). In a recent 
study, Mark Taylor et al. provided convincing evidence that depletion of Wolbachia by 
doxycycline kills most adult worms, without causing severe side-effects (Taylor et al. 
2005). 
An earlier study suggested that doxycycline has no direct microfilaricidal effect, but 
blocks the adult worms in producing microfilariae (Hoerauf et al. 2003). Taylor et al. 
(2005) showed for the first time that doxycycline indirectly kills the adult worm. Their 
conclusion is based on the strong reduction in the number of worm nests in the scrotum 
and levels of filarial antigen in the blood 14 months after treatment. The complete 
absence of microfilariae is consistent with death of the adult worms. 
The 80% difference between the doxycycline and placebo group in the mean 
number of worm nests observed by Taylor et al. (2005) with ultrasound suggests that 
about 80% of the adult worms were killed. (It could be higher if remaining worm nests 
contain fewer worms, or lower if smaller nests are missed on ultrasound.) This 
macrofilaricidal effect of doxycycline is high compared with that of the currently used 
drugs. No macrofilaricidal effect was found for ivermectin (Dreyer et al. 1995). Although 
there are indications that the fertility of worms is reduced (Plaisier et al. 1999), ivermectin 
is usually considered a pure microfilaricide, killing nearly all microfilariae (Richard-
Lenoble et al. 2003). Some macrofilaricidal effect might occur, though, if ivermectin is 
combined with the broad-spectrum albendazole (Ottesen et al. 1999). A single dose of 
diethylcarbamazine has good microfilaricidal effect and is thought to kill about 50% of 
adult worms (Norões et al. 1997; Kshirsagar et al. 2004). Only the combination of 
diethylcarbamazine and albendazole had macrofilaricidal effects comparable to 
doxycycline (56–87%) (El Setouhy et al. 2004; Kshirsagar et al. 2004). 
The availability of a new generation of drugs with a different working mechanism 
(killing the symbiont bacteria) is good news. New drugs are needed to anticipate the 
possible development of resistance in the many mass-treatment programmes that have 
been started worldwide for the elimination of lymphatic filariasis. For African countries, a 
new macrofilaricidal drug would be especially welcome: diethylcarbamazine cannot be 
used in this region because of severe side-effects in Onchocerca-infected people, and 
ivermectin is contraindicated where Loa loa is endemic. Although the 8-week treatment 
regimen (200 mg doxycycline daily) is not suitable for use in mass administration, as 
Taylor et al. rightly mentioned, it is interesting to contemplate how effective doxycycline 
would be if used in mass treatment. 
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Models show that mass treatment with doxycycline could well be more effective 
than mass treatment with ivermectin plus albendazole or only diethylcarbamazine to 
achieve elimination (Table 4-1). The effectiveness of doxycycline would be comparable to 
that of diethylcarbamazine plus albendazole, even though doxycycline was assumed to 
have no microfilaricidal effect. With either of these regimens, six annual rounds of mass 
treatment with 65% coverage would suffice in an endemic setting such as Pondicherry 
(India), whereas (a less realistic) 80% coverage would require only four rounds. These 
estimates should, however, be regarded with some care. The assumed macrofilaricidal 
effects are based on a few studies, and individual variation in the effects of treatment 
(which might even double the time to elimination if some people respond poorly) was not 
considered. Possible sterilisation of worms by doxycycline and ivermectin was also not 
considered, but the effectiveness of mass treatment would be similar if worms are 
sterilised rather than killed. In regions other than Pondicherry, elimination might be 
harder to achieve because of more favourable conditions for transmission or more 
problematic operational conditions. Then programmes could shift their focus to the less 
ambitious aim of reducing lymphatic filariasis as a public-health problem, but conclusions 
about the performance of doxycycline relative to other drugs will not change.  
In conclusion, anti-Wolbachia treatment has high potential for use in lymphatic 
filariasis control. Research should now focus on identification of regimens, based on 
doxycycline or other antibiotics, that are practical for use in mass treatment and have 
similar strong macrofilaricidal, or equivalently sterilising, effects to doxycycline. 
 
 
 
 
Table 4-1. Predicted number of annual rounds of mass drug-treatment required to achieve 
elimination with 99% certainty in an area such as Pondicherry.a  
 
Assumed treatment effects 
(proportion killed) 
Predicted number of rounds for 
elimination, with coverage 
Drug(s) adult worms microfilariae 65%  80%  
Ivermectin + albendazole 35% 100% 10 6 
Diethylcarbamazine 50% 70% 8 5 
Diethylcarbamazine + 
albendazole 
65% 70% 6 4 
Doxycycline 80% 0% 6 4 
a Pretreatment prevalence of microfilaraemia = 8.5%. A simulation model for transmission of 
lymphatic filariasis, validated against longitudinal data from Pondicherry (Subramanian et al. 
2004), was used as explained elsewhere (Stolk et al. 2003). Assumptions of efficacy were 
based on literature review, including Taylor et al. (2005) 
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Abstract 
Mathematical simulation models for transmission and control of lymphatic filariasis are 
useful to study the prospects for elimination of lymphatic filariasis. Two simulation 
models are currently being used. The first, EPIFIL, is a population-based, deterministic 
model that simulates average trends in infection intensity over time. The second, 
LYMFASIM, is an individual-based, stochastic model that simulates acquisition and loss 
of infection for each individual in the simulated population, taking account of individual 
characteristics. The two models, which were both quantified using data from a vector 
control programme in Pondicherry (India), give similar predictions of the coverage and 
number of treatment rounds required to bring microfilaraemia prevalence below a 
threshold level of 0.5%. LYMFASIM can in addition assess the risk of infection 
recurrence after reaching this threshold. The two main challenges for future work are: 1) 
quantification of the models for simulation of transmission dynamics in other regions; 2) 
application of the models for decision-making in ongoing elimination programmes. 
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Introduction 
Lymphatic filariasis is a mosquito-borne parasitic disease and an important cause of 
chronic morbidity in tropical countries. In 1998, the Global Programme to Eliminate 
Lymphatic Filariasis (GPELF) was initiated, aiming at the worldwide elimination of this 
parasitic disease as a public health problem (Molyneux & Zagaria 2002). The main 
strategy in the global programme is to interrupt transmission by annual population 
treatment with antifilarial drugs (diethylcarbamazine or ivermectin plus albendazole). In 
addition, morbidity management should reduce the suffering of patients who have 
chronic manifestations. Thirty-two countries had started elimination programmes in 2002 
(World Health Organization 2003) and this number is still growing.  
The goal of elimination is ambitious. Past mass treatment programmes had varying 
degrees of success. In some areas transmission was apparently interrupted (Schlemper et 
al. 2000). In other areas elimination was not achieved, in spite of long-term control 
programmes (VCRC, Annual Report 2003; Esterre et al. 2001). How strategic choices, and 
operational or biological factors contribute to success or failure is poorly understood. It is 
unknown which coverage and duration of mass treatment programmes (and possible 
additional measures) are required to achieve elimination and how this depends on the 
vector and parasite strain, endemicity level, and the drugs that are used. Mathematical 
models can help to clarify these issues and application of such models is considered 
important for support of GPELF (Anonymous 2004).  
Mathematical models have been used widely in parasitology. They help to 
understand the complex transmission dynamics of parasitic diseases and are useful tools 
for planning and evaluation of control programmes (Habbema et al. 1992; Goodman 
1994). Models have also played an important role in lymphatic filariasis research (Das & 
Subramanian 2002; Michael et al. 2004). Targeted models, which consider part of the 
processes involved in transmission, helped for example to clarify the role of acquired 
immunity (Michael & Bundy 1998; Michael et al. 2001) and the macrofilaricidal effects of 
treatment (Plaisier et al. 1999; Stolk et al. in press). This paper concentrates on so-called 
‘full transmission models’, which relate the rate of transmission to the intensity and 
distribution of infection in a human population and can be used to predict the impact of 
interventions on transmission and the probability of elimination. 
To our knowledge, three full transmission models have been described in the 
literature. The first was specifically developed for the evaluation of a vector control 
programme and is not considered here (Rochet 1990). The two other models, called 
EPIFIL (Chan et al. 1998; Norman et al. 2000) and LYMFASIM (Plaisier et al. 1998), are 
both being used for planning and evaluation of elimination programmes. After a brief 
introduction of the processes involved in transmission and control of lymphatic filariasis, 
we describe the basic structure of these models, compare and discuss some critical model 
predictions, and outline future research priorities.  
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Figure 5-1. Transmission cycle of lymphatic filariasis with density dependent mechanisms. This 
figure shows the life cycle of Wuchereria bancrofti, the main parasitic cause of lymphatic filariasis. 
The adult worms (macrofilariae) are located in the lymphatic system of the human host, where 
they live for 5-10 years (Vanamail et al. 1996; Subramanian et al. 2004). After mating with male 
worms, female worms can produce millions of microfilariae (mf), which can be found in the 
bloodstream and have a lifespan of 6-24 months (Plaisier et al. 1999). A mosquito that takes a 
blood meal may engorge some mf. Inside the mosquito, mf develop in about 12 days into L3 
stage larvae (L3), which are infectious to humans. When the mosquito takes another blood meal, 
the L3 can enter the human body and some will migrate to the lymphatic system and will develop 
into mature adult worms. The immature period lasts about 6-12 months (World Health 
Organization 1992). Mf cannot develop into adult worms without passing through the 
developmental stages in the mosquito. Larval development and mosquito survival are density 
dependent (Subramanian et al. 1998; Krishnamoorthy et al. 2004). Two possible mechanisms of 
acquired immunity are shown (Michael & Bundy 1998). 
Mosquito survival 
declines with 
higher Mf intake The proportion of Mf developing into 
L3 declines (or, in some species, 
increases) with higher Mf intake
Acquired immunity: 
reduced L3 survival 
with higher exposure
Acquired immunity:    
reduced fecundity 
with higher
worm load
human
mosquito
Adult
worms
Larval 
development
Lifespan 5 – 10 years
~ 12 days
Immature period 6-12 months Lifespan 6 –24 months
Mf in 
blood
L3
larvae
 
Processes in lymphatic filariasis transmission and control 
Models for lymphatic filariasis control basically describe the main biological processes 
involved in transmission (Figure 5-1). To study the dynamics of transmission and how 
intervention affects transmission, it is specifically important to take account of density-
dependence and heterogeneities (Anderson & May 1991; Churcher et al. 2005; Duerr et al. 
2005).  
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Density dependence means that the outcome of a process depends on the 
abundance of the parasite stages involved. Several limiting mechanisms may reduce 
transmission when the average worm burden increases. For example, the proportion of 
microfilariae (mf) that develops into infectious L3 larvae saturates in Culex quinquefasciatus 
when the mf intake is higher, limiting the transmission of infection (Southgate & Bryan 
1992; Subramanian et al. 1998). Further, the survival probability of mosquitoes is reported 
to reduce with their infection load (Krishnamoorthy et al. 2004). Acquired immunity may 
limit infection intensity in the human host. Different mechanisms for this have been 
proposed (Woolhouse 1992), but evidence for the operation of such immunity is 
inconclusive (Michael & Bundy 1998; Stolk et al. 2004). These limiting mechanisms all 
negatively affect the impact of interventions, because transmission becomes relatively 
more efficient when infection levels are lower. Density dependence, however, may also 
occur in the opposite direction (called facilitation). The probability that a female worm 
mates with a male worm increases with higher worm burdens. Further, in some 
anopheline mosquito species, larval development might increase with higher mf intake 
(Southgate & Bryan 1992). It is unknown whether density dependence, either limitation 
or facilitation, occurs in parasite establishment and survival in humans, their fertility, and 
mf survival.  
The term heterogeneity points at variation between individuals. Individuals differ for 
example in genetic background, nutritional status and behaviour, which may cause 
differences in exposure to mosquitoes, susceptibility to infection, and the survival, 
maturation and fecundity of parasites. Therefore, individuals may be predisposed to heavy 
or light infection, leading to an aggregated or overdispersed distribution of parasites (with 
a few hosts harbouring the majority of the parasites). Individuals also differ in compliance 
and responsiveness to treatment, which may also contribute to aggregation of parasites 
(Plaisier et al. 1999; Stolk et al. in press). This aggregation enhances transmission, because 
it increases the probability that female and male worms mate. Heterogeneity may also 
occur in the parasite population, e.g. with respect to the life span and resistance to 
treatment. 
 
 
Available models 
Both available models for lymphatic filariasis transmission and control, EPIFIL and 
LYMFASIM, mainly differ in the amount of detail that is included. Specific variants of 
both models have been developed for Wuchereria bancrofti transmitted by Culex 
quinquefasciatus, using data from an integrated vector management control programme that 
was carried out in Pondicherry, India, from 1981-1985 (Norman et al. 2000; Subramanian 
et al. 2004). These ‘Pondicherry model variants’ are described below. Table 5-1 gives the 
quantification of several key biological parameters of the models. Figure 5-2 illustrates the 
good fit of both models to the precontrol (1981) data from Pondicherry. 
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Table 5-1. Quantification of several key biological parameters in the EPIFIL and LYMFASIM 
model variants for Pondicherry, where Wuchereria bancrofti is transmitted by Culex quinque-
fasciatus.  
  LYMFASIM 
Parameter EPIFIL 
Anti-L3 
immunity 
Anti-
fecundity 
immunity 
Parasite lifecycle   
 Average adult worm life span in years (type of 
distribution)  
8 a 10.2 b 11.8 b 
 Average mf life span in months (type of distribution) 10 a 10 a 10 a 
 Premature period in months - 8 8 
Exposure variation by age   
 Exposure at age zero as fraction of maximum 
exposure 
0 0.26 0.40 
 Age in years at which maximum exposure is 
achieved 
9 19.1 21.3 
Density dependence in mosquitoes   
 Maximum number of L3 larvae that can develop in 
mosquitoes at high mf intensities 
6 c 6.6 d 6.6 d 
Acquired immunity   
 Duration of acquired immunity in years lifelong 9.6 e 11.2 e 
Other parameters   
 Monthly biting rate 5760 2200 2200 
 Proportion of L3 larvae in mosquitoes that enters the 
human host when a mosquito bites 
0.414*0.32 = 
0.13 
0.1 0.1 
 Proportion of inoculated L3 larvae that develops 
successfully into adult worms (x103) 
0.113 1.03 f 0.42 
 Mf production per worm 2 0.61 g 4.03 g,h 
- Not considered in the model; mf, microfilaria. 
a Assuming a negative exponential distribution. 
b Assuming a Weibull distribution with shape parameter α=2. 
c Exponential saturating function with initial increase when mf intake increases from zero = 0.047. 
d Hyperbolic saturating function with initial increase when mf intake increases from zero = 0.09. 
e This parameter defines the period in which the strength of the immune response is halved in the 
absence of boosting. 
f In the absence of anti-L3 immunity. 
g In the presence of at least 1 male worm, scaled to the number of mf per 20 µl peripheral blood. 
h In the absence of anti-fecundity immunity. 
 
 
 
 
EPIFIL  
EPIFIL simulates the average course of infection over age and time in a human 
population by a set of differential equations. The human population is constant in size 
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and age-structure. Limitation in the transmission of infection by culicine mosquitoes is 
taken into account, so that the number of infectious L3 larvae that can develop in 
mosquitoes saturates at higher mf intensities. Acquired immunity is included as a second 
limiting mechanism: it is triggered by incoming L3 larvae and reduces the probability that 
new larvae develop into adult worms. Heterogeneity is only included by age-related 
exposure to mosquitoes: i.e. the risk of infection increases with age, until a maximum 
level is reached at the age of 9 years. The mf prevalence is calculated using a negative 
binomial distribution, assuming a certain amount of aggregation of parasites in the human 
population.  
The model can be used to simulate the impact of vector control or mass treatment. 
Vector control is assumed to reduce the mosquito biting rate. Mass treatment leads to 
killing of a proportion of adult worms or mf and to temporal infertility of worms, 
depending on the proportion of the population that receives treatment and characteristics 
of the treatment regimen.  
The design of this population-based, deterministic model is based on a general 
differential equation framework describing the dynamics of macroparasitic infections 
(Anderson & May 1985, 1991; Woolhouse 1992).  
 
 
LYMFASIM  
LYMFASIM simulates the acquisition and loss of worms over age and time in a discrete 
number of human individuals, using stochastic microsimulation. Individuals interact 
through biting mosquitoes and together they form a dynamic population of which the 
size and age-structure may change over time. Like EPIFIL, LYMFASIM takes account of 
limitation in the proportion of engorged mf that develops into L3 larvae inside the 
mosquito and of acquired immunity in human hosts. Two model variants were developed 
for Pondicherry, which differed with respect to the type of acquired immunity: ‘anti-L3’ 
immunity is triggered by incoming L3 larvae and reduces the probability of successful 
adult worm establishment; ‘anti-fecundity’ immunity is triggered by the presence of adult 
worms and reduces the rate of mf production by female worms. By considering individual 
worms in individual hosts, the model automatically takes account of the declining mating 
probability of female and male worms with lower average infection intensities. Age-
dependent exposure is included, assuming that exposure increases until a maximum is 
reached at about 20 years of age. Other factors contributing to heterogeneity are variation 
in exposure to infection within age groups, inclination to participate in treatment 
programmes, the response to treatment, and the ability to develop immune responses. 
Parasites may vary with respect to their life span (about 10 years on average). Individual 
mf intensities are translated into the number of mf that would be counted in a 20 µl 
blood smear, taking account of random variability in these counts and reduced sensitivity 
of diagnostic tests at lower mf densities. The mf prevalence and (geometric or arithmetic) 
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Figure 5-2. Comparison of model predictions with microfilaraemia prevalence by age observed 
before the start of vector control in Pondicherry, India, in 1981. (A) LYMFASIM predictions for 
models with anti-L3 immunity (solid line), anti-fecundity immunity (dashed line), and a model 
variant without immunity (dot-dashed line); the latter model does not fit the data and was 
therefore rejected. Source: Subramanian et al. (2004). (B) EPIFIL predictions of a model with 
acquired immunity. Source: Norman et al. (2000). Symbols in both graphs indicate the observed 
prevalence levels with corresponding confidence intervals. Figures were reprinted with 
permission.
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mean mf intensity can be directly calculated from the smear counts, using data from all 
simulated individuals or specific subgroups.  
Similar to EPIFIL, LYMFASIM simulates the impact of vector control by reducing 
the mosquito biting rate. Treatment takes place at the individual level, and results in 
killing (part) of adult worms or mf and a temporal or permanent reduction in the fertility 
of female worms. Selective or mass treatment can be simulated.  
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This individual-based model uses the technique of stochastic microsimulation, which 
was earlier applied in the modelling of onchocerciasis transmission and control (Habbema 
et al. 1996).  
 
 
Comparison of model predictions 
Both EPIFIL and LYMFASIM have been used to predict the impact of control measures 
(Das & Subramanian 2002; Stolk et al. 2003; Michael et al. 2004; Stolk et al. 2005). In this 
report, we focus on model predictions of the coverage and duration of annual mass 
treatment programmes that will be required for elimination. All published predictions 
were based on the Pondicherry variants of the model, although acquired immunity was 
left out of the model in the EPIFIL predictions. From the predictions of both models we 
can conclude that it is possible to eliminate lymphatic filariasis by yearly mass treatment, 
but the number of treatment rounds largely depends on coverage, precontrol mf 
prevalence and the macrofilaricidal effects of drugs. This is illustrated in Tables 5-2 and 
5-3, and Figure 5-3. Often the required number of yearly treatment rounds is predicted to 
be higher than the 4-6 rounds, which was hoped to be sufficient when GPELF was 
initiated. As an alternative to longer programmes, one might consider more frequent mass 
treatment (e.g. half-yearly) or applying vector control in addition to mass treatment 
(Figure 5-4). 
The predictions of EPIFIL and LYMFASIM cannot be compared directly, because 
the original publications reported results for different treatment regimens, with different 
assumptions on efficacy of the drugs, and different precontrol mf prevalence levels. 
Further, different criteria for elimination were used: in EPIFIL elimination was assumed 
to occur if the mf prevalence after treatment was below 0.5%; in LYMFASIM elimination 
 
 
 
 
Table 5-2. LYMFASIM – Predicted number of annual rounds of mass drug treatment required to
achieve elimination in 99% of the simulation runs in an area like Pondicherry, for four different
drugs or drug combinations and two coverage levels. Predictions are based on the anti-L3 variant 
of the model for Pondicherry, with a precontrol microfilaraemia prevalence of 8.5%. Elimination is
defined as zero microfilaraemia prevalence 40 years after the start of treatment. Source: Stolk et
al. (2005). 
 
Assumed treatment effects 
(proportion killed) 
Predicted number of rounds for 
elimination, with coverage 
Drug(s) adult worms  microfilariae  65%  80%  
Ivermectin + albendazole 35% 100% 10 6 
Diethylcarbamazine 50% 70% 8 5 
Diethylcarbamazine + 
albendazole 
65% 70% 6 4 
Doxycycline 80% 0% 6 4 
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was defined as a zero mf prevalence 40 years after the start of control in 99% of the runs. 
To allow better comparison of the models, we did a series of additional simulations with 
LYMFASIM for mass treatment with the combination of diethylcarbamazine plus 
albendazole, using the same assumptions on drug-efficacy and the same criterion for 
elimination as in published EPIFIL predictions (Table 5-3). Simulations were done with 
the anti-L3 variant of the LYMFASIM model.  
It is reassuring that both models come to comparable conclusions regarding the 
number of treatment rounds required to achieve elimination, although LYMFASIM’s 
predictions are slightly more optimistic than EPIFIL’s, when population coverage is high. 
This finding of nearly equal predictions is not straightforward. The LYMFASIM model 
contains several assumptions and mechanisms, which, relative to EPIFIL, limit the impact 
of the intervention on transmission: 1) a longer adult worm life span (~10 vs. 8 years); 2) 
acquired immunity; 3) heterogeneities in exposure to mosquitoes, in compliance to mass 
treatment, and in adult worm life span. However, the limiting effect of these assumptions 
and mechanisms on the impact of mass treatment is apparently counteracted by the 
enhancing effect of a reduced mating probability of worms at lower average worm 
burdens in LYMFASIM.  
 
 
Criteria for elimination 
EPIFIL’s predictions were based on the assumption that transmission will not continue 
when the mf prevalence falls below 0.5%. The choice for this threshold is somewhat 
Table 5-3. Prediction of number of yearly mass treatment rounds that is required to reach a 0.5% 
microfilaraemia prevalence threshold, using a combination diethylcarbamazine plus albendazole 
in relation to endemicity and coverage. The combination treatment is assumed to kill 55% of all 
adult worms and 95% of the microfilariae, and to interrupt the microfilaria production for 6 months. 
EPIFIL simulation were published (Michael et al. 2004) and concerned a model without acquired 
immunity. LYMFASIM results from the model with anti-L3 immunity were added for comparison for 
an average pretreatment microfilaraemia prevalence of 10%. 
 Coverage 
Pretreatment mf prevalence 60% 70% 80% 90% 
EPIFIL     
 2.5% 7 6 5 4 
 5% 9 7 6 5 
 10% 10 8 7 6 
 15% 12 9 8 7 
LYMFASIM a     
 10% 10 8 6 5 
a Based on the average trend in microfilaraemia prevalence of 100 simulation runs. 
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Figure 5-3. LYMFASIM – Prediction of the duration of yearly mass treatment with ivermectin 
required to reach elimination (zero microfilaraemia prevalence 40 years after the start of 
treatment) with 99% certainty, in relation to coverage. Ivermectin is assumed to sterilize 77% of 
female worms permanently and to kill all microfilariae. Results are shown for two variants of the 
LYMFASIM model for Pondicherry, that differ in the type of acquired immunity assumed, 
assuming a precontrol microfilaraemia prevalence of 8.5%. Source: Stolk et al. (2003).
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Figure 5-4. EPIFIL – The impact of different control strategies on the mean microfilaraemia 
prevalence in an endemic community with precontrol prevalence of 10%. The plot shows the 
impact of mass treatment alone (5 rounds of annual mass treatment with diethylcarbamazine + 
albendazole, with a coverage of 80%), vector control alone (assuming a 90% reduction in biting 
rate during 5 years), and the combination of the two. Reprinted from Michael et al. (2004), with 
permission. 
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arbitrary in the absence of evidence from the field. Given its individual-based structure, 
LYMFASIM is more suitable to examine in how many runs infection is ‘truly’ eliminated, 
as indicated by zero mf prevalence 40 years after the start of control. For example, in the 
runs with 10% precontrol prevalence, 8 rounds with 70% coverage were required to bring 
the average mf prevalence below 0.5% (Table 5-3). However, in only 87% of the runs this 
resulted in zero mf prevalence 40 years after the start of control. To be 99% certain of 
elimination (as was the criterion in Table 5-2), longer continuation of mass treatment 
would be required (1 or 2 extra rounds).  
More extensive simulation studies are required to determine a more precise 
threshold level below which elimination would occur. This threshold level (or threshold 
levels) will depend on local transmission dynamics and mosquito biting rates, inmigration 
of parasite carriers or infected mosquitoes, but also on heterogeneities and population 
size in view of the stochastic processes involved. 
 
 
Application of models for other regions 
The existing model variants were all quantified for transmission of W. bancrofti by Culex 
quinquefasciatus and tested against data from Pondicherry (Norman et al. 2000; 
Subramanian et al. 2004). The basic structure of the models is generalisable to other areas, 
but various model parameters may take different values. Most importantly, this concerns 
the relationship between mf density in the human blood and the number of L3 larvae 
developing in mosquitoes. Unfortunately, few data are available to quantify this 
relationship for the different mosquito species involved (Snow & Michael 2002). 
Especially for the anopheline mosquito species that are responsible for transmission in 
the large parts of Africa more field research is needed. Other parameters that may need 
requantification relate to the composition of the human population, mosquito biting rates 
and heterogeneity in exposure, and operational characteristics of interventions.  
Biological parameters are not expected to vary much between regions. However, our 
understanding of the biology of infection (in spite of in-depth model-based analysis of the 
Pondicherry data) is incomplete and there is uncertainty on the quantification of several 
key parameters, such as the parasite life span or the role of acquired immunity. Therefore, 
it is crucial to continue testing the validity of existing and new model variants against 
epidemiological data. Testing models against age-specific data may help to determine the 
role of acquired immunity or other processes (Duerr et al. 2003). Trends during vector 
control are especially informative on the adult worm life span (Vanamail et al. 1996; 
Subramanian et al. 2004). Trends during mass treatment may give information on the 
effects of drugs on worm survival and productivity. And trends after cessation of control 
may help to determine whether density-dependent mechanisms have appropriately been 
included in the model. Better information on all these aspects should eventually come 
from field research: using combinations of available diagnostic tests (mf and antigen 
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detection, ultrasound to visualize adult worms) it may be possible to further increase the 
validity of our existing models.  
Some work has already been done to prepare models for use in other areas. The 
LYMFASIM model has been applied to age-patterns observed in an area in South-East 
India that has the same vector-parasite combination and presumably the same 
transmission dynamics as Pondicherry. This led to the development of new model 
variants with less strong or no immunity (Subramanian, unpublished data). Comparison 
of predictions from the new LYMFASIM model variant and EPIFIL with observed 
trends during mass treatment in this region indicated that assumptions regarding efficacy 
of drugs or possibly coverage and compliance patterns had to be adapted (Subramanian, 
unpublished data; Michael et al. 2004). Using published data of uptake and development 
of mf in Anopheles mosquitoes (Bryan & Southgate 1988a, b; Southgate & Bryan 1992; 
Boakye et al. 2004), LYMFASIM was adapted for transmission in Africa (Stolk, 
unpublished data). Model parameters were adapted so that the predicted age-prevalence 
reflect the observed data from this region (Stolk et al. 2004). 
 
 
Challenges in the evaluation of current elimination programmes 
The available models soon have to face new challenges in the ongoing programmes for 
elimination of lymphatic filariasis. Predictions of the number of treatment rounds 
required for elimination were only a first step. However, specific programmes also need 
to be monitored and evaluated. For example, the observed results can be compared with 
model predictions to see whether progress is as expected. If results lag behind, 
programmes can be adapted. Also, the models could help to determine when mass 
treatment can be stopped with low risk of recrudescence, taking account of the specific 
local conditions, local coverage and compliance levels, and the achieved reduction in mf 
prevalence and intensity. Analogously, models can help to determine cost-effective 
surveillance strategies for early detection of recrudescence of infection after cessation of 
control and measures to be taken to stop this recrudescence.  
To address the discussed issues on monitoring and surveillance, the models must be 
extended to include results of antigen detection, which is widely used in the monitoring 
and surveillance of ongoing control programmes. Other possibly useful extensions of the 
model include migration of parasite carriers and infected mosquitoes and development of 
resistance to available drugs.  
Although discussion until now focused on the elimination of transmission, this goal 
may be difficult to achieve in some areas. In some situations focus may shift to reducing 
the public health problem without explicitly eliminating infection. To address this with 
the models, more attention is required for the development of disease. Simple 
mechanisms of disease development are included in both models, but disease 
development has received little attention in published work until now.  
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Conclusions 
There are currently two models for lymphatic filariasis transmission and control, 
LYMFASIM and EPIFIL, that have been used in the prediction of the impact of mass 
treatment programmes. These models give more or less similar predictions on the 
number of treatment rounds that will be required for elimination, at least in Pondicherry-
like situations. These models differ however in defining when elimination occurs, which 
leads to different advices on the duration of mass treatment. In view of current 
elimination programmes, it is crucial to obtain better criteria on when to stop control, 
taking account of stochasticity in the eventual outcome of elimination. Antigen tests 
should be included in the model, and the disease part of the models may need more 
attention. Model variants that are adjusted to local situations are powerful tools to aid 
decision making in current control programmes.  
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Abstract 
The role of acquired immunity in lymphatic filariasis is uncertain. Assuming that 
immunity against new infections develops gradually with accumulated experience of 
infection, models predict a decline in prevalence after teenage or early adulthood. A 
strong indication for acquired immunity was found in longitudinal data from Pondicherry, 
India, where microfilara (mf) prevalence was highest around the age of 20 and declined 
thereafter. We reviewed published studies from India and Sub-Saharan Africa to 
investigate whether their age-prevalence patterns support the models with acquired 
immunity. By comparing prevalence levels in 2 adult age groups we tested whether 
prevalence declined at older age. For India, comparison of age groups 20–39 and 40+ 
revealed a significant decline in only 6 out of 53 sites, whereas a significant increase 
occurred more often (10 sites). Comparison of older age groups provided no indication 
that a decline would start at a later age. Results from Africa were even more striking, with 
many more significant increases than declines, irrespective of the age groups compared. 
The occurrence of a decline was not related to the overall mf prevalence and seems to be 
a chance finding. We conclude that there is no evidence of a general age-prevalence 
pattern that would correspond to the acquired immunity models. The Pondicherry study 
is an exceptional situation that may have guided us in the wrong direction. 
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Introduction 
It remains unclarified whether humans, who are lifelong exposed to lymphatic filariasis 
infection, develop a protective immune response (Maizels et al. 2000). The possible 
operation of acquired immunity in regulating filarial infection has received special 
attention, because of its potential consequences for the long-term effects of control 
measures (Anderson & May 1985), but also because understanding immunity may help in 
the development of vaccines against lymphatic filariasis (Kazura 2000). 
There is a large body of research on the role of acquired immunity in helminthic 
diseases in men, especially for schistosomiasis (Hagan 1992). In experimental animal 
models, protective immunity against new infections has been generated by repeated 
infection with infective larvae or by immunization with irradiated larvae from different 
filarial species (Selkirk et al. 1992). It is more difficult to determine whether acquired 
immunity also plays a role in human individuals who are naturally exposed to lymphatic 
filariasis, because neither an individual’s exposure to infective mosquitoes nor the number 
of adult worms present in the human body can be quantified easily. Therefore, 
immunological studies in humans focussed on the correlation of various types of immune 
responses with infection status. Although these studies revealed many differences 
between infected and presumably uninfected hosts, it is unclear to which extent this is 
indicative of an acquired protective immune response (Kazura 2000; Ravindran et al. 
2003). 
Epidemiological studies can be helpful in investigating the role of acquired immunity 
in helminths. Based on pioneering epidemiological and immunological studies in Papua 
New Guinea, it was suggested that the acquisition of new infections may be reduced in 
adults due to acquired immunity against infection (Day et al. 1991a; Day et al. 1991b). 
Assuming that exposure is constant with age and that prolonged exposure leads to 
(partial) resistance against new infections, mathematical models predict an increase in 
infection intensity to a peak at a certain age followed by a decline in older individuals who 
have acquired immunity against new infections; the peak would occur at a higher level 
and younger age in areas with higher transmission intensity (the so-called peak-shift 
theorem) (Anderson & May 1985; Woolhouse 1992). If transmission intensity is stable 
over time, these age-patterns should be reflected in cross-sectional data on prevalence and 
intensity of infection. 
A strong indication for the operation of acquired immunity in lymphatic filariasis 
was found in a study from urban Pondicherry (India) that examined the long-term effects 
of vector control (Rajagopalan et al. 1989; Subramanian et al. 1989). With the availability 
of longitudinal data on microfilaria (mf) intensity for a large number of individuals and on 
transmission by mosquitoes, this study is ideal for examining the dynamics of filarial 
infection. Mf prevalence in Pondicherry was found to decline after about 20 years of age 
(Figure 6-1) (Rajagopalan et al. 1989). Mathematical simulation models had to include 
strong acquired immunity to explain these data and alternative models without immunity 
failed (Chan et al. 1998; Subramanian et al. 2004). Additional epidemiological evidence for 
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Figure 6-1. Age-pattern in mf prevalence in urban Pondicherry, 1981. Figure reproduced using 
data from Rajagopalan et al. (1989). The symbols indicate the observed mf prevalence per age 
group with 95% confidence intervals, plotted against the mid-point of the age range.
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acquired immunity in lymphatic filariasis comes from a literature review that showed a 
peak in prevalence in various studies. The peak appeared most pronounced in areas with 
high transmission intensity, and the age at which the peak occurred decreased with 
increasing endemicity (Michael & Bundy 1998). 
However, there are also locations where mf prevalence does not decrease in the 
oldest age groups. Acquired immunity is not required to explain these patterns (Michael et 
al. 2001; Simonsen et al. 2002). This raises the question whether it is justified to attribute a 
decline in prevalence among older age groups, such as in the Pondicherry study, to this 
form of immunity. To answer this question, insight into observed patterns of lymphatic 
filariasis infection prevalence by age is required. We carried out a meta-analysis of all 
published age-specific data on prevalence of bancroftian filariasis in India and Sub-
Saharan Africa, to investigate whether a decline in mf prevalence in older age groups is 
common in these regions and whether its occurrence is related to transmission intensity. 
 
 
Material and methods 
 
Data sources 
We searched Medline (entry dates through September 2003) combining search terms 
Africa or India and Wuchereria bancrofti or filariasis to identify papers that possibly contain 
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age-specific data on mf prevalence. Other papers were identified by checking references 
from selected papers and recently published reviews. Full text copies were retrieved for all 
papers. Additional data were available from published books and reports from the WHO 
library. All publications that presented data on mf prevalence of bancroftian filariasis 
from India or Sub-Saharan Africa for at least 2 adult age groups were selected for 
inclusion in the review. Reasons for exclusion were: age-specific data on the number of 
individuals examined and positive were not given; the overall infection prevalence was 
very low (<1%); vector control or mass treatment was carried out in the 10-year period 
preceding the survey; the study population concerned a non-representative sample of the 
total population (e.g. selected on clinical or parasitological status, hospitalised patients); a 
large part of the population concerned migrants. Two studies reporting data from the 
same location were both included if the surveys took place with an interval of at least 10 
years; otherwise only the study with the largest sample size was included. If a study 
separately presented data from different locations, these data were included as different 
observations in the final database and analysed separately, with the exception of 1 study 
that provided separate data for 17 villages with small sample size (Zielke & Chlebowsky 
1979). For each observation we recorded: bibliographic information, country, and the 
numbers of persons examined and positive for mf in each reported age group. 
Differences in diagnostic tests between studies were ignored, because these were not 
expected to influence the patterns of mf prevalence by age. In some studies, more than 
one diagnostic test was used. The occasional use of different tests in children versus 
adults does not influence our analyses, since we compare adult age groups only. Few 
studies reported the use of multiple diagnostic tests in adults. If data from different 
diagnostic tests were provided separately, then only the data from the most sensitive 
diagnostic test (resulting in the highest prevalence levels) were used.  
 
 
Statistical analysis 
To investigate whether mf prevalence declined after the age of 20, we compared the mf 
prevalence in 2 adult age groups. The aim was to compare age groups 20–39 vs. 40+, but 
the many studies with age groups 21–40 vs. 41+ or 25–44 vs. 45+ and the few studies 
that only allowed comparison of age groups 15–39 vs. 40+, 16–40 vs. 41+, 15–44 vs. 
45+, or 15–34 vs. 35+ were also included in this comparison. Per observation, we 
calculated the ratio of the prevalence rate in the older over the prevalence rate in the 
younger group. In order not to miss studies with a possible decline in prevalence, we 
assessed significance at the α=10% level. That is, we calculated 90% confidence intervals 
around the prevalence ratio rather than the more common, but wider, 95% confidence 
intervals, so that we will sooner conclude that a difference in prevalence between age 
groups is significant. In the few cases with zero mf prevalence in one of the age groups of 
interest, we calculated the relative risk and confidence limits assuming that 0.5 individual 
was mf positive. The number of observations that showed a significantly lower prevalence 
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in the oldest age group was compared to the number of observations with no change in 
mf prevalence or with a significantly higher prevalence in the oldest age group. Using the 
overall mf prevalence in the study population (children and adults) as indicator for 
transmission intensity, we assessed whether a possible decline in prevalence in older age 
groups occurred more frequently in areas with higher transmission intensity. To allow for 
the possibility that a decline starts in older age groups, we carried out similar analyses with 
30–49 vs. 50+ and 40–59 vs. 60+. 
All statistical analyses were carried out in SAS (version 6.12). 
 
 
Results 
We identified 79 publications that contained age-specific data on mf prevalence for either 
India or Sub-Saharan Africa. Together, the studies contained n = 122 observations, 
including 66 observations for Africa from 15 countries and 56 for India from 14 states. 
There was a large variation in the sample size, ranging from 84 to about 4000 in African 
studies and from 153 to 1.6 million in Indian studies. The overall community mf 
prevalence ranged from 2.7% to 48.1% in the African data and from 1.2% to 18.8% in 
the Indian data. A complete list of the articles that provide data for the current analysis is 
given in the Appendix to this chapter. For each study it is indicated whether comparisons 
of age groups 20–39 vs. 40+, 30–49 vs. 50+ and 40–59 vs. 60+ were included. 
Figure 6-2A plots the relative risks of infection in the 40+ groups compared with 
20–39 year olds with 90% confidence limits for India. Values <1 indicate a lower mf 
prevalence in the older group. A significant decline with age was found in only 6 out of 53 
Indian observations. A significant increase occurred more frequently (10 observations), 
but most often the difference between the two age groups was not significant. The data in 
Figure 6-2A were sorted by overall mf prevalence in the community. An association with 
endemicity level is not apparent. When age groups 30–49 and 50+ were compared, only 6 
out of 52 observations showed a significant difference: 4 with lower and 2 with higher 
prevalence in the oldest age groups. Out of 17 observations that allowed comparison 
between age groups 40–59 and 60+, there was none with a significant decline and 1 with 
a significant increase. 
In Africa, the comparison between age groups 20–39 and 40+ revealed only 1 out of 
65 observations with a significantly lower prevalence in the oldest group and 18 with a 
significantly higher prevalence. Taking non-significant increases into account, 80% of 
observations had higher mf prevalence in the oldest group. This indicates that any decline 
in prevalence would occur at a later age than in India. However, in the comparison of age 
groups 30–49 and 50+ respectively 1 and 9 out of 48 observations showed significantly 
lower and higher prevalence among 50+ (Figure 6-2B). In the comparison between 40–59 
vs. 60+ these numbers were 0 and 4 (n = 41). As in India, a decline was not more 
common in areas with higher prevalence. 
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Figure 6-2 (A). Relative risk of infection with mf in two adult age groups. Results for India: ratio of 
mf prevalence in age group 40+ vs. 20–39. On the Y-axis, overall mf prevalence in the entire 
study population and the study number are given for each observation; study numbers refer to 
the list in the Appendix. Symbols indicate the point-estimate for the relative risk of infection in the 
older vs. the younger group; horizontal bars give the 90% confidence intervals around the point-
estimate. Plus and minus signs on the right side of the figure indicate observations with a 
significantly higher (+) or lower (–) prevalence in the older group.
India
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Figure 6-2 (B). Relative risk of infection with mf in two adult age groups. Results for Africa: ratio 
of mf prevalence in age group 50+ vs. 30–49. On the Y-axis, overall mf prevalence in the entire 
study population and the study number are given for each observation; study numbers refer to 
the list in the Appendix. Symbols indicate the point-estimate for the relative risk of infection in the 
older vs. the younger group; horizontal bars give the 90% confidence intervals around the point-
estimate. Plus and minus signs on the right side of the figure indicate observations with a 
significantly higher (+) or lower (–) prevalence in the older group.
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Discussion 
This meta-analysis shows that patterns with declining prevalence in the oldest age groups, 
which would be expected if acquired immunity plays an important role in preventing 
infection, are not common in areas endemic for bancroftian filariasis. In India, 
comparison of age groups 20–39 vs. 40+ showed that the number of sites with a 
significant decrease in prevalence with age was low and comparable to the number of 
sites with a significant increase. In Africa, comparison of age groups 30–49 vs. 50+ even 
showed that an increase in prevalence with age occurred much more frequently than a 
decrease. Assessing significance at the α=5% level resulted in a somewhat lower number 
of studies with significant differences between the age groups of interest, but did not lead 
to different proportions of significant decreases and increases. 
Based on a recent study of age-infection patterns of lymphatic filariasis in East 
Africa, it was suggested that the impact of acquired immunity in moderating infection 
levels, may only be apparent in areas with high transmission intensity and especially in the 
oldest age groups (Michael et al. 2001). This hypothesis is not supported by our results: 
using overall mf prevalence in the study population as an indicator for transmission 
intensity, we found no indication that a decline in prevalence occurred more frequently in 
areas with higher transmission intensity. This pattern did not change when we compared 
older age groups. A peak in mf prevalence and subsequent decline seems to be a chance 
finding, which has no relation to endemicity level. 
Our results do not confirm the results of the earlier study by Michael & Bundy 
(1998), who also analysed age-prevalence patterns to investigate the role of acquired 
immunity in lymphatic filariasis transmission. Their analysis was restricted to locations for 
which combined data were available on annual infective biting rate (as the indicator for 
transmission intensity) and age-specific mf prevalence. The authors showed that a peak in 
mf prevalence occurred at younger ages and higher levels in areas with higher 
transmission intensity; this ‘peak shift’ has been interpreted as a strong indication for the 
operation of acquired immunity. However, the authors a priori assumed a peak in mf 
prevalence in all studies and estimated the peak level and age at which the peak occurred 
by fitting a quadratic curve to the data from each study. This curve, though, does not 
accurately describe patterns with stabilizing prevalence above a certain age. In fact, the 
estimated peak level was sometimes considerably higher than the prevalence level 
observed in any age group. Based on the results of our meta-analysis, the earlier 
conclusion that prevalence patterns are shaped by acquired immunity may have to be 
reconsidered. 
The quality of data in our study may to some extent be compromised by the 
variation in sample sizes. Several Indian studies provided highly aggregated data, e.g. for 
an entire district, with very low overall mf prevalence levels. Age-patterns from these 
studies could be biased if endemicity levels vary within the region and if there was 
imbalance in sampling of different age groups from different locations. Also, details on 
past control activities in Indian sites were often not provided. For example, in many 
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urban areas, vector control and selective treatment may have taken place as part of the 
National Filariasis Control Program (NFCP). Nevertheless, there is no reason to assume 
that these factors introduce such strong bias that patterns with declining prevalence were 
masked completely. African studies were usually confined to well-defined, small 
geographical areas and, in most areas, there were no previous control activities. 
Overall, our results do not suggest that prevalence is systematically reduced in older 
age groups, which would be expected as a consequence of acquired immunity. This has 
implications for the modelling of lymphatic filariasis transmission. Two currently available 
simulation models, which were both quantified based on data from Pondicherry, included 
strong acquired immunity to explain the data from this area (Chan et al. 1998; 
Subramanian et al. 2004). Our study revealed that Pondicherry is one of only few locations 
with declining prevalence at higher ages (study number 28 in Figure 6-2A). Nevertheless, 
this exceptional pattern was found in data from both the integrated vector management 
arm and the control arm (Rajagopalan et al. 1989). Also, it was visible in subsequent cross-
sectional surveys from the area (Das et al. 1992; Manoharan et al. 1997) and in individual-
level longitudinal data (Vanamail et al. 1989). Other factors than immunity may have to be 
considered to explain these data, such as trends in transmission intensity over time, 
immigration from areas with low endemicity levels or emigration of infected cases from 
urban Pondicherry, differences in treatment history between age groups, or a site-specific 
decline in exposure to mosquito bites with age. Changing assumptions on acquired 
immunity may influence model predictions of the long-term effects of mass treatment 
and of the probability of elimination (Stolk et al. 2003). 
The absence of a decline in mf prevalence in older ages does not necessarily 
preclude the operation of acquired immunity. Theoretically, it is possible that exposure 
increases until the oldest age groups but that prevalence stabilizes at a certain level due to 
acquired immunity. However, there is no reason to assume that exposure would increase 
with age among adults. It is also possible that the immune response regulates the density 
of mf rather than presence or absence. However, the number of studies reporting age-
specific data on mf intensity is much smaller than the number of studies that report 
prevalence data and information on variance to be used for statistical comparison is 
usually lacking. Scanning through the available articles for patterns on mf density, though, 
we also found no indication of a regularly occurring decline in mf intensity in older age 
groups (unpublished data). It may also be useful to analyse data on prevalence and 
intensity of antigenaemia by age in a similar way (Simonsen et al. 1996; Onapa et al. 2001; 
Steel et al. 2001; Tisch et al. 2001; Simonsen et al. 2002). Nevertheless, the age-patterns of 
mf prevalence in published studies were not consistent with existing models of acquired 
immunity. Possibly, models for acquired immunity can be adapted so that the predicted 
patterns are more consistent with the aggregated data from literature (e.g. with different 
assumptions on parasite mortality, the parasite stages that trigger immunity, the rates of 
acquisition or decay of immunity, the effects of immune responses, or the strength of 
immunity). In this respect, it is interesting to note that Day et al. (1991b), who also did not 
find a decline in infection intensity in older age groups, suggested that acquired immunity 
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may only affect the rate of parasite establishment and the plateau worm burden. Further, 
even if acquired immunity does not protect against new infections, it may for example 
protect against development of disease. 
This meta-analysis has shown that a decline in prevalence in older age groups is not 
found more frequently than an increase in W. bancrofti-endemic areas, and that the 
occurrence of such patterns is not related to transmission intensity. The aggregated data 
thus provide no indication that mf prevalence among adults is moderated by a form of 
acquired immunity. More detailed analysis of age-patterns in lymphatic filariasis infection 
may enhance our understanding of the factors that shape age-prevalence curves. For 
vaccine development, for predicting the long-term effects of mass treatment and for 
assessing the prospects of achieving elimination, better understanding of the dynamics of 
infection in the human host and the role of acquired immunity is crucial. 
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Abstract 
Understanding density dependence in the transmission of lymphatic filariasis is essential 
for assessing the prospects of elimination. This study seeks to quantify the relationship 
between microfilaria (mf) density in human blood and the number of third stage (L3) 
larvae developing in the mosquito vectors Aedes polynesiensis Marks and Culex quinque-
fasciatus Say (Diptera: Culicidae) after blood-feeding. Two types of curves are fitted to 
previously published data. Fitting a linearized power curve through the data allows for 
correction for measurement error in human mf counts. Ignoring measurement error leads 
to overestimation of the strength of density dependence; the degree of overestimation 
depends on the accuracy of measurement of mf density. For use in mathematical models 
of transmission of lymphatic filariasis, a hyperbolic saturating function is preferable. This 
curve explicitly estimates the mf uptake and development at lowest mf densities and the 
average maximum number of L3 that can develop in mosquitoes. This maximum was 
estimated at 23 and 4 for Ae. polynesiensis and Cx. quinquefasciatus, respectively.  
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Better understanding of the transmission of lymphatic filariasis is crucial for predicting 
the impact of control programmes and assessing the prospects of elimination. The 
occurrence of density dependence in the vector part of the transmission cycle has been 
addressed in several studies. In a recently published meta-analysis in this journal, Snow & 
Michael (2002) examined density dependence in the uptake of microfilariae (mf) in 
relation to mf density in the human blood for the three major vectors of Wuchereria 
bancrofti, the predominant cause of lymphatic filariasis: Culex, Aedes and Anopheles. Their 
study showed ‘limitation’ in mf uptake by all three species: the mf uptake relative to mf 
density in the human blood decreases when human mf densities are higher. This effect 
appeared to be strongest for Anopheles and weakest for Culex species.  
Density dependence, however, also occurs in the subsequent development of mf 
into L3 larvae: the proportion of ingested mf that develops successfully into L3 larvae 
may decrease (limitation) or increase (facilitation) with higher mf uptake (Southgate & 
Bryan 1992; Pichon 2002). The combined impact of density dependence in both uptake 
and development of mf determines the relationship between mf density in the human 
blood and the number of L3 larvae eventually developing in mosquitoes after feeding. For 
modelling the transmission of lymphatic filariasis, we aimed to describe this relationship 
quantitatively. In this short communication, we discuss several issues that play a role in 
choosing a mathematical function and estimating its parameters. 
We re-analysed paired data on human mf density and the average number of L3 
larvae per mosquito for Ae. polynesiensis and Cx. quinquefasciatus. Data for Ae. polynesiensis 
were available from Tahiti, French Polynesia (Rosen 1955). This dataset included 22 
paired observations from 17 individuals. Mf density in the human blood was determined 
as the average count in eight 20-µL blood smears; 13–138 (median 46) mosquitoes were 
dissected for L3 larvae 13 days after feeding. For Cx. quinquefasciatus we used data from 
Pondicherry, India (Subramanian et al. 1998). This dataset included 72 paired observations 
from 12 individuals. Mf density in the human blood was determined as the average count 
of two or three 20 µL blood smears; 1–22 (median 5) mosquitoes were dissected for L3 
larvae 13 days after feeding. 
Analogously to Snow & Michael (2002), we quantified the association between mf 
density in human blood and L3 in vector mosquitoes by fitting the power curve 
L3 = a mf  b  through the data; the curve is linearized by log10 transformation of both sides 
of the equation after adding +1 to mf and L3 counts: 
)1log()log()13log( ++=+ mfbaL  (7-1) 
The parameters of this equation were estimated by standard linear regression and the 
resulting equations are plotted in Figure 7-1 (solid lines). The steeper slope for Ae. 
polynesiensis (b=0.53, 95% CI 0.48–0.58) compared to Cx. quinquefasciatus (b=0.30, 95% CI 
0.22–0.39) indicates that the combined impact of limitation in uptake and development is 
much stronger for Culex. The estimate of b for Cx. quinquefasciatus was much lower than 
that estimated by Snow & Michael (2002) for the association between mf in the blood and 
mf uptake by this mosquito (b=0.73). This suggests that limitation occurs not only in mf 
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Figure 7-1. Average number of L3 developing in mosquitoes in relation to mf density in the 
human blood (mf / 20 µL) for Ae. polynesiensis (A) and Cx. quinquefasciatus (B). The open 
circles indicate the observations, plotted on a log-scale. The lines show the best fitting linearized 
power curve of Equation 7-1 without (solid) or with (dotted) taking account of measurement error 
in the human mf density. The parameters of the regression equation were the same in both 
analyses for Ae. polynesiensis: log10(a) = -0.05, b = 0.53. For Cx. quinquefasciatus the parameter 
estimates were log10(a) = -0.03, b = 0.30 when measurement error was not taken into account, 
and log10(a) = -0.08, b = 0.34 after correction.
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uptake but also in the subsequent development of engorged mf. For Ae. polynesiensis the 
slopes from the current study (b=0.53) and Snow & Michael (2002) (b=0.57) were 
comparable, suggesting that density dependence in the development of mf into L3 is 
limited. Thus, whereas Snow & Michael (2002) found that limitation in mf uptake was 
stronger for Aedes than for Culex, the current analysis shows that limitation may be 
stronger in the latter species when density dependence in the development of mf in L3 
larvae is also taken into account. 
The parameter estimates presented above did not take account of measurement 
error in the mf density in human blood. There is therefore a risk of underestimating the 
slopes of the regression equations (Armitage & Berry 1987). The degree of measurement 
error depends on the diagnostic test, the volume of blood that is examined and the 
amount of ‘true’ variation that may occur between mf counts in the same individual due 
to periodicity or day-to-day variation. ‘Deming regression’ takes account of measurement 
error, assuming that variance in the independent variable is proportional to the variance in 
the dependent variable (Polman et al. 2001). We used this method to explore the impact 
of measurement error on the accuracy of the estimated regression equations, assuming 
that variances in the log-transformed mf + 1 and L3 + 1 are equal (ratio λ = 1). The 
difference between corrected and uncorrected slopes for Ae. polynesiensis was negligible 
(see Figure 7-1). The data on Cx. quinquefasciatus showed a much weaker association, 
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which can be explained by less accurate estimation of both mf density in human blood 
(based on two or three mf counts instead of eight) and the average number of L3 
developing in mosquitoes (based on dissection of a median of five mosquitoes rather than 
46). Using Deming regression we found a somewhat higher slope, implying less strong 
limitation (b = 0.34, CI  0.25–0.42). If the variance in the human mf density was larger 
than the variance in the number of L3 per mosquito (λ > 1), the underestimation of the 
slope – and thereby overestimation of the limitation effect would be stronger than shown 
in Figure 7-1. For a more accurate estimation of the slopes of the regression equation, the 
parameter λ should be estimated from ideally independent but otherwise similar data.  
Fitting a linearized power curve is very convenient for assessing the strength of 
density dependence in the relationship between mf density in the blood and intake and 
development of mf in mosquitoes, and standard methods – such as Deming regression – 
can be used to correct for intra-individual variation in mf counts. However, this curve is 
not ideal to give a realistic description of this relationship in transmission models such as 
LYMFASIM or EPIFIL (Plaisier et al. 1998; Norman et al. 2000). The relationship 
between mf density in the blood and the number of L3 developing in the mosquito is 
distorted at the lowest mf densities due to the log(+1) transformation of mf counts and 
(unless a=1) the curve of Equation 7-1 does not go through the origin. Using the original 
power function L3 = a mf  b would lead to an infinite slope at the start of the curve, where 
a proportional association would be more realistic. Furthermore, biologists would argue 
that there is a maximum to the number of L3 that can develop successfully, which is not 
properly accounted for by the continuously increasing curve of Equation 7-1. For 
mathematical modelling, the correct estimation of the number of L3 developing in 
mosquitoes after biting on a carrier with very low mf density is crucial for predicting the 
probability of interrupting transmission after reducing mf density by mass treatment, 
whereas the saturation level is an important determinant of the endemicity level in the 
absence of control efforts. The hyperbolic saturating curve is a better alternative for 
relating L3 to mf in a transmission model (Pichon et al. 1974; Subramanian et al. 1998): 
Mf
MfL
βα
α
+= 13
 
(7-2) 
Parameter α quantifies the initial slope of the relationship, whereas β indicates the average 
maximum number of L3 that can develop in mosquitoes. We fitted this curve to the data 
by the ordinary least squares method after log(+1) transformation of both sides of the 
equation to stabilize the variance in the dependent variable. In the absence of standard 
methods to correct for measurement error in the independent variable in non-linear 
regression, measurement error in mf counts was not taken into account. Therefore, the 
results for Cx. quinquefasciatus especially should be interpreted with caution. The results are 
plotted in Figure 7-2 and compared with the (uncorrected) linearized power curve. The 
average number of L3 larvae per mosquito was found to saturate at 23.1 (95% CI 16.9–
29.3) for Ae. polynesiensis; especially at higher mf densities (>100 mf/20 µL) the hyperbolic 
Chapter 7 
 112
Figure 7-2. The relationship between the number of L3 developing in mosquitoes and the mf 
density in the human blood for Ae. polynesiensis and Cx. quinquefasciatus. The dots indicate the 
observations. The lines show the linearized power curve of Equation 7-1 (solid) and the best 
fitting hyperbolic saturating curve of Equation 7-2 (dashed). Parameter estimates for the 
hyperbolic saturating function were α=0.22, β=23.15 for Ae. polynesiensis and α=0.11, β=3.92 
for Cx. quinquefasciatus. Parameters for the linearized power curve are given in the legend of 
Figure 7-1.
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saturating function performs better than the power curve. The saturation level was much 
lower for Cx. quinquefasciatus (3.9, 95% CI 2.0–5.8). Based on the same dataset, the satura-
tion level was previously estimated at 6.6 (95% CI 4.3–17.0) (Subramanian et al. 1998). In 
this earlier publication, individual level data were used, whereas the current methods are 
based on analysis of aggregated data, which are more widely available in literature.  
Our study showed that there is limitation in the relationship between mf density in 
the human blood and the number of L3 larvae developing in mosquitoes, which is 
stronger for Cx. quinquefasciatus than for Ae. polynesiensis. Measurement error in the mf 
density in the human blood can lead to overestimation of the strength of limitation when 
this is not accounted for in the analysis. A hyperbolic saturating curve may be more 
appropriate to describe the association in mathematical models, but its use is limited to 
datasets with minimal error in the measurement of mf density. To understand fully how 
transmission intensity depends on the mf density in the blood of human individuals, 
excess mortality among (heavily) infected mosquitoes should be considered as well (Das et 
al. 1995; Failloux et al. 1995). 
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Abstract 
Ivermectin and diethylcarbamazine (DEC) are used in mass treatment programmes for 
the elimination of lymphatic filariasis because of their strong effects on microfilaraemia. 
However, the effects of treatment on adult worms and the degree of individual variation 
in efficacy are unclear. We analyzed series of microfilaria (mf) counts from individuals 
treated with a single dose of 400 µg/kg ivermectin or 6 mg/kg DEC (n=23 in each 
group; 1 year follow-up). For each individual, we estimated the microfilaricidal effect and 
the reduction in overall mf production (e.g., caused by death or sterilization of worms, or 
inhibited mf release from the female worm uterus). Ivermectin on average killed 96% of 
mf and reduced mf production by 82%. DEC killed 57% of mf and reduced mf 
production by 67%, with some individuals responding very poorly. The strong reduction 
in overall mf production is good news for control of lymphatic filariasis, but the 
prospects of elimination will be diminished if part of the population systematically 
responds poorly to treatment. 
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Introduction 
Programmes are being initiated worldwide to eliminate lymphatic filariasis by yearly mass 
treatment with ivermectin or diethylcarbamazine (DEC), given alone or in combination 
with albendazole. It is unclear, though, how many treatment rounds will be required to 
achieve the goal of elimination. A major problem is our incomplete understanding of the 
effects of treatment on the adult worm. Control needs to be continued for many years if 
overall microfilaria (mf) production by adult worms is largely unaffected by treatment. 
Antigen tests have been used to demonstrate macrofilaricidal effects (Weil et al. 1991; 
McCarthy et al. 1995), but it is unclear how the reduction in antigen level relates to the 
proportion of worms killed. Ultrasound has been used to assess the macrofilaricidal 
effects of treatment directly (Dreyer et al. 1995a; Norões et al. 1997); however, its 
application is limited to the scrotal area and superficial lymphatics. Neither of these tools 
can assess an effect on fecundity. 
Most commonly, the effects of treatment have been assessed by measuring the 
change in mf density over time. Many clinical trials and community-based interventions 
showed that treatment with ivermectin or DEC, given alone or in combination with 
albendazole, leads to a strong and sustained reduction in mf density (reviewed in Ottesen 
et al. 1999; Brown et al. 2000; Melrose 2002; International Filariasis Review Group 2004). 
Mathematical models that describe the development of parasites in the human body can 
be used to analyze such trends in mf density for indirect quantification of the effects of 
treatment. In this way, it was estimated from published data that a single dose treatment 
with 200 or 400 µg /kg ivermectin not only results in immediate killing of all mf, but also 
in a reduction in the overall mf production in the follow-up period of respectively 35% or 
65% at least (Plaisier et al. 1999). The reduction in mf production indicates that adult 
worms are affected, but the nature of this effect (e.g., death or sterilization of worms, 
reduced mf release from female worm uterus) cannot be determined. However, there was 
no indication that the reduction in mf production was only temporary. Similar estimates 
for the efficacy of a single dose of DEC are not available yet. 
Another aspect of interest is the variation in treatment efficacy that occurs between 
individuals. This has received little attention in literature. However, the impact of mass 
treatment may be undermined when there is a number of individuals who respond poorly 
to treatment and who continue to transmit infection in the population (Stolk et al. 2003). 
Here, we present the results of a double-blind, randomized, hospital-based trial that 
was carried out to investigate the efficacy of a single dose of ivermectin (400 µg/kg body 
weight) or DEC (6 mg/kg body weight) for treatment of bancroftian filariasis 
(Subramanyam Reddy et al. 2000). We analyzed the one-year follow-up trends in mf 
density at the individual level to quantify the effects of treatment and the individual 
variation in these effects. 
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Material and methods 
Data 
A double-blind, randomized, hospital-based trial was carried out in Pondicherry, India, to 
compare the safety and efficacy of a single dose of ivermectin (400 µg/kg body weight) or 
DEC (6 mg/kg body weight) for treatment of bancroftian filariasis (Subramanyam Reddy 
et al. 2000). In each treatment group, 30 mf carriers with pretreatment mf counts ≥100 
mf/mL were included. Mf density in the blood was determined by membrane filtration of 
1 mL venous night blood, and all blood samples were taken between 8.30 PM and 9.30 
PM (not always on the exact same time for an individual). Mf counts were taken with 
monthly intervals during the first year after treatment. Available observations for part of 
the individuals made 24 months after treatment were not included in our analysis. This 
was because these observations are not only determined by the effects of treatment, but 
to a large extent also by trends in transmission intensity or other external factors that are 
not accounted for in our model. One year follow-up is long enough to measure the 
effects of treatment, but distortion of the trends due to reinfection will be minimal 
because of the long immature period of the worms. Only individuals with complete 
follow-up were included in the analysis (23 individuals in each group). 
 The two treatment groups were comparable with respect to age and gender: the 
mean age was 20 years in the ivermectin group and 22 years in the DEC group, and the 
male:female ratio was 14:9 and 12:11, respectively. The mean pretreatment mf load was 
higher in the ivermectin group than in the DEC group (538 mf /mL vs. 338 mf /mL), but 
this difference was not significant (t-test on log-transformed values, p=0.118). 
 
Statistical analysis 
We used a mathematical model, which describes the course of Wuchereria bancrofti infection 
in individuals over time and the impact of treatment on the different parasite stages (see 
the Appendix to this chapter). We assumed that the pretreatment mf density represents 
an equilibrium situation where the acquisition of worms and mf is balanced by the loss. 
This equilibrium is disturbed by two immediate and irreversible effects of treatment: a 
fraction of mf is killed (resulting in an immediate drop in mf density) and the overall mf 
production is reduced by a certain fraction (resulting in a lower rate of mf recurrence in 
the blood than expected if mf production had not been affected). The cause of the 
reduced mf production (e.g., death or sterilization of adult worms or any other 
mechanism that inhibits the release of mf from the female worm uterus) cannot be 
determined from the data on mf density.  
The rate of recurrence of mf after treatment (relative to an individual’s pretreatment 
level) depends not only on the effects of treatment, but also on assumptions on the 
duration of the immature period of worms and the adult worm and mf life span. Based 
on literature, we assumed these durations to be, respectively, 8 months (World Health 
Organization 1992), 8 years (Vanamail et al. 1996; Subramanian et al. 2004), and 12 
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Figure 8-1. Individual estimates of the fraction of mf killed and the reduction in overall mf 
production due to treatment with ivermectin (A) or DEC (B). The histograms along the upper and 
right axes of the graphs show the corresponding frequency distributions of the efficacy estimates.
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months (Plaisier et al. 1999) on average. As argued above, new infections acquired during 
the first year after treatment will have little impact on trends in mf density and were 
ignored in this analysis. Under these assumptions, mf density one year after treatment is 
61% of the pretreatment level if treatment kills all mf but has no effect on adult worms. 
The behavior of the model is further explained elsewhere (Plaisier et al. 1999).  
Individual trends in mf density are described by the pretreatment force-of-infection 
(β), the fraction mf killed due to treatment (δ), and the effect of treatment on overall mf 
production (λ). The values of these parameters are estimated by fitting the model to the 
individual data using non-linear regression and assuming extra-Poisson variation. A more 
detailed description of the model and the estimation procedure is given in the Appendix. 
In a sensitivity analysis, we assessed how the estimates of the efficacy parameters 
depend on assumptions on the immature period and the worm and mf life span by 
halving and doubling their values. We also checked how the results change if we take 
account of new infections acquired during follow-up with the rate of acquisition being 
equal to the pretreatment rate. Spearman’s rank correlation was used to test for 
correlations between efficacy estimates (δ or λ) and the predicted pretreatment mf 
intensities (reflected by β). 
 
 
Results 
The results of the analysis are summarized in Figure 8-1 and Table 8-1. On average, the 
efficacy of ivermectin was higher than that of DEC. The fraction of mf killed (δ) was high 
Chapter 8 
 120
in all ivermectin-treated individuals; in 87% of the individuals even more than 90% of the 
mf was killed. Usually there was also a strong reduction in overall mf production (λ). The 
effects of DEC treatment were somewhat lower on average and varied strongly between 
individuals. In both groups, there was no significant correlation between the individual 
estimates of δ or λ and the pretreatment mf intensity β, indicating that the effects of 
treatment do not depend on the pretreatment level of infection.  
Figure 8-2 shows the average trend in observed and predicted mf intensities. Figure 
8-3 gives some typical examples of individual trends in mf density after treatment. 
Ivermectin led to a strong initial reduction of mf density in all individuals and usually the 
density remained low during follow-up (Figure 8-3A and B), indicating that the treatment 
killed nearly all mf and almost completely interrupted mf production. Three individuals 
even had zero mf counts at all measurements post-treatment, suggesting complete 
effectiveness of treatment. In several individuals, the strong immediate reduction was 
followed by a gradual increase, which indicates that mf production was not completely 
interrupted (Figure 8-3C). In the DEC-group, only few individuals showed the nearly 
ideal pattern of Figure 8-3A or B and there were no individuals who had zero mf counts 
during the entire follow-up period. Often, a limited immediate reduction in mf density 
after treatment was followed by gradual decline during the follow-up period (Figure 
8-3D). This pattern reflects little direct effect on mf and a strong effect on mf production. 
Table 8-1.Variation in the estimated fraction of microfilariae (mf) killed and the reduction in overall 
mf production between individuals who were treated with ivermectin or diethylcarbamazine (DEC). 
Parameter and description 
      Ivermectin 
         (n=23) 
        DEC 
       (n=23) 
     
Impact on mf     
 Fraction of mf killed (δ)     
  Average (sd)  0.96 (0.05) 0.57 (0.39) 
  Median (25th – 75th percentile) 0.98 (0.95 – 1.00) 0.77 (0.00 – 0.87) 
 Number (%) of individuals with all mf killed (δ > 0.999) 7 (30%) 0 (0%) 
 Number (%) of individuals with no mf killed (δ < 0.001) 0 (0%) 6 (26%) 
   
Impact on mf production   
 Reduction in overall mf production (λ)    
  Average (sd) 0.82 (0.27) 0.67 (0.36) 
  Median (25th – 75th percentile) 0.96 (0.78 – 1.00) 0.87 (0.38 – 0.96) 
 Number (%) of individuals with complete cessation of 
mf production (λ > 0.999)  
7 (30%) 5 (22%) 
 Number (%) of individuals with no change in mf 
production (λ < 0.001) 
1 (4%) 2 (9%) 
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Figure 8-2. Observed and predicted trends in arithmetic mean mf density. Symbols indicate the 
mean of the observed individual mf counts; the lines show the average of the individual predicted 
mf densities () and -- for DEC; ( and — for ivermectin).
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Sometimes there was no immediate effect on microfilaraemia (Figure 8-3E). In several 
DEC-treated individuals, mf counts during follow-up remained high. Due to the high 
variability in mf counts, such trends were difficult to interpret, but anyway the effects are 
poor (Figure 8-3F). In one individual treated with DEC, treatment did not have any effect 
on mf or mf production. 
The sensitivity analysis showed that our results did not depend on the duration of 
the immature period and worm life span. Only the assumptions on mf life span 
influenced the individual efficacy estimates, although the change was not always in the 
same direction. Assuming a mf life span of 6 or 24 months, the average reduction in 
overall mf production was 0.63 or 0.69, respectively, in the DEC group and 0.86 or 0.75, 
respectively, in the ivermectin group. Allowing for acquisition of new infections during 
the post-treatment period, we found slightly (around 0-3%) higher estimates for the 
reduction in overall mf production; the estimated fraction of mf killed hardly changed at 
all. 
 
 
Discussion 
Our analysis of individual-level trends in mf density after treatment showed that a single 
dose of ivermectin (400 µg/kg) in all treated individuals resulted in death of a large 
fraction of mf and in most instances also in a strong reduction in overall mf production. 
The effects of DEC were somewhat lower on average and more variable. In some 
individuals treated with DEC, almost all mf were killed and mf production was nearly 
completely interrupted; in others, the drug had little effect. The data provide no 
information about the cause of the reduction in overall mf production. For DEC it is 
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Figure 8-3. Observed and predicted trends in mf density for 6 individuals with typical patterns for 
ivermectin (A-C) or DEC (D-F). Corresponding values of both efficacy parameters are given 
above each graph.
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probably explained by a macrofilaricidal effect (Weil et al. 1991; Figueredo-Silva et al. 
1996; Norões et al. 1997). Ivermectin probably does not kill adult worms (Dreyer et al. 
1995c; Dreyer et al. 1996). Possibly, ivermectin causes damage to the reproductive system 
of female worms, so that embryogenesis, maturation or release of mf from the uterus is 
inhibited. 
Efficacy of DEC and ivermectin for lymphatic filariasis treatment 
 123 
Based on ultrasound examination of the male scrotum, it was previously estimated 
that a single dose of DEC kills about half of the adult worms (Norões et al. 1997). The 
estimated reduction in overall mf production in our study was only slightly higher. Care is 
required in this comparison: the reduction in mf production may be higher than the 
proportion of adult worms affected, because unmated worms may have survived and 
retained their ability to produce mf. Any effect of ivermectin on the fertility of adult 
worms cannot directly be measured. However, the current estimates are in agreement 
with the results of a previous model-based analysis (Plaisier et al. 1999). This analysis of 2-
year follow-up data provided no indication that the effect on mf production was only 
temporal, but studies with longer follow-up are required to be more certain on this aspect. 
Analysis of combined data on mf and antigen density and on the presence of motile 
worms (Freedman et al. 2001; Ismail et al. 2001; El Setouhy et al. 2004; Kshirsagar et al. 
2004) may enhance our qualitative and quantitative understanding of the effects of 
treatment on adult worms. 
The validity of our efficacy estimates depends on the validity of the model that was 
used to describe the average trends. We do not know exactly how the filarial worm 
develops in the human body. However, assumptions about the immature period or worm 
life span proved to have little impact on our efficacy estimates and did not change the 
main conclusions. The results were more sensitive to assumptions about the mf life span. 
The effect of changing the assumed mf life span depends on the observed trend. 
Assuming a shorter mf life span results in higher estimates of the reduction in overall mf 
production, if a strong initial decline in mf density is followed by a gradual increase. 
However, it results in lower estimates, if a gradual decline in mf density is observed over 
time. Assuming a longer mf life span results in changes in the other direction. Although 
individual estimates were influenced by assumptions on the mf life span, the impact on 
the average efficacy estimate was rather limited and strong variability remained. 
Assumptions on the acquisition of new infections during follow-up had little impact 
on the outcomes. Because of the long immature period of the worm (8 months), the 
contribution of newly acquired infection on the mf density one year after treatment is 
very limited. Indeed, when we allowed for the acquisition of new infections, assuming 
that transmission in the post-treatment period continues at the same rate as before 
treatment, we found only slightly higher estimates for the reduction in overall mf 
production and the estimated fraction mf killed hardly changed. 
 To assess the generalizability of our efficacy estimates, we compared our data with 
that from other trials. Higher effectiveness of ivermectin (400 µg/kg) compared to DEC 
(6 mg/kg) was reported in several studies (Addiss et al. 1993; Kazura et al. 1993; Moulia-
Pelat et al. 1993), but other studies revealed only small differences between both treatment 
regimens (Moulia-Pelat et al. 1996; Nicolas et al. 1997) and one study found that DEC was 
even more effective than ivermectin (Dreyer et al. 1995b). For DEC, the geometric mean 
mf density one year after treatment varied widely in published studies from 4.5% to 
33.4% (average 12%) of the pretreatment level (Kimura et al. 1985; Addiss et al. 1993; 
Moulia-Pelat et al. 1993; Andrade et al. 1995; Dreyer et al. 1995b; Moulia-Pelat et al. 1996; 
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Nicolas et al. 1997; Pani et al. 2002). In our data, it was reduced to about 17% of the 
pretreatment level, which is within the range of other studies. For ivermectin, too, trends 
in mf density varied between studies (Cao et al. 1997). Analysis of data from other studies 
may therefore yield somewhat different efficacy estimates.  
For part of the individuals in our study one additional observation made two years 
after treatment was available, but these observations were not used. These observations 
were usually low relative to the observed trend during the first year after treatment (Cao et 
al. 1997). Explorative attempts to fit the model to all data (including the 2-year follow-up 
data) resulted in somewhat higher estimates of the reduction in overall mf production, but 
a poorer fit. This suggests that these observations were probably influenced by (external) 
factors that are not accounted for by our model. 
A problem in the analysis of individual level data is the large variability in mf counts, 
so that sometimes trends were difficult to interpret. The pretreatment mf density was 
based on only one measurement. In some individuals the pretreatment mf count by 
chance will have been lower than the true density. This was probably seen in some DEC-
treated individuals, who had higher mf counts during follow-up than before treatment 
(e.g. Figure 8-3E and F). In other individuals, the observed mf count will by chance have 
been higher than the true mf density. With our approach, however, we cannot identify 
when this occurs. This might have led to a small overestimation of the average effects of 
treatment. The selection of mf positives for our study population may have added to the 
overestimation. In the whole population, therefore, the average efficacy may be somewhat 
lower than we estimated.  
Our study provides important information for the ongoing elimination programmes 
for lymphatic filariasis, which are based on mass treatment with DEC and ivermectin in 
combination with albendazole. The average effects of DEC and ivermectin treatment are 
high, which triggers optimism about the potential impact of mass treatment. However, 
ivermectin is usually given in lower dosages (150-200 µg/kg instead of the 400 µg/kg 
given in this study), which is less effective in reducing the overall mf production (Plaisier 
et al. 1999). It is unknown to what extent the impact of treatment is improved by giving 
the drugs in combination with albendazole (International Filariasis Review Group 2004). 
Especially in the DEC group, there was much variation in treatment efficacy and in 
several individuals the effects were poor. A remaining question is whether the observed 
variation is random or systematic. More information is needed about the impact of a 
second treatment in individuals who had a poor response. The presence of systematic 
non-responders in a population will considerably reduce the probability of elimination, or 
at least necessitate a longer duration of treatment programmes (until most adult worms 
have died naturally). It would be interesting to study whether the average efficacy of 
treatment increases and whether the number of people with poor response to treatment is 
reduced when ivermectin or DEC are given in combination with albendazole, as is 
recommended for the ongoing elimination programmes (Ottesen et al. 1997). 
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Appendix 
Mathematical description of the model 
The structure of the model is schematically presented in Figure 8A-1. The dynamics of 
parasite development and mf production are described by the following set of differential 
equations: 







−=
−=
+−=
)()()(
)()()(
)()()(
2
1
1
tMtW
dt
tdM
tWtL
dt
tdW
tL
dt
tdL
i
µρ
µγ
µγβ
 (A1) 
Let W be the number of adult and productive worms in a person, L the number of 
immature worms, and M the number of mf. The rate of acquisition of new worms 
depends on the force-of-infection βi, which is defined as the average number of 
successfully inoculated new parasites per year. The rate of maturation, γ, is defined by the 
duration of the immature period (immature period = 1/γ). Similarly, the death rate of 
larvae and worms, µ1, is defined by the average life span of the parasites (parasite life span 
= 1/µ1). Mature adult worms start producing mf (M) at a constant per capita rate ρ. 
Parameter ρ is defined as the rate of mf production per mature worm per unit of blood 
Figure 8A-1. Flow-chart of the model, showing the dynamics of immature worms (L), adult worms 
(W), and microfilariae (M) in the human host.
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M
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taken for diagnosis. The death rate of larvae and worms, µ2, is defined by the average mf 
life span (mf life span = 1/µ2). 
We assume that the force-of-infection has been constant over time, so that the 
worm and mf density are in equilibrium prior to treatment, meaning that death of worms 
is balanced by new infections. The force-of-infection varies between individuals, reflected 
in different pretreatment counts. Because of the long immature period of worms, new 
infections acquired during the first year after treatment will have little impact on trends in 
mf density, and we ignore these in our analysis. In other words, βi = 0 in the post-
treatment period for all individuals. 
At the moment of treatment (t = 0), a fraction δi of the mf (M) is being killed 
instantaneously and a fraction λi of all worms present in the body (L and W) stop 
producing mf or, in the case of immature worms, lose their ability to produce mf. 
 
Solution of the differential equations 
For estimating the effects of treatment, we are interested in the relationship between the 
mf density M and time t. By solving the set of differential equations A1 for 
dL(t)/dt=dW(t)/dt=dM(t)/dt=0, we derived the following relationship for the equilibrium 
mf density pretreatment M*: 
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From the moment of treatment onwards, the relationship is given by a non-linear 
function: 
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with βi reflecting the pretreatment individual force-of-infection. For t = 0 (i.e. directly 
after treatment), this becomes: 
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Estimation of model parameters 
Equations A2 and A3 were fitted to the data. Since we have no sound knowledge of the 
worm load of a person or the mf production per worm, and since mathematically one of 
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the parameters βi and ρ is redundant, we put ρ =1 and only estimated βi. Further, we 
estimated the individual values of δi and λi. These parameters were estimated by non-
linear regression, using SAS (v. 8.2). In doing so, we assumed that mf counts follow a 
Poisson distribution with overdispersion (i.e. extra-Poisson variation, the variance being a 
factor θ larger than the mean mf density). The value of θ was estimated at 30.9, indicating 
a high variation in mf counts. Assuming a negative binomial distribution of mf counts 
resulted in a worse fit to the data. 
Explorative analyses showed that the individual level parameters did not follow a 
normal distribution and that efficacy estimates were frequently on the boundaries of the 
possible range of values (implying full or no effect on mf or mf production). Including 
these parameters as random effects in the model was not useful, and we therefore 
estimated all parameters as fixed effects. 
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Abstract 
Combinations of ivermectin (IVM) or diethylcarbamazine (DEC) and albendazole (ALB) 
are recommended for use in mass treatment programmes against lymphatic filariasis. We 
reviewed published trends in microfilaria (mf) intensities after treatment with these 
combination therapies. By fitting a mathematical model of treatment effects to the trial 
data, we quantified the efficacy of treatment, distinguishing between the killing of mf (mf 
loss) and a reduction in mf production by adult worms (worm-productivity loss). The mf 
density after DEC-ALB treatment showed an immediate drop, followed by a slow but 
steady further decrease (n=4 trials). After IVM-ALB treatment, mf densities immediately 
dropped to near-zero levels, followed by a small increase (n=5). For DEC-ALB, the 
average mf loss and worm-productivity loss were estimated, respectively, at 83% (ranging 
from 54-100% in the different studies) and 100% (for all studies). For IVM-ALB, the 
respective estimates were 100% (ranging from 98-100%) and 96% (ranging from 83-
100%). Stronger effects were found for treatment with higher doses. Sensitivity analysis 
showed that the estimates did not depend on assumptions on worm life span or 
premature period and little on assumptions on mf life span. It can be concluded that the 
two therapies differ with respect to their direct effect on mf, but both are highly effective 
against adult worms. With high coverage, mass treatment with these combination 
therapies can have a large impact on lymphatic filariasis transmission. 
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Introduction 
Lymphatic filariasis is endemic in 80 countries, with the largest population at risk in 
Africa and the Indian region. An estimated 119 million people are affected by lymphatic 
filariasis worldwide, with 43 million people suffering from elephantiasis or hydrocele; 
Wuchereria bancrofti accounts for 89% of the cases (Michael & Bundy 1997). These chronic 
manifestations can be severely disabling and have a large social impact due to stigma, 
embarrassment, depression and sexual dysfunction; economic losses occur due to costs of 
medical care, but also due to temporary or permanent productivity loss (Evans et al. 
1993). 
Lymphatic filariasis is considered a potentially eradicable disease, due to the absence 
of a non-human reservoir for W. bancrofti, the availability of cheap and highly effective 
drugs (DEC, ivermectin and albendazole) and of easy-to-use, highly specific and sensitive 
antigen tests (Centers for Disease Control 1993). In 1997, WHO therefore adopted a 
resolution to advocate the global elimination of lymphatic filariasis as a public health 
problem by interrupting its transmission (World Health Organization 1997). Yearly mass 
drug administration (MDA) has become the primary strategy (Ottesen et al. 1997). 
Nowadays, the recommended treatment regimens for use in elimination 
programmes are combinations of diethylcarbamazine (DEC, 6 mg/kg) and albendazole 
(ALB, 400 mg) or of ivermectin (IVM, 200 µg/kg) and ALB (400 mg), administered 
yearly in a single dose. These treatment regimens have shown to be very effective in 
reducing microfilaria (mf) intensity in several trials (Ottesen et al. 1997).  
The success of MDA greatly depends on drug effects on mf and adult worms. 
Especially the effects on adult worms will greatly determine the long-term impact of 
MDA. Measuring the effect of therapy on the adult worms is difficult. Ultrasound 
detection is a powerful tool to visualize living adult worms in an individual and to 
investigate the macrofilaricidal effect of treatment (Dreyer et al. 1996; Norões et al. 1997). 
However, it has some limitations: living worms cannot be visualized in all parts of the 
body and sterilization of worms cannot be measured. Other tools to detect the amount of 
living adult worms in an individual are not yet available. Mathematical models provide a 
means for indirect estimation of the effects of treatment. Plaisier et al. (1999) developed a 
mathematical model that considers the life cycle of the worm, mf production and survival, 
and the effects of treatment on mf and on mf production by adult worms. The latter can 
be reduced by death or sterilization of the worm. This model was used to estimate the 
efficacy of ivermectin treatment from published trends in mf intensity. The authors 
concluded that IVM (400 µg/kg) reduced mf production by adult worms by at least 68%; 
for a lower dosage of 200 µg/kg (the one used in MDA) they found a reduction in mf 
production of the adult worms of at least 36%. 
In this study, we review the published trends in mf intensities after treatment with a 
combination of ALB with DEC or IVM and quantify the efficacy of treatment, 
distinguishing between the killing of mf and the reduction in mf production by the adult 
worm using an adapted version of the mathematical model of Plaisier et al. (1999). 
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Materials and methods 
 
Literature search 
The MEDLINE database was searched up to May 2004 to identify all published studies 
about treatment of lymphatic filariasis with combinations of ALB with IVM or DEC. The 
search terms used were: ‘albendazole’, ‘filariasis’, ‘Wuchereria bancrofti’, or ‘clinical trial’, 
combined with ‘ivermectin’, ‘DEC’ or ‘diethylcarbamazine’. The hits were screened on 
basis of title and abstract, the relevant full text articles were retrieved and references were 
screened for other potentially relevant articles.  
 
 
Study selection and quality assessment 
The studies were selected using the following inclusion criteria: W. bancrofti infection was 
treated with combination therapy consisting of DEC and ALB or IVM and ALB; results 
were reported for a group of individuals who were all mf positive at the start of the 
treatment; follow-up was at least one year and mf density was measured at least at three 
time-points post-treatment. If results from one study were reported in several articles, the 
article that reported most post-treatment measurements of mf density was included. The 
methodological quality of the included studies was assessed using the criteria of the 
Cochrane Infectious Diseases Group (Garner et al. 2004). 
 
 
Data 
Our analysis concerns trends in mf density after treatment in groups of individuals who 
were all mf positive before the start of treatment. Most studies included several 
subgroups, that were treated with different treatment regimens or concerned different 
groups of patients. We use the term ‘study arm’ to refer to subgroups in studies. Mf 
intensities as a percentage of pre-treatment level were extracted and entered in an Excel 
database for each relevant study arm. When a second treatment was given, observations 
after this second treatment were ignored. If relative mf intensities were not provided, 
these values were calculated by dividing geometric mean absolute mf intensities at 
different follow-up moments by pre-treatment geometric mean mf intensity. Several 
studies have already shown that higher doses of IVM or DEC induce greater and more 
sustained mf reduction (Ottesen 1985; Cao et al. 1997). Therefore four treatment regimen 
groups were distinguished: low dose IVM-ALB (IVM ≤200 µg/kg, ALB 400 mg), high 
dose IVM-ALB (IVM >200 µg/kg, ALB ≥400 mg), low dose DEC-ALB (DEC ≤6 
mg/kg, ALB 400 mg) and high dose DEC-ALB (DEC >6 mg/kg, ALB ≥400 mg). In the 
remainder of the paper we will refer to these groups by ‘treatment regimen group’. The 
lower dosages are currently recommended for use in MDA programmes. 
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Model 
Description. A description of the model is given in the appendix. Because study 
participants are from known endemic areas and probably were not treated previously for 
lymphatic filariasis (4 studies stated this explicitly; only Ismail 1998/2001 gave no 
information on this), we can assume that the pre-treatment infection intensity represents 
an equilibrium situation: mortality of worms and mf is balanced by new infections and 
newly produced mf. Freshly acquired parasites are unproductive during the premature 
period. Thereafter, the mature adult parasites produce mf at a per capita constant rate (ρ). 
The effect of treatment is assumed to be two-fold: a fraction δ of mf is killed and a 
fraction λ of the worms stops producing mf (mature worms) or lose their ability to do so 
(premature worms). In the remainder of the paper we will refer to these effects as ‘mf 
loss’ or ‘worm-productivity loss’. The latter can be due to death (as assumed for DEC and 
ALB), sterilization (as assumed for IVM), or another mechanism that prevents release of 
mf into the blood. We assume that worm-productivity loss is permanent, or at least not 
reversed within the 2-year follow-up period. New infections could be acquired during 
follow-up, if transmission continues. The key outcome of the model is the calculated 
relative trend in mf density over time after treatment. 
Parameter quantification. Based on estimates from literature and earlier analyses, 
the premature period was assumed to be eight months (World Health Organization 1992), 
the life span of the adult female worm eight years (Vanamail et al. 1996; Subramanian et al. 
2004) and the life span of mf one year (Thooris 1956; Plaisier et al. 1999). We ignored the 
possible acquisition of new infections during the post-treatment period. In the 
community-based studies, the reinfection rate will be low due to reduced transmission. 
But even if new infections occur, they are expected to have little influence on post-
treatment trends of lymphatic filariasis, because of the long premature period of the 
worm. Alternative values for these parameters were considered in a univariate sensitivity 
analysis. By fitting the model outcomes to the observed trends in mf intensity, we 
estimated the following three parameters: the fraction of mf killed (δ), the fraction of 
worm-productivity loss (λ) and the linear factor ‘reinfection rate pre-treatment × mf 
production’ (β0 × ρ). This is further explained below.  
Sensitivity analysis. We examined how the results would change if we assumed 
reinfection to occur post-treatment (assuming that transmission intensity was not affected 
by treatment). We further tested how halving and doubling the assumed durations of the 
premature period, worm life span and mf life span would affect the efficacy estimates and 
the goodness of fit in the situation with and without reinfection. Univariate and 
multivariate sensitivity analysis was done. 
Estimation procedure. Parameters were estimated by fitting the model outcomes 
to the observed data. Assuming that the relative mean mf intensities follow a normal 
distribution, the least squares method was used for testing the goodness of fit. In a first 
analysis, we estimated mf and worm-productivity loss for each treatment regimen group, 
assuming that there was no difference between study arms within each group. Because 
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sample sizes varied between studies, we used weighted least squares, weighing for the 
number of patients at inclusion. The following expression was minimized: 
( ) ( )[ ]2
1 1
,, ,,,∑∑
= =
−⋅=
d
i
s
j
jiojipi
i
tmtmnSS ρβλδ  (9-1) 
We subsequently tested whether the goodness-of-fit improved in a second analysis, 
in which we estimated the efficacy for each study arm separately, thus allowing variation 
in efficacy between study arms within a treatment regimen group. Since loss-to-follow-up 
was limited and data on the number of patients at every follow-up time point were 
lacking, we used ordinary least squares for parameter estimation, minimizing the following 
expression:  
( ) ( )[ ]2
1
,, ,,,∑
=
−⋅= i
s
j
jiojip tmtmSS ρβλδ  (9-2) 
With: 
SS sum of squared errors; 
i index for study arm; 
d total number of study arms within a treatment regimen; 
j post-treatment follow-up time-point of study arm i ; 
si total number of follow-up time-points of study arm i ; 
ni number of patients in study arm i at inclusion;  
mp,i (tj , δ, λ, β.ρ)  model-predicted relative mf density of study arm i, at follow-up time-
point j as a function of time and the parameters δ, λ, β.ρ; 
m0,i (tj) observed relative mf density of study arm i, at follow-up moment j ; 
 
Likelihood-based confidence intervals were calculated for δ and λ (Kalbfleish 1979). 
Briefly, we calculated the scale as SSopt /df , with SSopt = the sum of squared errors of the 
optimised model (corresponding to the point-estimates for δ and λ) and df = the degrees 
of freedom. The maximum acceptable SS (corresponding to the boundaries of the 95% 
confidence interval for the parameters) are then given by SSopt + 3.84 × scale. The 
corresponding confidence intervals for δ and λ were derived.  
 
 
Results 
Nineteen potentially relevant articles were identified. Six articles met the inclusion criteria, 
with 11 relevant study arms in total (Ismail et al. 1998; Dunyo et al. 2000; Ismail et al. 2001; 
Pani et al. 2002; Makunde et al. 2003; El Setouhy et al. 2004). In Table 9-1, characteristics 
of the included studies can be found per study arm. The study arms will further be 
referred to by name of first author and year and, in two cases, an additional two-letter 
code to denote special features of the study arm.  
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Table 9-2. Point estimates (confidence intervals between parentheses) of fraction of microfilariae 
killed (mf loss) and fraction of worms with productivity loss (worm-productivity loss) per study arm 
after low or high dose IVM-ALB or DEC-ALB treatment. Model assumptions: mf life span 1 year, 
worm life span 8 years, premature period 8 months and reinfection rate post-treatment 0. 
Study arm  
by treatment regimen a Mf loss (δ) Worm-productivity loss (λ) 
IVM-ALB low dose 
     Dunyo 2000 1.00 (0.94-1.00) 0.83 (0.76-0.92) 
     Makunde 2003 1.00 (1.00-1.00) 1.00 (1.00-1.00) 
     Makunde 2003 CI 0.98 (0.96-1.00) 0.96 (0.92-1.00) 
     Ismail 2001  1.00 (1.00-1.00) 0.97 (0.97-0.97) 
     Average  1.00 0.94 
IVM-ALB high dose 
     Ismail 1998  1.00 (1.00-1.00) 0.99 (0.98-0.99) 
     Ismail 2001 1.00 (1.00-1.00) 0.98 (0.98-0.98) 
     Average 1.00 0.99 
DEC-ALB low dose 
     El Setouhy 2004 0.85 (0.82-0.89) 1.00 (0.94-1.00) 
     Pani 2002 0.54 (0.31-0.69) 1.00 (0.84-1.00) 
     Ismail 1998 0.83 (0.80-0.86) 1.00 (0.96-1.00) 
     Ismail 2001 0.91 (0.88-0.95) 1.00 (0.97-1.00) 
     Average 0.78 1.00 
DEC-ALB high dose 
     El Setouhy 2004 MD 1.00 (1.00-1.00) 1.00 (1.00-1.00) 
Note: These fractions are rounded; therefore 1.00 can be any value ≥0.995. This implies that mf 
density does not have to be reduced to zero post-treatment, even when worm-productivity loss (λ) 
and mf loss (δ) both have the value of 1.00. 
a See Table 9-1 for explanation. 
 
 
 
 
For DEC-ALB treatment, four study arms used the low dose; one study arm, El 
Setouhy 2004 MD, used multidosing and was included in the high dose group. For IVM-
ALB, four and two study arms, respectively, were included in the low dose and high dose 
group. Drug allocation was always randomised. Details about allocation concealment were 
usually not mentioned, but Pani 2002 and Dunyo 2000 used look-alike drugs coded by a 
third party. Double blinding was applied in most studies, but in Makunde 2003, El 
Setouhy 2004 and El Setouhy 2004 MD no blinding was used. Loss-to-follow-up at the 
end of the study was usually smaller than 10%. Only the DEC-ALB study arms of Ismail 
1998 and Ismail 2001 had a higher loss-to-follow-up of 15% and 19%, respectively. 
Most studies reported geometric mean mf density, calculated as antilog [Σ(log 
(x+1))/n] -1, where x was mf intensity in mf/ml and n the number of individuals in the 
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study arm. Ismail 1998 (DEC-ALB and IVM-ALB) calculated the relative mf intensity per 
individual, as percentage of pre-treatment level, and then calculated the geometric mean 
of these percentages. For three study arms (Dunyo 2000, El Setouhy 2004, El Setouhy 
2004 MD) relative geometric mean mf intensities were presented in a table, for the others 
these data had to be read from graphs. 
 
 
Review of published trends 
The observed relative mf densities are plotted in Figure 9-1 (symbols). In all four 
treatment regimen groups a decrease in mf intensity can be found. The initial decrease is, 
however, more pronounced and immediate after IVM-ALB than after DEC-ALB 
treatment. The more gradual decrease caused by DEC-ALB treatment did not show a 
tendency to bounce back during the whole of the 720 days of post-treatment follow up, 
in contrast to the relative mf density after IVM-ALB treatment. For low dose IVM-ALB 
or DEC-ALB, treatment reductions in relative mf density were variable and smaller than 
for the high dose treatment regimens groups. 
 
 
Efficacy estimates 
Assuming that the effects of treatment on mf and on worm-productivity differed between 
study arms resulted in a significantly better sum of squared errors than assuming an equal 
effect within each of the four treatment regimen groups, especially in the low dose 
groups.  
The results of the analysis per study arm are summarised in Figure 9-1 and Table 
9-2. In general, predicted trends fitted the observations closely. For low-dose IVM-ALB, 
estimated mf loss was near 100% in all study arms; worm-productivity loss was more 
variable. Relative mf density increased much faster in Dunyo 2000 than in the other study 
arms (Figure 9-1A), resulting in a lower estimate of worm-productivity loss. For high dose 
IVM-ALB, estimated mf and worm-productivity losses were very high, approximating 
100% (Figure 9-1B). In the low dose DEC-ALB group, estimated worm-productivity loss 
was 100% for all study arms, but the mf loss was variable. Mf loss was lowest for Pani 
2002, which showed a smaller initial decline in mf intensity than the other study arms 
(Figure 9-1C). For this study arm, the model predicted higher mf intensities on the long 
term than observed. For the one study arm that used high dose DEC-ALB, both mf and 
worm-productivity losses were estimated at 100% (Figure 9-1D). 
Allowing for acquisition of new infections during follow-up (with the rate equalling 
that of the pre-treatment situation) resulted in a better model-fit, but did not influence the 
efficacy estimates: we only found very minor increases in estimated mf loss for DEC-
ALB and worm-productivity loss for IVM. Assumptions on mf life span had more impact 
on goodness of fit and efficacy estimates. A shorter mf life span usually gave a better fit 
for the DEC-ALB study arms, whereas a longer mf life span gave a better fit for
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the IVM-ALB study arms. Nevertheless, efficacy estimates for the different study arms 
usually did not change much, except for Pani 2002 and Dunyo 2000. For Pani 2002 
(DEC-ALB low dose), the estimated mf loss was considerably lower (0.46) or higher 
(0.61) when we assumed the mf life span to be six or 24 months, respectively; the 
estimated worm-productivity did not depend on mf life span. For Dunyo 2000 (IVM-
ALB low dose), the estimated worm-productivity loss was higher (0.89) or lower (0.71) 
for the shorter and longer mf life span, respectively; the estimated mf loss did not depend 
on mf life span. Halving and doubling the premature period or the worm life span did not 
have an effect on the estimates for any study arm. The effect of changes in the various 
model-parameters remained the same, when they were varied at the same time in a 
multivariate sensitivity analysis. 
 
 
Discussion 
Nowadays DEC-ALB and IVM-ALB are the recommended combination therapies in 
mass drug administration programmes for lymphatic filariasis. In the studies analysed 
here, both therapies proved to be very effective. IVM-ALB immediately reduced mf 
density to extremely low levels, and although the density slightly increased during follow-
up, it remained below 5% of pre-treatment level in most studies. In spite of a lower 
immediate decline, on the long term DEC-ALB also reduced mf density to less than 5% 
of pre-treatment level at one year post-treatment. Using a mathematical model, we 
estimated that DEC-ALB treatment reduced worm-productivity to zero in all study arms, 
whereas the immediate mf loss was variable (range 54%-100%). IVM-ALB had a very 
strong effect on both mf and worms (estimated mf loss 98-100%; estimated worm-
productivity loss 83%-100%). For both drug-combinations, efficacy estimates were higher 
in the high-dose group. Sensitivity analysis showed that these estimates did not depend 
much on assumptions on worm life span, premature period, or changes in parasite 
reinfection rates, and only slightly on assumptions on mf life span (see below). 
Explanations in literature for worm-productivity loss include death of the adult 
worms (as assumed for DEC and ALB) (Ottesen 1985; Ottesen et al. 1999) and 
irreversible sterilization (as assumed for IVM) (Dunyo et al. 2000b). Based on the available 
data we cannot determine with certainty whether the (nearly) complete worm-productivity 
loss is irreversible; this would require longer follow-up. Plaisier et al. (1999) assumed a 
'recovery period' for the adult worms in their mathematical model during which mf 
production is temporarily interrupted, but found no evidence for such a transient effect in 
addition to an irreversible productivity loss. 
Overall, the methodological quality of the studies included in our review was good, 
although loss-to-follow-up in Ismail 1998 and Ismail 2001 was high. One drawback of 
our study was the data extraction from graphs. Graphs may be inaccurate and reading 
data from graphs may introduce an error. However, a small error in reading the mf 
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density will not have a large effect on the analysis of the relative trends and the resulting 
efficacy estimates.  
The trend in mf density in Pani 2002 showed a much smaller initial decline in mf 
density than the other DEC-ALB studies. The observed trend in this study, which had a 
very low mean mf count before treatment in comparison to other studies (Table 9-1), may 
have been influenced by reduced sensitivity of the mf diagnostic test at lower densities 
and relatively large fluctuations in mf counts. However, other differences between the 
studies (done under different circumstances in different areas) might also have played a 
role. Dunyo 2000 showed high resurgence of the relative mf density post-treatment 
compared to the other IVM-ALB studies. There is no reason to assume that the different 
diagnostic tool used in this study (see Table 9-1) could explain the different pattern. It 
might be due to the relatively high mf load pre-treatment, which would indicate a larger 
worm load and possibly a greater chance of worm pairs surviving after treatment and 
producing mf. The number of included studies is too small to come to a profound 
understanding of the causes underlying these different patterns.  
Uncertainty about the dynamics of parasite development in the human host 
complicates our analysis. For example, the mf life span determines the death rate of mf 
that survived treatment and the rate of mf recurrence of mf due to mf producing worms. 
Uncertainty on the mf life span therefore influences the estimated effect of treatment. 
Assumptions in this life span had strongest impact in Pani 2002 and Dunyo 2000, but had 
less influence in other studies where the effects of treatment were more complete.  
Another uncertainty in the model was the change in the rate of parasite acquisition 
after treatment. It could be expected that in hospital-based studies transmission intensity 
would not change much due to the limited number of individuals treated within a 
community, whereas it could decrease in community-based trials. The model, however, 
gave a better fit when post-treatment reinfection rates were assumed to be zero for all 
studies, hospital-based and community-based. There may be other explanations for the 
long-term reduction in mf density, though, that were not considered in our model. 
Treatment could not only have a direct effect on present infection (different parasite 
stages), but might also have a long-term prophylactic effect against new incoming 
infections, which is not included in the model. It is also possible that the impact of new 
infections is not visible in the mf density in the blood in the first two years after 
treatment. Furthermore monitoring effects may have had an effect: trial participants may 
have been more careful in preventing mosquito bites. 
The relative trends analysed in this study were based on geometric mean mf counts 
(obtained from log-transformed data to which 1 had been added). Smaller mf counts 
receive more weight in this measure; therefore reductions in mf intensities will be 
stronger than when considering the individual mf intensities (Fulford 1994). Together 
with a diagnostic test that is less sensitive with lower mf counts this probably has led to a 
systematic overestimation of the effect. In addition, only mf-positives were included; mf-
negatives becoming positive despite treatment were disregarded, which could lead to 
further overestimation of the effects of treatment.  
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Model-based analysis of trial data concerning IVM (≥ 200 µg/kg) treatment 
estimated 100% microfilaricidal effect and a loss of mf production of ≥ 77%, while using 
the same parasite demographic parameter values as in this study (Plaisier et al. 1999). Our 
estimates for IVM-ALB were higher, which could be explained by the added effect of 
ALB (Addiss et al. 1997; Dunyo et al. 2000; Makunde et al. 2003). Using this model, we 
cannot determine whether the worm-productivity loss results from killing of adult worms, 
sterilization or another mechanisms that inhibits the appearance of mf in the blood. Using 
ultrasound, the macrofilaricidal effect of treatment can be estimated directly. In this way, 
it was estimated that DEC in doses of 6 mg/kg or higher killed 51% of the worm nests 
(Norões et al. 1997). Ultrasound investigations after IVM treatment indicated no killing of 
worms (Dreyer et al. 1996). Our estimates for the worm-productivity loss caused by DEC-
ALB and IVM-ALB were much higher than those indicated by the ultrasound studies. 
The added effect of ALB may not be the only explanation for this finding. Sterilization of 
(female) worms could also explain this difference: worms stop producing mf, but remain 
visible on ultrasound. Similarly, single-sex or single-worm infections may remain visible 
after treatment, although these infections do not contribute to mf density. In addition, 
ultrasound detection can only evaluate the effect on whole nests in the scrotum and the 
superficial lymphatics (Dreyer et al. 1996; Norões et al. 1997).  
In four studies included in our review, circulating filarial antigen was measured post-
treatment (Ismail et al. 1998; Dunyo et al. 2000; Ismail et al. 2001; Pani et al. 2002). It is still 
not clear how circulating filarial antigen is associated with death or sterilization of worms 
(Eberhard et al. 1997). We did not analyse the antigen data. It was striking, however, that 
our model predicted a very high worm-productivity loss, whereas few of the subjects 
totally cleared circulating filarial antigen. 
In conclusion, the observed data showed that treatment with combinations of IVM-
ALB or DEC-ALB results in a strong reduction in mf density for long periods. The 
estimated mf loss and worm-productivity loss after treatment with either of the 
combinations were very high, even if uncertainties and possible overestimation of the 
effect due to the use of geometric means are taken into account. Applied in yearly MDA, 
these drug-combinations can have strong impact on lymphatic filariasis transmission, 
provided that coverage and compliance are sufficiently high. Although high-dose 
regimens may be more effective, the lower (standard) dosages may be preferred for use in 
MDA because of practical reasons. Widespread use of drugs in MDA entails a risk that 
resistance develops. This has not been observed yet, and is not expected to develop fast 
because the transmission cycle from one generation of W. bancrofti to the next is very long 
compared to other nematodes in which drug resistance has occurred (Eberhard et al. 
1991) and drug combinations are used instead of single drugs. Since ALB is also highly 
effective for the treatment of common species of intestinal helminths of humans (Horton 
2000), the impact of MDA has a broader public health impact, which goes beyond 
lymphatic filariasis.  
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Appendix 
 
Formal description of the model 
NB. This model is the same as the model used in Chapter 8 of this thesis. 
The dynamics of parasite development and mf production are described by a set of 
differential equations. Let W be the number of adult and productive worms in a person, L 
the number of premature worms, and M the number of mf. Tp , Tl and Tm are the 
premature period, the life span of the worm and the life span of the mf respectively. Tl - 
Tp is the productive life span of worms. Then: 
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 (A1) 
with β0,i = the pre-treatment force of infection (no. of new worms/person/year), γ = the 
per capita rate of maturation to adult and productive parasite (γ =1/Tp ), µ1 = the per 
capita death rate of premature and adult worms (=1/Tl ), µ2 = per capita death rate of mf 
(=1/Tm ), ρ = the rate of mf production of an adult worm per unit of blood taken for 
diagnosis, and i an index for study arm: persons treated with a certain therapy and a 
certain dose in a certain study. 
Assuming that the force-of-infection, β0,i , in the population has been constant for a 
long time, the pre-treatment numbers of premature and mature worms and mf are equal 
to the equilibrium values L, W, and M (denoted with * ), which can be derived by solving 
the equations for dL(t)/dt = dW(t)/dt = dM(t)/dt = 0: 
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Efficacy of drug combinations for lymphatic filariasis treatment 
145 
Equations A1 and A2 are the same as in Plaisier et al. (1999). However, the effects of 
treatment in the current paper are slightly different: we do not consider a temporal effect 
of treatment so that ‘recovering’ worms are not considered in the present model; 
furthermore, we assume that both premature and mature worms are affected by the 
treatment. At the moment of treatment, a fraction δi of the mf (M) is killed 
instantaneously and a fraction λi of all worms present in the body (L and W) stops 
producing mf (W) or loses its potential ability to produce mf (L) in the case of premature 
worms. Hence, at treatment time-point t , the following immediate changes occur: 

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−⇐
−⇐
)()1()(
)()1()(
)()1()(
tMtM
tWtW
tLtL
i
i
i
δ
λ
λ
 (A3) 
(the symbol ⇐ means ‘becomes’) 
 
After treatment, individuals are again exposed to infection. The post-treatment force-of-
infection (βt,i ) is defined as a fraction s of the pre-treatment force, so that βt,i = s β0,i .  
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This thesis aims to support decision making in lymphatic filariasis control, through the 
development and application of a transmission model for this infection. This final chapter 
provides concise answers to the questions posed in the introduction (section 10.1), 
discusses remaining challenges for model-based support of lymphatic filariasis control 
(section 10.2), and lists the main conclusions and recommendations (section 10.3). 
 
 
10.1 Answering the research questions 
 
10.1.1 What are the prospects for elimination of lymphatic filariasis by mass 
treatment?  
Our simulation studies on the impact of mass treatment (chapters 3 and 4) showed that 
prospects of elimination are good if coverage levels are sufficiently high – at least in areas 
like Pondicherry (India), where infection is transmitted by Culex quinquefasciatus and the 
pretreatment microfilariae (mf) prevalence is about 8.5%. Six annual rounds of mass 
treatment with the recommended combination of diethylcarbamazine (DEC) and 
albendazole are needed for elimination if population coverage is 65% per round. Only 
four rounds are sufficient if coverage is 80%. More treatment rounds are required if DEC 
is used without albendazole or if the pretreatment mf prevalence level is higher.  
There is uncertainty in our model-prediction, because the processes involved in 
transmission and mass treatment are not completely understood and quantified. 
Important uncertain factors are the parasite life span, the effects of existing antifilarial 
drugs on adult worm viability or mf productivity, and the role of human immune 
responses (section 10.1.2.). Although the accuracy of our predictions can only be 
determined in retrospect, important conclusions can nevertheless be drawn.  
Our studies clearly showed the overwhelming importance of achieving high 
coverage levels for the success of elimination programmes. Coverage levels vary widely in 
ongoing programmes. Countries like Egypt and French Polynesia report very high 
coverage of >90% (World Health Organization 2005), but in a number of Indian studies 
much lower coverage levels were achieved (Ramaiah et al. 2000; Vanamail et al. 2005). 
Programmes should make strong efforts to reach and maintain high coverage levels. The 
determinants of population coverage and compliance are still incompletely understood 
and it is not clear how social mobilization should be organized in different resource-poor 
settings. For strengthening the Global Programme to Eliminate Lymphatic Filariasis 
(GPELF) more research is urgently needed on these issues (Anonymous 2004).  
We also showed that the duration of mass treatment required for elimination 
strongly depends on the efficacy of the treatment regimen, especially on the effect on 
adult worms. Although existing drugs are quite effective, the prospects for elimination 
would improve if drugs with better macrofilaricidal efficacy were available. For this 
reason, but also to anticipate the possible development of resistance against existing 
drugs, the search for new drugs or drug-combinations remains an important priority for 
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further research (Anonymous 2004). Anti-Wolbachia treatment has shown promising 
results in this respect, but the investigated 6- or 8-week treatment regimens (Hoerauf et al. 
2003; Taylor et al. 2005) are not suitable for use in mass treatment.  
Our simulations further indicated that the required duration of mass treatment 
increases with pre-treatment endemicity level. This has two reasons. Firstly, the average 
worm burden is higher and more treatment rounds are needed to clear the infection with 
the available drugs. Secondly, the higher pre-treatment prevalence levels are presumably 
caused by higher mosquito biting rates, implying a higher risk of infection recurrence after 
stopping control. Prevalence levels therefore will have to be reduced to lower absolute 
levels. 
These findings are important for GPELF. Based on an assumed adult worm life 
span of about 5 years, it was hoped that 4-6 years of annual mass treatment would be 
sufficient for elimination in most situations (Gyapong et al. 2005). Programme managers 
and policy makers should be aware that the duration can be considerably longer if 
coverage levels are low or endemicity levels are high. For reducing the total duration of 
elimination programmes in highly endemic areas, one might consider to increase the 
frequency of mass treatment (e.g. from yearly to 6-monthly) or to implement vector 
control in addition (Michael et al. 2004). Distribution of DEC-medicated cooking salt 
provides an interesting alternative approach to mass treatment (Houston 2000). If 
circumstances make elimination of the parasite very difficult, focus may be shifted to 
elimination of the public health problem rather than the infection. To achieve this goal, 
transmission does not necessarily have to be interrupted completely, but sustained control 
measures are required to keep transmission at such low levels that serious disease will be 
infrequent. 
Some important aspects remain to be investigated, such as the potential impact of 
parasite resistance against the used drugs or the risk of recurrence of infection due to 
migration. But first and foremost, we need to study the prospects of elimination for 
regions with other vector-parasite combinations than in Pondicherry, in particular for 
Sub-Sahara Africa where mf prevalence levels can be considerably higher than in India 
(Stolk et al. 2004). Recent advances in this respect are reported in section 10.2.1. 
 
 
10.1.2 Does protective immunity develop after prolonged exposure to lymphatic 
filariasis infection? 
In our model-based analysis of longitudinal data from Pondicherry, India, we attributed 
the observed pronounced decline in prevalence in the older age groups to acquired 
immunity (chapter 2). If this acquired immunity assumption is correct, a similar decline in 
prevalence would be expected in other areas. However, our subsequent analysis of 
published age-patterns from India and Africa showed that such a decline is an exception 
rather than the rule (chapter 6). The acquired immunity assumptions in the Pondicherry 
model should be reconsidered.  
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We cannot definitely exclude a role for acquired immunity, but, if it exists, it will 
work in a different way than assumed for Pondicherry. Animal studies found evidence 
that past exposure to infection can indeed reduce the acquisition of new infections 
(Selkirk et al. 1992). Theoretical work further showed that acquired immunity does not 
necessarily lead to down regulation of infection in the oldest age groups (Woolhouse 
1992). For example, a decline is not expected if immunity rapidly decays when the host is 
not longer exposed to the infection. Better understanding of the role of human immune 
responses is required for accurate assessment of the elimination prospects for lymphatic 
filariasis.  
It was initially hoped that the Pondicherry model with minimal changes could be 
used for other Indian areas as well, since the vector species is the same (Cx. 
quinquefasciatus) and transmission dynamics are thought to be similar. However, the 
Pondicherry model does not correctly simulate the generally observed age-patterns of 
infection. This underscores the importance of validating models against several 
independent datasets. A model without acquired immunity may better explain normal age-
patterns in India, but in chapter 2 we found that such a model has difficulty to explain the 
low mf prevalence level in Pondicherry (8.5%) in the presence of a ubiquitous vector. The 
challenge to develop a more widely applicable model for Culex-transmitted infection in 
India has been taken up by the Vector Control Research Centre in Pondicherry 
(Subramanian et al., unpublished work). 
 
 
10.1.3 How do mosquito species differ with respect to their efficiency in 
transmitting lymphatic filariasis infection? 
A large number of mosquito species can transmit lymphatic filariasis infection and we 
considered only Cx. quinquefasciatus and Aedes polynesiensis (chapter 7). For both species, we 
found saturation in the number of mf that on average develops successfully into L3 larvae 
(i.e. limitation), but the maximum was much higher for Ae. polynesiensis than for Cx. 
quinquefasciatus (23 vs. 4). 
The relationship between infection intensity in humans and L3 larvae in mosquitoes 
(here referred to as ‘vector uptake curve’) has received much attention, because density 
dependence in this relationship influences the impact of control (Southgate & Bryan 
1992; Duerr et al. 2005). In the absence of density dependence in the vector uptake curve, 
the number of L3 larvae in mosquitoes would increase linearly with mf density in the 
human blood. In case of ‘limitation’, the number of L3 larvae increases less than 
proportional with mf density in the blood and approximates a maximum at higher 
densities. The transmission is most efficient at lowest mf densities: few mf may be 
engorged, but a large proportion will survive to become L3. In case of ‘facilitation’, the 
number of L3 increases more than proportional with mf density (until at higher densities 
limiting mechanisms get the upper hand). Transmission efficiency is least efficient at the 
lowest densities: only a small proportion of few engorged mf will survive. For elimination, 
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a situation with facilitation is favourable, because of the low transmission efficiency at 
lowest mf densities. 
An earlier analysis already showed that there is limitation in the vector uptake curve 
for Cx. quinquefasciatus (Subramanian et al. 1998), the main vector in India. We found the 
same for Ae. polynesiensis, the vector in French Polynesia. The two curves were very 
different, though, with many more L3 per mosquito in Aedes than in Culex. Implications 
of this difference for elimination are not straightforward, since transmission also depends 
on other factors such as vector density, feeding behaviour, density dependence in 
mosquito survival, etc. The uptake curve for Ae. polynesiensis can be used to develop a 
simulation model for transmission in French Polynesia. 
An important gap in knowledge concerns the quantification of the vector uptake 
curve for Anopheles. Mosquitoes of the genus Anopheles are responsible for transmission in 
Africa and are the second most important for filariasis transmission after Culex 
quinquefasciatus (Zagaria & Savioli 2002). There is evidence of facilitation in Anopheles 
mosquitoes (Southgate & Bryan 1992; Pichon 2002). However, accurate quantification of 
the uptake curve for Anopheles is currently difficult, because only few studies investigated 
the relationship. These studies are not directly comparable, because they considered 
different Anopheles species, used natural or laboratory-reared mosquito populations, used 
different methods for mosquito feeding, and used different diagnostic tests for measuring 
mf density in the human blood. In an explorative analysis, we nevertheless aggregated the 
data from these studies for quantification of the vector uptake curve (Appendix A). 
Results are shown in Figure 10-1. The number of L3 larvae developing in anopheline 
mosquitoes seems to be lower than in Cx. quinquefasciatus, but the data do not allow 
accurate estimation of the maximum. There was no indication of strong facilitation. The 
resulting curve was implemented in LYMFASIM as part of a simulation model for the 
African situation (see Section 10.2.1). 
In our studies, we only considered density dependence in the relationship between 
mf density in human blood and the number of L3 developing in mosquitoes. However, 
density dependence may also occur in mosquito survival (Pichon 2002; Krishnamoorthy et 
al. 2004). If this increases the total degree of limitation in the transmission cycle, it would 
further limit the eradicability of the infection. Possible density dependence in mosquito 
survival is currently not considered in the LYMFASIM model and remains to be 
quantified for many species. 
 
 
10.1.4 What are the effects of DEC, ivermectin, and their combinations with 
albendazole, on adult worms and microfilariae? 
By analyzing trends in mf density after treatment, we estimated that a 6-mg/kg dose of 
DEC kills on average 57% of mf and reduces mf production by 67% (chapter 8). The 
reduction in mf production is presumably caused by worm death. A 400-µg/kg dose of 
ivermectin was found to be more effective, killing almost all mf (96%) and reducing mf 
General discussion 
 153 
Figure 10-1. The relationship between mf density in the human blood and the number of L3 
developing in Anopheles mosquitoes. Dots give the observed data, sized according to their 
weight in the analysis; the line gives the fitted curve (fit based on log-transformed values for the 
average number of L3 per mosquito; presented curve gives values after back-transformation). 
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production by 82%. The latter effect is probably caused by reduced fertility or inhibition 
of mf release from the female uterus. Especially the DEC effects varied strongly between 
individuals. Treatment efficacy estimates were higher for these drugs in combination with 
albendazole (chapter 9). 
Effects of treatment cannot directly be measured and we therefore used the indirect 
approach of analyzing post-treatment trends in mf density. Although information from 
other studies (histology, ultrasound) is required to determine the nature of the effect on 
adult worms, our approach is powerful for its quantification and as yet the best way to 
quantify an effect on fertility. Our efficacy estimates could be too optimistic, because 
observed trends may have been biased by the reduced sensitivity of mf diagnostic tests at 
very low mf densities (Dreyer et al. 1996) and the use of geometric means (Fulford 1994). 
Further, we should be aware that the reduction in mf production can be larger than the 
proportion of adult worms affected, because surviving worms may have been left 
unmated and therefore also have stopped producing mf.  
The estimated effects of DEC treatment on adult worms can be compared with 
results from ultrasound studies: the proportion of worms killed can be estimated from the 
disappearance of the so-called filarial dance sign after treatment (i.e. random movement 
of the adult worms, visible on ultrasound). The few available ultrasound studies suggest 
that the proportion of worms killed by DEC treatment is slightly lower (~50%) than our 
estimate of the reduction in mf production (Norões et al. 1997; Kshirsagar et al. 2004). 
The estimated effects on adult worms of ivermectin treatment cannot be compared with 
other studies: the drug does not kill worms and there are no methods available to measure 
an effect on adult worm fertility or mf-productivity. 
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Table 10-1. The probability of elimination after 5 rounds of mass treatment with 65% coverage, in 
relation to assumptions on variation in treatment efficacy. Exact, asymmetric 95%-confidence 
intervals (CI) are given. Elimination was said to occur if the prevalence had been reduced to zero, 
35 years after the last treatment. Mean and variability in treatment effects were quantified based 
on results from chapter 8. On average, the effects of treatment are always the same: DEC is 
assumed to kill 57% of mf and 67% of worms. Ivermectin is assumed to kill 96% of mf and to 
reduce the female worm fertility by 82%.  
 Probability of elimination after 5 rounds  
of MDA with 65% coverage (95% CI) 
Assumptions on variation in treatment efficacy DEC Ivermectin 
No variation  98% (93% – 100%) 81% (72% – 88%) 
Random variation 92% (85% – 96%) 80% (71% – 87%) 
Systematic between-person variation 43% (33% – 53%) 72% (62% – 81%) 
 
 
 
 
Our individual-level analysis provided important new information on variability in 
treatment effects. Variability limits the impact of mass treatment, especially if some 
individuals systematically have a poor response to treatment. To investigate how strong 
this effect can be, we did some additional simulations with the Pondicherry model of 
chapter 2. We simulated the probability of elimination after 5 rounds of mass treatment 
with 65% coverage. Estimates of treatment effects (mean and variability) were directly 
taken from chapter 8, assuming that the reduction in mf production is caused by killing of 
worms for DEC and by permanent sterilization of female worms for ivermectin. Results 
are shown in Table 10-1. For DEC, our model predicted elimination in 98% of runs 
(n=100) when we assumed no variation in treatment efficacy. Elimination still occurred in 
92% of the runs, when we assumed treatment efficacy to vary randomly without any 
relation to personal characteristics. However, when we assumed that individuals always 
have the same (sometimes poor) response to treatment, elimination occurred in only 43% 
of the runs. The differences were smaller for ivermectin, because this drug had less 
variable effects and never had no effect at all. 
 
 
10.2 Remaining challenges for model-based support of lymphatic 
filariasis control 
We have worked on the development and application of a lymphatic filariasis trans-
mission model, aiming to support decision making in lymphatic filariasis control. Chapter 
5 described the advances in this respect and identified remaining challenges in view of the 
rapidly expanding GPELF. The two main challenges are: 1) quantification of models for 
regions with different vector-parasite combinations, and 2) application of models to 
monitoring and evaluation issues of relevance for current elimination programmes. These 
issues are further discussed in this section. 
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10.2.1 Application of models for regions with different vector-parasite 
combinations 
The limited field evidence available and our model analyses for Pondicherry have 
provided an indication of the duration of mass treatment required for elimination, but it is 
unclear whether the same outcomes can be expected in regions with other vector species 
or parasite strains and higher endemicity levels. Models can be used to explore how the 
prospects of elimination depend on the vector-parasite combination and local 
transmission dynamics.  
Since almost 40% of the global burden of lymphatic filariasis is in Africa, where 
Anopheles species are the main vectors of lymphatic filariasis, it is of particular relevance to 
develop a model for this vector species. Building on the work presented in this thesis, we 
developed a first, preliminary version of an Africa-model (“Africa-model v0.1”). In line 
with conclusions of chapter 6, acquired immunity was not considered. We further used 
the uptake curve of Figure 10-1 and quantified the other model-parameters as described 
in Appendix B. The resulting model could explain the whole range of prevalence levels 
occurring in Africa (from <5% to >40%), the observed age-patterns, and the observed 
relationship between mf prevalence and mf intensity, but has some difficulty in explaining 
the relationship between overall mf prevalence with the mosquito biting rates (Figure 
10-2). However, the observations of Figure 10-2-F are somewhat difficult to interpret for 
several reasons. Large measurement errors in average biting rate estimates introduce a 
bias in the observations, leading to a lower slope in the observations than expected. This 
effect is strengthened because biting rates are not constant over time. The relationship is 
further blurred because the observations come from different studies, which employed 
various different mf diagnostic tests (not necessarily the same as in our model). We 
therefore accepted the relatively poor fit in Figure 10-2-F for now. 
We did some explorative simulation runs with the Africa-model, to investigate the 
prospects of elimination by yearly mass treatment (Table 10-2). These prospects seem to 
be greatly determined by the pre-treatment mf prevalence level (which varies with the 
monthly biting rate according to the line in Figure 10-2-F). In areas with relatively low mf 
prevalence levels of 10%, elimination can be achieved in a limited number of treatment 
rounds, even if coverage levels are low. The higher the prevalence, the more difficult it 
becomes to achieve elimination. In areas with prevalence of 30% or 40%, very high 
coverage levels and many yearly treatment rounds would be needed to reach this goal.  
These preliminary results are worrying for current elimination efforts in Africa: high 
prevalence levels are not uncommon (see Figure 6-2) and experience learns that often it is 
difficult to achieve high coverage levels (World Health Organization 2005). Especially in 
high-endemic areas, therefore, we may want to consider alternative interventions or to 
shift focus to bringing down infection to such low levels that disease is prevented without 
completely interrupting transmission.  
Clearly, these model-predictions must be interpreted with care. Some further work 
should be done to investigate whether the goodness-of-fit of the Africa-model can be 
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Figure 10-2. Comparison of predicted (lines) and observed (dots) microfilaria (mf) prevalence and 
intensities, for the Africa-model v0.1. (A) Mf prevalence by age; (B) Geometric mean mf intensity 
(GMI) among mf-positives by age; (C) Relative mf prevalence by age, calculated as age-specific 
prevalence / overall prevalence in the study population; (D) Relative mf intensity by age, 
calculated as age-specific GMI among postives / overall GMI among positives in the study 
population; (E) GMI among mf-positives by mf prevalence; (F) Overall mf prevalence by monthly
biting rate (mbr, average number of bites per person per month). GMI is always in mf per 20 µl 
night blood. Lines in figures A-E show the simulation results for different biting rate levels (solid: 
mbr = 500, long-dashed: mbr = 752; short-dashed: mbr = 2015). In figure F, closed dots were 
used for studies that used repeated landing catches to determine biting rates, open dots for all 
other methods (the former are considered most reliable).
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improved, e.g. by including another density dependent mechanism besides limitation in 
the vector uptake curve. Further, the model needs to be validated by comparison of 
predicted trends during and after mass treatment with already available data. An 
interesting dataset in this respect is available from Tanzania, which has 10 year follow-up 
data after three different strategies of mass treatment with diethylcarbamazine 
(Meyrowitsch et al. 2004).  
Similar approaches can be used to quantify the model for other regions. This is a 
time-consuming process, because data on different aspects of transmission must be 
brought together. Excellent understanding of the data and of the processes involved in 
transmission and control is required. This basic model quantification can therefore best 
be done by experienced modellers, hand in hand with researchers who are familiar with 
the local situation considered. Ideally, this yields a vector-parasite specific model that can 
easily be calibrated to local endemicity levels by adjustment of just 1 or 2 parameters.  
 
 
10.2.2 Application of models to monitoring and evaluation issues of current 
elimination programmes 
Many countries have initiated mass treatment and others will follow. All these elimination 
initiatives face the same questions: Is the program making enough progress to achieve 
elimination within the expected timeframe or do we need to intensify / adapt our control 
efforts? When can mass treatment be stopped?  
To help address these issues, extensions of the available models (LYMFASIM and 
EPIFIL) could be useful. For example, current elimination programmes use different 
diagnostic tests to monitor their progress. Besides mf detection, this includes antigen 
detection and xenomonitoring (determining infection prevalence and intensity in 
Table 10-2. Predicted number of treatment rounds that is required to be 99% certain of elimination 
in African communities with varying pretreatment mf prevalence levels. Predictions for Pondicherry, 
India, are shown for comparison. Methods are as described in chapter 3, using the models that 
were developed for Africa (section 10.2.1) and Pondicherry, India (chapter 2). Treatment is 
assumed to kill 65% of adult worms and 70% of mf per treatment, without variability. 
 Pretreatment Population coverage 
Model mf prevalence 60% 70% 80% 90% 
Africa 10% 6 4 3 3 
 20% 14 9 7 5 
 30% * * 11 8 
 40% ** * * 13 
Pondicherry (India) 8.5% 7 5 4 3 
* / ** Estimated number of treatment rounds was 16-29 (*) or 30+ (**); in both cases, estimates 
were not exact, because they were based on logistic regression extrapolations beyond 15 
treatment rounds. 
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mosquitoes). These tests should be included in the model output for comparison of 
observed and predicted trends. This would allow the determination of stop-criteria based 
on the different tests or their combinations. Simulation models should also consider 
disease development (hydrocele, lymphoedema, acute attacks), to predict the impact of 
intervention on disease prevalence and severity. This might be especially relevant in areas 
where elimination of the parasite is difficult. 
Quantified and validated models can be used in simulation experiments to address 
issues that are of relevance for all ongoing programmes. For example, simulation 
experiments can be done to estimate the threshold level of mf or antigen prevalence, 
below which transmission will usually extinguish without further intervention. They can 
also help to identify cost-effective approaches for enhancing the effectiveness of the 
programme or for monitoring trends during and after mass treatment. Model-predicted 
trends in infection and disease are useful to check whether a programme is on track and 
will achieve its goal of elimination in the expected timeframe.  
From the field, there is a strong demand to use the model-tool for evaluation of 
specific ongoing elimination programmes. This demand follows the positive experience of 
using the ONCHOSIM simulation model (Plaisier et al. 1990) in planning and evaluation 
of the large-scale Onchocerciasis Control Programme in West-Africa that ran from 1975-
2002 (Habbema et al. 1992; Plaisier et al. 1997). The situation in lymphatic filariasis is a bit 
more complex, because transmission dynamics can differ markedly between regions due 
to different vector-parasite combinations and other factors. Before models can be used 
Figure 10-3. Input screen of the Windows-interface for LYMFASIM, which contains specifications 
for predicting the trends after 5 rounds of mass treatment with varying levels of coverage 
(hypothetical situation).
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for evaluation of specific programmes, they should first be quantified and validated for 
the local situation as illustrated above for Africa. When this is completed, models could 
be transferred to programme managers and others involved in planning and evaluation of 
lymphatic filariasis control programmes.  
Indeed, eventual transfer of the model to ongoing elimination programmes has 
received due attention in our project. Successful use of the model by others requires a 
more user-friendly interface and some training. A simple Windows-interface is in 
development: the user will be able to adapt a (vector-specific) model to the local situation 
in a simple way and to simulate the impact of interventions (Figure 10-3). Several people 
from the Vector Control Research Centre (Pondicherry, India) and the World Health 
Organization-secretariat of the GPELF have already been trained in the use of 
LYMFASIM. Representatives of control programmes of specific countries will follow in 
the framework of ongoing and new collaborations. 
 
 
10.3 Conclusions and recommendations  
 
Conclusions: 
• The prospects for elimination of lymphatic filariasis by mass treatment vary between 
regions with different vector-parasite strains and depend strongly on the pre-
treatment endemicity level, the applied treatment regimen, and the proportion of the 
population treated per round.  
• Prospects for elimination of bancroftian filariasis in a Pondicherry-like situation (an 
Indian area with about 8.5% pretreatment mf prevalence) are good if the highly 
effective combination of DEC and albendazole is used in mass treatment and 
coverage is sufficiently high: predictions suggests that six annual rounds of mass 
treatment with population coverage of 65% are sufficient for elimination. 
• It is too optimistic to assume that elimination of lymphatic filariasis can be achieved 
by 4 to 6 rounds of mass treatment in any area: many more rounds may be required 
when coverage is low or pretreatment endemicity levels are high. The goal of 
eliminating the disease as a public health problem without necessarily interrupting 
transmission may sometimes be more realistic. 
• The strength and direction of density dependence in the relationship between mf 
density in the human blood and the average number of L3 developing in mosquitoes 
vary between mosquito species. Therefore, vector-specific models should be used for 
prediction and results should not be generalized across areas with different vectors. 
• Summarized epidemiological data of mf prevalence by age from India and Africa 
provide no indication that the prevalence of infection is down regulated in older age 
groups as a consequence of acquired immunity. The acquired immunity assumptions 
of the Pondicherry model should therefore be reconsidered. 
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• DEC and ivermectin, given alone or in combination with albendazole, are highly 
effective, killing a large proportion of mf and affecting viability or reproductive 
capacity of adult worms 
 
Recommendations:  
• Elimination programmes should be monitored carefully, using operational indicators 
(population coverage, systematic non-participation) and epidemiological indicators 
(infection prevalence and intensity). 
• Simulation models should be quantified for different vector-parasite combinations 
and their validity should be tested against data from areas with varying endemicity 
levels. 
• Validated simulation models should be used to address the following issues, which 
are of crucial importance for the Global Programme to Eliminate Lymphatic 
Filariasis: 
o Define criteria for stopping mass treatment; 
o Identify cost-effective approaches to enhance programme effectiveness; 
o Determine the short- and long-term impact of mass treatment on disease 
prevalence and severity; 
o Determine the circumstances under which elimination of infection is so 
difficult, that programmes should better focus on elimination of the disease as a 
public health problem. 
• Validated models should be transferred to policy makers and programme managers 
for use in planning and evaluation of ongoing programmes. 
• Research for drugs with better macrofilaricidal efficacy than the existing ones should 
continue to further improve elimination prospects and anticipate the potential 
development of resistance. 
• Potential density dependence in parasite establishment or mf production in the 
human host should be examined, using the modern diagnostic methods that allow 
quantification of the adult worm burden. 
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Appendix A. The uptake curve for Anopheles 
 
 
Data 
To quantify the uptake curve for Anopheles (describing the relationship between mf 
density in the human blood and the number of L3 larvae developing in mosquitoes) we 
analyzed paired data on human mf density and the average number of L3 developing in 
mosquitoes after taking a blood meal. Detailed data were available from a study in Ghana 
that was carried out to investigate this relationship for anopheline mosquitoes (Boakye et 
al. 2004). The few data that were available from literature were also used (Bryan & 
Southgate 1988a, b; Southgate & Bryan 1992). To come to a crude quantification of the 
vector uptake curve, we aggregated the data from different studies, even though these 
studies differed in the type of mosquitoes considered (natural populations or laboratory-
reared mosquitoes of different Anopheles-species), used different methods for mosquito 
feeding, and used different methods to determine mf density.  
All mf densities were first scaled to mf counts in 20 µl night blood smears. If mf 
counts were measured in fingerprick blood taken at night, this only concerned a 
correction for the volume of blood considered. If mf counts were measured by filtration 
of 1 ml venous blood taken at night, we used the following relationship to calculate mf 
density in 20 µl fingerprick blood, which was derived by Snow & Michael (2002): 
0309.01449.0037.0 2 −+= xxy  (A-1) 
with y = log10 (1+mf count in 20 µL finger prick blood); and x = log10 (1+mf count in 1 
mL venous blood). At the lowest mf counts (<1.246 per 1 mL venous blood), this 
function yields negative values for mf in 20 µl fingerprick blood, which are replaced by 
zero’s. This reflects the higher detection limit of mf diagnosis in the smaller 20 µl blood 
sample. Correcting for bloodvolume, the estimated mf densities in finger prick blood are 
higher than in venous blood (except for the lowest mf densities), as has been observed in 
field data. 
 
 
Fitted curve 
It has been suggested that there is facilitation in the mf uptake and development, meaning 
that the proportion of mf developing into L3 larvae initially increases with mf density in 
the human blood and saturates only at higher mf intensities (Southgate & Bryan 1992; 
Duerr et al. 2005). Such a pattern can be described by the sigmoid curve of equation A-2, 
which was fitted to the aggregated data.   
( )( )cbMeaL −−= 13  (A-2) 
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with L3 = the number of L3 larvae developing in mosquitoes; and M = the mf density in 
human blood (mf / 20 µl night blood). 
To quantify the vector uptake curve, we fitted Equation A-2 to the pooled data from 
the three studies. Both sides of the equation were log10-transformed to normalize the 
residuals. To deal with zero’s, it is common practice to add 1 to the observed and 
predicted number of L3. However, since adding 1 introduces a major distortion to the 
data, we rather added a number equal to the half detection limit (D) to the average 
number of L3 per mosquito (D is calculated as 0.5 / total number of mosquitoes 
examined). Thus, we fitted the curve of Equation A-3: 
( ) ( )( )( )DeaDL cbM +−=+ −1log3log 1010  (A-3) 
 
 
Parameter estimation 
Using the non-linear regression procedure (PROC NLIN) in SAS (v8.2), we estimated the 
values of parameters a, b and c in Equations A-2 and A-3 with the least squares method. 
Observations were weighed for the number of mosquitoes examined, weights (Wi ) being 
calculated as: 
 ∑= n
i
iii xxW  (A-4) 
with xi the number of mosquitoes examined for observation i, and n the total number of 
observations included in the analysis.  
Figure A-1. Residuals of equation 3 fitted to the data plotted against mf density in the human 
blood (mf / 20 µL).
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Results 
Point-estimates of the parameters of Equation A-2/A-3 were: a = 1.80, b = 0.016 and c = 
1.14. The fitted curve is shown elsewhere (Section 10.1.3, Figure 10-1). The plot of 
residuals indicates a reasonably good fit, although there are some outliers (Figure A-1).  
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Appendix B. Quantification of LYMFASIM for 
Anopheles-transmitted infection in Africa 
 
 
Model design and quantification of fixed parameters 
We set out to develop a model for Anopheles-transmitted infection in Africa. Following the 
conclusions of chapter 6 of this thesis, we aimed at development of a model without 
acquired immunity, because this would be the most parsimonious model for the observed 
age-patterns in the region. As far as possible, the model parameters were quantified based 
on literature, expert opinion, and analysis of local data (Tables B-1 and B-2). The value of 
only two parameters was not fixed, namely αE (i.e. the not age-related variation in 
exposure to mosquitoes) and the success ratio sr (i.e. the proportion of inoculated larvae 
that develops successfully into male or female adult worms in the human body). The 
value of these ‘free’ parameters (Table B-3) was estimated by fitting the model to the 
reference data as described below. 
 
 
Reference data 
Reference data were taken from our earlier literature review of age-prevalence patterns in 
India and Africa (chapter 6). We updated this database with recently published studies 
(Njenga et al. 2000; Boakye et al. 2004; Meyrowitsch et al. 2004). Since estimates of the 
variability of mf counts are already available for 20 µl blood smears (Subramanian et al. 
2004), but not for other mf diagnostic tests, we considered only the 9 African studies that 
used this test to estimate mf prevalence or intensity in model fitting1. Age-specific data on 
mf prevalence were available for 29 locations, but age-specific data on mf intensity only 
for 9. These data are shown in section 10.2.1, Figure 10-2 (A-E).  
To get an indication of the relationship between mf prevalence and biting rate and 
of the variability in biting rates, we also searched the literature for paired data on 
mosquito biting rates and mf prevalence levels in Africa. For 12 locations, mosquito 
biting rate data were based on repeated all-night man landing catches2; in 10 other 
locations, other methods were used or it was not clear how biting rates were determined3. 
The studies differed with respect to the diagnostic test that was used to measure mf 
prevalences, which blurs the relationship between biting rate and mf prevalence. The data 
are shown in section 10.2.1, Figure 10-2-F.  
                                                          
1  (McGregor et al. 1952; McFadzean 1954; Brengues et al. 1969; Brengues 1975; Brunhes 1975; Ripert et al. 
1982; Akogun 1991; Gyapong et al. 1998; Boakye et al. 2004) 
2  (Maasch 1973; Wijers 1977; Wijers & Kiilu 1977; Wijers & Kinyanjui 1977; Kuhlow & Zielke 1978; 
McMahon et al. 1981; Southgate 1992) 
3  (Maasch 1973; Udonsi 1988ab; Appawu et al. 2001; Onapa et al. 2001; Pedersen & Mukoko 2002; Mukoko 
et al. 2004; Rwegoshora et al. 2005) 
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Parameter estimation 
Fitting was done by manually adapting the free model parameters and comparison of 
simulation results with observations using a grid search. Each simulation started with a 
“warming-up” period, during which the population grows from 300 to 7000-8000 persons 
and a stable endemic situation develops. Simulations were always done for three different 
values of the monthly biting rate (corresponding to the median, the 16.7th and 83.3th 
percentile of the observed frequency distribution of biting rates). Our aim was to identify 
a model that, with these different values of monthly biting rate, was able to describe the 
range of observations from Africa. The goodness of fit was assessed by visual inspection 
of plots of observations and predictions.   
 
 
 
Table B-1. List of fixed biological parameters of the LYMFASIM model (symbols as chapter 1 of 
this thesis).  
Parameter and description Value Source 
a Parameter of the uptake curve  1.80 This thesis, App. A 
b ,,  0.016 ,, 
c ,,  1.14 ,, 
v Fraction of the L3 larvae, resulting from a single blood 
meal, that is released by a mosquito 
0.1 Fixeda 
Tl Average lifespan of adult parasites (years) 10 (Subramanian et al. 
2004)b 
αTl Shape parameter of the Weibull distribution that 
describes the variation in the worm lifespan 
2.0 Expert opinion 
Ti Duration of the immature stage of the parasite in the 
human host (months) 
8  (World Health 
Organization 1992) 
s Proportion of mf surviving per month 0.9 (Plaisier et al. 1999) 
r0 Number of mf produced per female parasite (per month 
per 20 µl of peripheral blood) in the presence  
of at least one worm, in the absence of acquired 
immunity and treatment  
0.58 (Subramanian et al. 
2004)a, b 
E0 Relative exposure at birth as fraction of exposure in 
adults 
0 Fixed 
amax Age at which exposure to mosquitoes reaches its 
maximum level 
20 (Subramanian et al. 
2004)b 
km Overdispersion parameter of the Negative Binomial 
distribution describing the variation in mf counts in 20 µl 
blood smears for an individual 
0.33 ,, 
a  Parameter v, r0, and the ‘success ratio (sr)’ (see Table B-2) are linear multiplication factors in the 
same sequence of calculations in this model without immunity. We have no sound knowledge on 
either of these parameters. We therefore fixed v and r0 at the given values, and only estimate 
the success ratio.  
b  Chapter 2 of this thesis. 
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Table B-2. Life table and fertility rates for the African region that were used as input specifications 
for LYMFASIM.  
Age group  
Life table (probability to survive until the 
upper limit of the age-range) a 
Fertility b (birthrate per female 
per year) 
   0-5 0.804 0.000 
   5-15 0.780 0.000 
   15-20 0.755 0.116 
   20-25 0.730 0.230 
   25-30 0.707 0.245 
   30-35 0.654 0.207 
   35-40 0.605 0.147 
   40-45 0.560 0.077 
   45-50 0.506 0.031 
   50-60 0.407 0.000 
   60-70 0.255 0.000 
   70-80 0.051 0.000 
   80-99 0.000 0.000 
Total fertility rate  5.3   
a  The lifetable gives the probability to survive, assuming that age-specific mortality risks observed 
in the year 2002 apply during the entire life time of a hypothetical cohort of people. Source of 
mortality risks: Global Burden of Disease study, 2002 for the WHO-AFRO region; available from 
the WHO website (www.who.int) 
b  Source: age-specific fertility rates for Sub-Sahara Africa, available on the internet from the US 
Census Bureau (U.S. Census Bureau 2004). Total fertility rate: number of children per women, 
who survives throughout the fertile period. 
 
 
 
Table B-3. Estimated value of the ‘free’ model parameter (symbols as in chapter 2 of this thesis). 
Parameter Description  Value 
sr Success ratio: fraction of inoculated L3 larvae developing into an 
adult male or female worm (in the absence of immune regulation) 
0.10 
αE Shape parameter of the gamma-distribution describing individual 
variation in exposure to mosquitoes (mean=1) 
0.3 
 
 
 
Results 
Table B-3 gives the estimates of the free model parameters. The goodness-of-fit is shown 
in Figure 10-2. Results are discussed in section 10.2.1. 
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Summary 
 
 
Lymphatic filariasis: infection, disease and elimination 
Lymphatic filariasis is a disfiguring and debilitating parasitic disease that is endemic in 
many tropical and subtropical countries. This mosquito-borne disease is caused by 
different species of thread-like, filarial worms, of which Wuchereria bancrofti is most 
widespread. The worms live in the human lymphatic system and have a lifespan of 5 to 10 
years. During their lifespan, female worms can bring millions of immature microfilariae 
(mf) into the blood. These mf can stay alive for about one year, but cannot develop into 
adult worms, unless they are engorged by mosquitoes taking a blood meal. Inside a 
mosquito, mf develop via several stages into L3 larvae. These can be transmitted to 
humans when the mosquito bites, where they can develop further into adult worms. Many 
different mosquito species can transmit the infection. 
Many people may be infected without even knowing it. However, the infection 
causes damage to the lymphatic system, impairing the lymph drainage in the body. This 
can eventually lead to gross swelling of extremities and external genitalia (lymphoedema 
or, in the end stage, elephantiasis) or, in males, to enlargement of the scrotum due to 
serous fluid accumulation (hydrocele). A hydrocele can be removed surgically, but 
advanced lymphoedema and elephantiasis cannot be treated. These chronic 
manifestations are an important cause of disability and reduced quality of life. 
Approximately 120 million people are affected worldwide, with more than 40 million 
people suffering from the chronic manifestations. 
Public health interventions aim at prevention of the chronic manifestations by 
reducing the infection load in the population. Commonly used indicators for the infection 
load are the proportion of people with mf in the blood (mf prevalence) and the mean 
concentration of mf in the blood (mf intensity). Mf prevalence and intensity can be 
brought down by reducing infection transmission through mosquito control measures. 
However, nowadays the preferred strategy is regularly repeated treatment of all individuals 
in the population with antifilarial drugs. For this purpose, diethylcarbamazine (DEC) or 
ivermectin can be used, given alone or in combination with albendazole. A single dose of 
these drugs leads to a sustained reduction of mf intensity in the blood. These drugs are 
safe, so that is is possible to treat all individuals in an area at the same time, without 
determining who is infected and who is not (‘mass treatment’). This is easier, cheaper and 
more effective than screening followed by selective treatment of infected individuals. 
Yearly repeated mass treatment causes such a strong decline in mf prevalence and 
intensity, and thereby also in transmission, that it is thought possible to eliminate the 
infection completely. Recognizing this, the World Health Assembly called in 1997 for the 
‘elimination of lymphatic filariasis as a public health problem’ and mass treatment 
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programmes are being initiated worldwide under the umbrella of the Global Programme 
to Eliminate Lymphatic Filariasis.  
 
 
This thesis 
There is much optimism about the possibility of eliminating lymphatic filariasis. However, 
it is uncertain how long mass treatment would have to be continued to achieve this goal 
and how the required duration depends on the proportion of the population that receives 
treatment (coverage), the treatment regimen, the pretreatment mf prevalence, and the 
local vector species. These questions are addressed in this thesis. Much of the reported 
work was done in close collaboration with the Vector Control Research Centre in 
Pondicherry (Indian Council of Medical Research), India. 
 
 
Elimination prospects 
In the first part of this thesis, we used a mathematical simulation model for transmission 
and control of lymphatic filariasis, to predict the long-term effects of mass treatment and 
to estimate the duration of mass treatment required for elimination. The employed model, 
which is called LYMFASIM, was previously developed at our department in collaboration 
with researchers of the Vector Control Research Centre in Pondicherry, India, and the 
Centro de Pesquisas Aggeu Magalhães in Recife, Brazil. 
We quantified the LYMFASIM model so that it reflects the situation in Pondicherry, 
India, where lymphatic filariasis is transmitted by mosquitoes of the species Culex 
quinquefasciatus (chapter 2). For this purpose, we used the wealth of data that were 
collected for evaluation of a 5-year ‘integrated vector management’ programme, which ran 
in Pondicherry from 1981 to 1986 and aimed to reduce the transmission by lowering the 
number of mosquitoes. We could use individual level data on mf intensity before and 
after the control programme. In addition, data were available on the mean number of 
mosquito bites per person per month for the whole programme period. From these data, 
we estimated that adult parasites live for about 10 years. We further deduced that 
individuals after prolonged exposure acquire some kind of immunity that protects against 
new infections or reduces the mf production. Predictions of the resulting matched well 
with the observations from Pondicherry. 
The model was subsequently used to predict the long-term effects of mass treatment 
(chapters 3 and 4). We found that the duration of mass treatment required for 
elimination depends strongly on the proportion of the population treated per round, the 
efficacy of the applied treatment regimen, and the pretreatment endemicity level. In the 
Pondicherry-situation, with a pretreatment mf prevalence of about 8.5%, four yearly 
rounds of mass treatment with the recommended drug-combination DEC plus 
albendazole are sufficient to achieve elimination if 80% of the population is treated per 
round. Such high coverage levels are not always easy to achieve, though. If a more 
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realistic 65% of the population is treated per round, mass treatment has to be continued 
for 6 years. We assumed in these simulations that the DEC-albendazole combination kills 
on average 65% of worms and 70% of mf per individual treatment. Mass treatment needs 
to be continued for a longer period, if the treatment regimen is less effective or if 
pretreatment mf prevalence is higher. Although a 1-year interval between treatments may 
be practical, more frequent treatment could reduce the total duration of the programme.  
We compared LYMFASIM’s predictions with those from another model for 
lymphatic filariasis, EPIFIL, which was developed by Michael c.s. from the United 
Kingdom. The two models make similar predictions of trends in mf prevalence and 
intensity during mass treatment. However, LYMFASIM simulates the transmission of 
infection in more detail and is better adapted for assessing the risk of recurrent infection 
after stopping mass treatment (chapter 5). 
Overall, prospects for elimination of lymphatic filariasis by mass treatment in 
Pondicherry seem good, provided that the level of population coverage is sufficiently 
high. Qualitative conclusions on the impact of coverage, treatment efficacy, and 
pretreatment mf prevalence on the elimination prospects can be generalized to other 
areas. Quantitative estimates of the required duration should however be interpreted with 
some care. Our predictions may be optimistic, because we did not take account of 
variability in treatment effects between individuals, reintroduction of infection by infected 
immigrants, or the possible development of parasite resistance against treatment. Our 
estimates are further influenced by uncertainty about treatment effects and about the 
processes that play a role in parasite transmission. Results cannot simply be generalized to 
areas with other vector species: differences between species in transmission efficiency 
may be important determinants of the elimination prospects.    
 
 
Transmission dynamics 
For more accurate prediction of the long-term impact of mass treatment, better 
understanding of the processes involved in parasite transmission is required. We studied 
two of these processes in more detail. 
First, we investigated the role of acquired immunity (chapter 6). In Pondicherry, we 
observed that mean mf density and mf prevalence in the blood declined in older age 
groups. We explained this by assuming that individuals acquire some kind of immunity 
against infection after prolonged exposure, which protects against new infections or 
otherwise reduces the mf density in the blood. Evidence for the operation of such 
immunity has come from animal studies. However, when we reviewed age-patterns of 
lymphatic filariasis infection in other areas, we found that such patterns with a decline in 
older age groups are not common at all. Usually, the mf prevalence increases with age 
until a stable level is reached at about 20 years of age in India and 10 to 15 years later in 
Africa. In fact, the pattern in Pondicherry was rather exceptional. This raises doubts 
about the assumed role of acquired immunity in lymphatic filariasis. 
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Second, we examined how the mean number of infectious L3 larvae developing in 
mosquitoes depends on the mean mf density in human blood. This relationship differs 
between mosquito species and is an important determinant of elimination prospects. We 
compared the uptake and development of mf in Culex quinquefasciatus, the main vector of 
lymphatic filariasis in India, and Aedes polynesiensis, the main vector in French Polynesia. 
We found for both species that transmission is most efficient at the lowest mf densities: a 
large proportion of mf can develop into L3 larvae inside the mosquito. However, the 
number of L3 larvae in mosquitoes does not increase linearly with mf density in the 
blood, but approximates a maximum at higher mf densities (‘limitation’).  In other words, 
the proportion of mf that develops into L3 declines. The maximum number of L3 larvae 
developing in the mosquito was higher for Aedes (~23) than for Culex (~4). A different 
type of relationship has been hypothesized for the African Anopheles vector: the 
probability that mf develop into L3 larvae is lowest at low mf densities and increases with 
mf density (‘facilitation’). Only at the highest mf densities, limiting mechanisms would get 
the upper hand. We did an explorative analysis, combining data from the few available 
studies, to quantify the uptake curve for Anopheles (chapter 10.2). 
The differences between mosquito species are important when it comes to 
elimination. In the case of ‘facilitation’, mass treatment will have relatively strong impact 
on transmission intensity, because worm burdens and mean mf load are reduced and, in 
addition, a lower proportion of mf will develop successfully into adult worms. This helps 
elimination. The opposite is true in case of ‘limitation’, because transmission becomes 
more efficient at the lower levels.  
 
 
Treatment efficacy 
For realistic prediction of the long-term effects of mass treatment, accurate estimates of 
treatment effects on mf and adult worms are required. It is particularly relevant to know 
how the adult worms are affected, because any effect on transmission will be only 
temporary if adult worms survive and continue to produce mf. With currently available 
diagnostic methods, we cannot directly investigate the treatment effects on adult worms. 
We estimated these effects indirectly, by analyzing trends in mf density after treatment. 
We first investigated the efficacy of DEC and ivermectin (chapter 8). From the 
immediate reduction in mf intensity after treatment, we estimated that a single dose of 
DEC or ivermectin on average kills, respectively, 57% or 96% of mf. From the slow mf 
recurrence in the blood in the post-treatment period, we further concluded that these 
drugs reduce mf production by 67% and 82% on average, probably due to killing (DEC) 
or sterilization (ivermectin) of part of the adult worms. Especially the effects of DEC 
varied strongly between individuals, with some people responding poorly. Similar 
estimates for the currently used combinations of these drugs with albendazole were 
higher (chapter 9). The estimated reduction in mf production may be somewhat higher 
than the proportion of worms affected, because the mating probability of male and 
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female worms declines along with the number of worms. Our estimates are influenced by 
uncertainty about the mf life span and about the rate at which mf would recur in the 
blood if adult worms were not affected.  
 
 
Conclusion and recommendations 
We found that the prospects of lymphatic filariasis elimination by mass treatment are 
good for Pondicherry, India, especially if the very effective combination of DEC and 
albendazole is used. The for elimination required duration of mass treatment, however, 
depends strongly on the population coverage: 4 yearly rounds would be sufficient for 
elimination if 80% of the population is treated per round, but 2 more rounds would be 
required if only 65% can be treated. The accuracy of our predictions is influenced by 
uncertainty about the role of immunity and the efficacy of the treatment regimen. The 
efficiency of transmission differs markedly between mosquito species, which may have 
important implications for elimination. The results for Pondicherry should therefore not 
be generalized to other areas. 
When the Global Programme to Eliminate Lymphatic Filariasis was started, it was 
hoped that 4-6 yearly rounds of mass treatment would be sufficient for elimination in 
most regions, provided that coverage is sufficiently high. However, because of differences 
in the mosquito species responsible for transmission and pretreatment mf prevalence 
levels, elimination prospects may vary widely between areas. Preliminary predictions for 
Africa illustrate this and give reason for concern (chapter 10.2). Mf prevalence in this 
region can be much higher (sometimes > 40%) than in India (usually < 20%). In African 
areas with about 10% mf prevalence, the number of treatment rounds required for 
elimination is similar to the Pondicherry-situation, assuming that the same drugs are used 
and that population coverage levels are similar. However, in areas with 30% or 40% mf 
prevalence, elimination prospects are not as good: even if 80% or 90% of the population 
is treated per round, the number of treatment rounds would be much larger than the 
expected 4-6. In some circumstances it may be advisable to shift focus to the more 
realistic goal of eliminating the disease as a public health problem, without necessarily 
eliminating the infection, even though this would require continuous control efforts. 
Further research is required on the role of immunity, the efficacy of treatment, and 
the relationship between mf intensity in the human blood and the number of L3 larvae 
developing in different mosquito species. Future modelling-work should concentrate 
firstly on quantification of the model for other regions with different vectors. These 
models should be used to investigate issues that are of crucial importance for the ongoing 
Global Programme, including criteria for stopping mass treatment and cost-effective 
approaches to enhance programme effectiveness. Eventually, a more user-friendly version 
of the model should be developed and transferred to policy makers and programme 
managers for routine use in planning and evaluation of ongoing programmes for 
elimination of lymphatic filariasis.  
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Lymfatische filariasis: infectie, ziekte en eliminatie 
Lymfatische filariasis is een parasitaire infectieziekte, die veel voorkomt in tropische en 
subtropische gebieden en kan leiden tot ernstige misvorming en handicap. De ziekte is 
het gevolg van infectie met draadvormige wormpjes (‘filaria’), meestal van de soort 
Wuchereria bancrofti. Deze wormen leven in het lymfestelsel van de mens en hebben een 
levensduur van 5 à 10 jaar. Als ze bevrucht zijn, kunnen vrouwelijke wormen gedurende 
hun leven miljoenen microfilariën (mf) produceren die in het bloed te vinden zijn. Deze 
mf kunnen ongeveer een jaar blijven leven, maar kunnen zich alleen verder ontwikkelen 
tot volwassen worm als ze worden opgenomen door een mug. In de mug ontwikkelen mf 
zich via verschillende stadia tot L3 larven. Deze L3 larven kunnen via een muggenbeet 
weer worden overgebracht op mensen en kunnen zich dan verder ontwikkelen tot een 
volwassen worm. Veel verschillende muggensoorten kunnen de infectie overbrengen.  
Veel mensen zijn geïnfecteerd zonder het te weten. De infectie veroorzaakt echter 
schade aan het lymfesysteem waardoor de afvoer van weefselvloeistof in het lichaam 
verstoord wordt. Dit kan uiteindelijk leiden tot ernstige vergroting en misvorming van de 
ledematen of externe geslachtsorganen (lymfoedeem of, in het eindstadium, elefantiasis). 
Bij mannen zien we ook vaak vochtophoping in het scrotum, die daardoor ook grote 
afmetingen kan aannemen (hydrokèle). Een hydrokèle kan operatief verwijderd worden, 
maar vergevorderd lymfoedeem en elefantiasis zijn niet goed te behandelen. Deze 
chronische aandoeningen zijn een belangrijke oorzaak van invaliditeit en verminderde 
kwaliteit van leven. Naar schatting zijn wereldwijd 120 miljoen mensen geïnfecteerd met 
lymfatische filariasis, van wie meer dan 40 miljoen leiden aan lymfoedeem of hydrokèle.  
Volksgezondheidsinterventies richten zich op het voorkomen van chronische ziekte 
door de infectielast in de populatie te verminderen. Daarbij kijkt men meestal naar het 
percentage mensen met mf in het bloed (mf prevalentie) en de gemiddelde concentratie 
van mf in het bloed (mf intensiteit). Mf prevalentie en intensiteit kunnen omlaag gebracht 
worden door de overdracht van infectie te verminderen met maatregelen tegen muggen. 
Tegenwoordig geeft men er echter de voorkeur aan om regelmatig alle mensen in een 
gebied te behandelen met medicijnen tegen de infectie. Daarbij kan men gebruik maken 
van diethylcarbamazine (DEC) of ivermectine, al dan niet in combinatie met albendazol. 
Een enkele dosis van deze medicijnen leidt al tot een langdurige reductie in de mf 
intensiteit in het bloed. Deze medicijnen zijn veilig, wat het mogelijk maakt om iedereen 
in een gebied tegelijkertijd te behandelen, zonder eerst te onderzoeken wie er geïnfecteerd 
zijn (‘massabehandeling’). Dit is makkelijker, goedkoper en effectiever dan screening 
gevolgd door selectieve behandeling van geïnfecteerden. Jaarlijks herhaalde 
massabehandeling leidt tot zo een sterke daling in de mf prevalentie en intensiteit, dat de 
transmissie sterk verminderd wordt en de infectie mogelijk zelfs helemaal geëlimineerd 
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kan worden. Dit beseffend, nam de World Health Assembly in 1997 een resolutie aan die 
oproept tot de ‘eliminatie van lymfatische filariasis als een volksgezondheidsprobleem’ en 
werd een mondiaal programma voor eliminatie van lymfatische filariasis opgericht. In het 
kader van dit programma wordt er nu wereldwijd gestart met jaarlijkse massabehandeling. 
 
 
Dit proefschrift 
Men is optimistisch over de vooruitzichten op eliminatie van lymfatische filariasis. Het is 
echter onzeker hoe lang jaarlijkse massabehandeling door zou moeten gaan om eliminatie 
te bereiken en hoe de benodigde duur afhangt van het percentage daadwerkelijk 
behandelde mensen, de gebruikte medicijnen, de mf prevalentie voor de start van 
massabehandeling, en de soort mug die verantwoordelijk is voor de overdracht van 
infectie. Deze vragen staan centraal in dit proefschrift. Een groot deel van het werk is 
uitgevoerd in nauwe samenwerking met het Vector Control Research Centre (Indian 
Council of Medical Research) in Pondicherry, India. 
 
 
Vooruitzichten op eliminatie 
In het eerste deel van dit proefschrift gebruikten we een wiskundig simulatie model voor 
de overdracht van lymfatische filariasis om de lange termijn effecten van massa-
behandeling te voorspellen en te onderzoeken hoe lang massabehandeling voortgezet zou 
moeten worden om eliminatie te bewerkstelligen. Het gebruikte model, LYMFASIM, is 
eerder ontwikkeld op de afdeling Maatschappelijke Gezondheidszorg van het Erasmus 
MC, in samenwerking met onderzoekers van het Vector Control Research Centre in 
Pondicherry, India en het Centro de Pesquisas Aggeu Magalhães in Recife, Brazilië.  
Ons model hebben we zo gekwantificeerd dat het de situatie in Pondicherry, India, 
beschrijft, waar lymfatische filariasis verspreid wordt door de muggensoort Culex 
quinquefasciatus (hoofdstuk 2). De modelparameters konden we kwantificeren met behulp 
van de vele gegevens die eerder verzameld waren voor de evaluatie van een 5 jaar durend 
programma voor muggenbestrijding dat in Pondicherry liep van 1981 tot 1986. Er waren 
individuele gegevens beschikbaar over de mf intensiteit voor en na de interventie. 
Daarnaast hadden we gegevens over het gemiddeld aantal muggenbeten per persoon per 
maand voor de hele periode van muggenbestrijding. Uit deze gegevens konden we 
afleiden dat volwassen wormen een gemiddelde levensduur van ongeveer 10 jaar hebben. 
Daarnaast vonden we dat mensen, na langdurige blootstelling aan infectie, waarschijnlijk 
een soort immuniteit ontwikkelen, die beschermt tegen nieuwe infecties of het gemiddeld 
aantal mf in het bloed sterk vermindert. Voorspellingen van het resulterende model 
kwamen goed overeen met waarnemingen in Pondicherry. 
Het voor Pondicherry gekwantificeerde model hebben we vervolgens gebruikt om 
de lange termijn effecten van massabehandeling te voorspellen en om te onderzoeken hoe 
lang jaarlijkse massabehandeling door zou moeten gaan om eliminatie te bereiken 
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(hoofdstuk 3 en 4). We vonden dat de voor eliminatie benodigde duur sterk afhangt van 
het percentage mensen dat per keer behandeld wordt (‘bereik’), de effectiviteit van de 
gebruikte medicijnen, en de mf prevalentie voor de start van de massabehandeling. In 
Pondicherry, waar de mf prevalentie ongeveer 8.5% was voor de start van massa-
behandeling, zou men 4 jaarlijkse rondes van massabehandeling met de combinatie van 
DEC en albendazol nodig hebben voor eliminatie als 80% van de bevolking wordt 
behandeld per ronde. Het bereik is echter vaak minder hoog. Bij een realistischer bereik 
van 65% zouden er 6 jaarlijkse rondes nodig zijn. Hierbij gaan we ervan uit dat een enkele 
behandeling met DEC en albendazol steeds 65% van de aanwezige volwassen wormen en 
70% van de mf doodt. Massabehandeling zou langer moeten worden voortgezet als de 
gebruikte medicijnen minder effectief zijn of als mf prevalentie voor de eerste ronde van 
massabehandeling hoger is. Hoewel het misschien praktisch is om massabehandeling 
jaarlijks uit te voeren, zou de totale duur van een eliminatie programma sterk gereduceerd 
kunnen worden door het interval tussen behandelingen te verkorten.  
De voorspellingen van ons LYMFASIM model hebben we vergeleken met die van 
een tweede model, EPIFIL, dat in Engeland is ontwikkeld door Michael c.s. De twee 
modellen geven vergelijkbare voorspellingen van de verandering in mf prevalentie en 
intensiteit tijdens een periode van massabehandeling. Het LYMFASIM model is echter 
meer gedetailleerd en kan daardoor meer realistische voorspellingen doen over het risico 
dat infectie weer terugkomt na het stoppen van massabehandeling (hoofdstuk 5). 
Samenvattend kunnen we stellen dat de vooruitzichten op eliminatie van lymfatische 
filariasis door massabehandeling goed zijn voor Pondicherry, mits een voldoende groot 
percentage van de mensen bereikt wordt. Kwalitatieve conclusies over de invloed van het 
bereik van massabehandeling, behandelingseffecten, en mf prevalentie op de vooruit-
zichten op eliminatie zijn te generaliseren. Schattingen van het voor eliminatie benodigde 
aantal behandelingsrondes moeten echter voorzichtig geïnterpreteerd worden. Onze 
voorspellingen zijn mogelijk te optimistisch, omdat we geen rekening houden met variatie 
in de effectiviteit van behandeling tussen mensen, (her)introductie van infectie door 
geïnfecteerde immigranten, of de mogelijkheid dat de parasiet resistentie ontwikkelt tegen 
het geneesmiddel. Daarnaast zijn we niet zeker over de effectiviteit van de gebruikte 
medicijnen en over de processen en mechanismen die een rol spelen bij de transmissie 
van infectie. De voorspellingen kunnen niet zonder meer gegeneraliseerd worden naar 
gebieden waar een andere muggensoort verantwoordelijk is voor de transmissie van 
lymfatische filariasis, omdat verschillen in transmissie-efficiëntie tussen muggensoorten 
grote invloed kunnen hebben op de vooruitzichten op eliminatie. 
 
 
Dynamiek van transmissie 
Om de lange termijn effecten van massabehandeling nauwkeuriger te kunnen voorspellen, 
hebben we beter inzicht nodig in de processen die betrokken zijn bij de transmissie van 
infectie. Twee processen hebben we in detail onderzocht. 
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Ten eerste bestudeerden we de rol van immuniteit (hoofdstuk 6). In Pondicherry 
zagen we dat de gemiddelde mf intensiteit en prevalentie afnamen in oudere 
leeftijdsgroepen. Dit verklaarden we in ons model door aan te nemen dat oudere mensen, 
als gevolg van langdurige blootstelling aan infectie, een vorm van immuniteit hebben 
ontwikkeld die beschermt tegen nieuwe infecties of het aantal mf in het bloed vermindert. 
Als deze verklaring correct is, dan zouden we verwachten dat ook in andere gebieden de 
prevalentie en intensiteit van infectie afnemen bij oudere leeftijdsgroepen. Dit blijkt 
echter niet het geval te zijn. In een systematisch literatuur onderzoek vonden we dat de 
mf prevalentie meestal toeneemt met leeftijd totdat een min of meer stabiel niveau bereikt 
wordt op een leeftijd van ongeveer 20 jaar in India en 10 tot 15 jaar later in Afrika. Het 
leeftijdspatroon in Pondicherry was uitzonderlijk, wat tot twijfel leidt over de 
veronderstelde rol van immuniteit in lymfatische filariasis. 
Ten tweede onderzochten we hoe het gemiddeld aantal infectieuze L3 larven dat 
zich ontwikkelt in een mug afhangt van de mf intensiteit in het bloed. Deze relatie 
verschilt tussen muggensoorten en kan bepalend zijn voor de kans op eliminatie. In 
hoofdstuk 7 vergeleken we Culex quinquefasciatus, de belangrijkste vector van lymfatische 
filariasis in India, en Aedes polynesiensis, de vector van lymfatische filariasis in Frans 
Polynesië. Voor beide muggensoorten vonden we dat de transmissie van infectie het 
meest efficiënt is bij lage mf concentraties: een groot percentage van mf ontwikkelt zich 
in de mug tot L3 larven. Het gemiddeld aantal L3 larven per mug neemt niet lineair toe 
met de concentratie van mf in het bloed, maar gaat naar een maximum (‘limitatie’): het 
percentage van mf dat zich ontwikkelt tot L3 neemt dus af. Het maximum was aanzienlijk 
hoger voor Aedes polynesiensis (~23) dan voor Culex quinquefasiatus (~4). Voor Anopheles 
muggensoorten die verantwoordelijk zijn voor de verspreiding van lymfatische filariasis in 
Afrika is de relatie waarschijnlijk omgekeerd: de kans dat een mf zich ontwikkelt tot L3 
larve is juist het laagst bij lage mf intensiteit en neemt toe bij hogere intensiteiten 
(‘facilitatie’) tot op een gegeven moment de limiterende processen ook hier de overhand 
krijgen. Uit de literatuur zijn te weinig data beschikbaar voor nauwkeurige kwantificatie 
van deze relatie voor Anopheles, en onze analyses op dit gebied zijn exploratief (hoofdstuk 
10.2). 
De verschillen tussen muggensoorten zijn van belang als het gaat om eliminatie. In 
het geval van facilitatie (Anopheles) zal vermindering van de mf intensiteit in het bloed een 
relatief groot effect hebben op transmissie, omdat de kans dat mf zich ontwikkelen tot L3 
afneemt. Dit is gunstig voor eliminatie. Het omgekeerde is juist het geval bij limitatie 
(Aedes, Culex), omdat de transmissie juist efficiënter wordt bij lagere concentraties van mf 
in het bloed. 
 
 
Effectiviteit van medicijnen 
Om de lange termijn impact van massabehandeling goed te kunnen voorspellen, hebben 
we nauwkeurige schattingen nodig van de effectiviteit van de medicijnen. Vooral het 
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effect op volwassen wormen is van belang, omdat massabehandeling slecht een tijdelijk 
effect op transmissie zal hebben wanneer de volwassen wormen niet zijn aangedaan en 
doorgaan met het produceren van mf. Met de huidige diagnostische methoden kunnen we 
helaas niet direct bepalen wat er met de volwassen worm gebeurt. Daarom gebruikten we 
een indirecte methode om de effecten van behandeling te kwantificeren, namelijk de 
analyse van trends in mf intensiteit na behandeling. Eerst onderzochten we de effectiviteit 
van DEC en ivermectine (hoofdstuk 8). Uit de sterke reductie in mf intensiteit in het 
bloed direct na behandeling, concludeerden we dat een enkele dosis van DEC of 
ivermectine leidt tot de dood van, respectievelijk, 57% of 96% van de mf. Uit de 
langzame toename van mf intensiteit in het bloed in het eerste jaar na behandeling, 
leidden we verder af dat deze medicijnen de mf productie met respectievelijk 67% en 82% 
reduceren, wat waarschijnlijk het gevolg is van dood (DEC) of sterilisatie (ivermectine) 
van de volwassen wormen. Met name de effectiviteit van DEC bleek sterk te kunnen 
variëren tussen individuen, en bij sommige individuen lijkt het medicijn nauwelijks effect 
te hebben. Vergelijkbare schattingen voor de aanbevolen combinaties van DEC of 
ivermectine met albendazol waren hoger (hoofdstuk 9). Deze geschatte afname in mf 
productie zou wat hoger kunnen zijn dan het percentage wormen dat aangedaan is, omdat 
de kans op bevruchting van een vrouwelijke worm afneemt bij lagere worm aantallen. 
Onze schattingen worden beïnvloed door onzekerheid over de levensduur van mf en over 
de snelheid waarmee mf in het bloed zouden terug keren als volwassen wormen niet 
zouden zijn aangedaan.   
 
 
Conclusies en aanbevelingen 
We vonden dat de vooruitzichten op eliminatie van lymfatische filariasis door 
massabehandeling goed zijn voor Pondicherry, India, met name als de zeer effectieve 
combinatie van DEC en albendazol gebruikt wordt. De benodigde duur voor eliminatie 
hangt echter sterk af van het bereik: waar 4 jaarlijkse rondes voldoende zouden kunnen 
zijn voor eliminatie als 80% van de bevolking bereikt wordt, zouden er al 6 rondes nodig 
zijn als slechts 65% van de bevolking bereikt wordt per ronde. De nauwkeurigheid van 
deze voorspellingen wordt beïnvloed door onzekerheid over de rol van immuniteit en de 
effectiviteit van de gebruikte medicijnen. We vonden grote verschillen tussen muggen-
soorten in de efficiëntie van transmissie, wat belangrijke consequenties kan hebben voor 
de vooruitzichten op eliminatie. De resultaten voor Pondicherry zijn daarom niet zonder 
meer generaliseerbaar naar andere gebieden. 
Toen het mondiale programma voor eliminatie van lymfatische filariasis van start 
ging, hoopte men dat 4 tot 6 jaarlijkse rondes van massabehandeling meestal genoeg 
zouden zijn voor eliminatie, als het populatiebereik tenminste hoog genoeg is. Het is 
echter duidelijk dat de vooruitzichten op eliminatie sterk kunnen variëren tussen regio’s, 
bijvoorbeeld door verschillen in de muggensoort die verantwoordelijk is voor transmissie 
of de mf prevalentie voor de start van behandeling. Verkennende analyses voor Afrika 
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illustreren dit en zijn zorgwekkend (hoofdstuk 10.2). De mf prevalentie kan in deze regio 
veel hoger zijn (tot >40%) dan in India (meestal <20%). Bij een lage mf prevalentie van 
ongeveer 10% waren de vooruitzichten op eliminatie in Afrika vergelijkbaar aan die in 
Pondicherry, aannemend dat even effectieve medicijnen gebruikt worden en een even 
groot deel van de bevolking bereikt wordt. Bij hogere mf prevalenties van 30% of 40% 
zijn de vooruitzichten minder gunstig: zelfs wanneer 80% of 90% van de bevolking 
behandeld wordt per ronde, zou het aantal rondes nodig voor eliminatie veel groter zijn 
dan de verwachte 4 tot 6. Soms is misschien beter om te concentreren op eliminatie van 
de ziekte als volksgezondheidsprobleem, zonder noodzakelijkerwijs de parasiet ook te 
elimineren. Dit zou echter wel betekenen dat er continu maatregelen nodig blijven om te 
zorgen dat de infectie niet terug komt.  
Er is meer onderzoek nodig naar de rol van immuniteit, de effectiviteit van 
behandeling, en de relatie tussen mf intensiteit in het bloed van mensen en de 
ontwikkeling van L3 larven voor de verschillende muggensoorten. Verder werk met het 
model voor lymfatische filariasis zal zich in eerste instantie moeten concentreren op de 
kwantificatie van het model voor regio’s waar andere muggensoorten verantwoordelijk 
zijn voor de overdracht van infectie. Deze modellen kunnen vervolgens toegepast worden 
om een aantal belangrijke vragen voor de eliminatie programma’s te beantwoorden. De 
belangrijkste vraag is wanneer massabehandeling gestopt kan worden met minimaal risico 
dat infectie weer terugkomt. Daarnaast is het van belang om te onderzoeken op welke 
manier de effectiviteit van interventie op een kosteneffectieve manier verhoogd kan 
worden. Uiteindelijk zou er een meer gebruiksvriendelijke versie van het model 
ontwikkeld moeten worden, die door beleidsmakers en programmamanagers gebruikt kan 
worden in de routinematige planning en evaluatie van programma’s ter bestrijding van 
lymfatische filariasis.  
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